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SUMMARY
Asthma is a chronic inflammatory disease characterised by airway inflammation, 
bronchoconstriction, airway hyperresponsiveness (AHR) and airway remodelling. Most 
models o f asthma focus on acute allergen challenges, where airway remodelling is absent. 
The thesis aimed to compare acute and chronic allergen challenge models of asthma and 
analyse the effects of anti-inflammatory drugs on these models.
Acute and chronic challenges with ovalbumin in conscious guinea pigs and mice caused 
impared lung function, measured as specific airway conductance (sGaw) and enhanced pause 
(Penh), respectively. This was characterised by early (EAR) and late (LAR) asthmatic 
responses, AHR and cellular influx. Multiple challenges with ovalbumin caused airway 
remodelling distinguished by increased bronchiolar collagen and goblet cells compared to 
control. No airway remodelling was observed in acute ovalbumin models.
Treatment with the corticosteroid, fluticasone propionate (FP), attenuated the LAR, AHR and 
cellular influx in all models. In both chronic ovalbumin models, FP treatment partially 
reversed airway remodelling, though not to naive levels. This was also the case with 
treatment with the phosphodiesterase IV inhibitor, roflumilast. However, roflumilast also 
attenuated the EAR. Treatment with the iNOS inhibitor, GW274150F, reduced the LAR and 
AHR and showed some inhibition of cellular influx in the acute ovalbumin challenged 
animals. However, GW274150F was ineffective in chronic ovalbumin models. Lung oedema, 
assessed by magnetic resonance imaging in acute and chronic ovalbumin challenged guinea 
pigs, was increased and correlated temporarily with the LAR. Dexamethasone treatment 
attenuated the level of oedema though not to control levels.
Acute ovalbumin challenged models showed airway functional changes which were partially 
resolved with drug treatment. Chronic ovalbumin challenges provoked lung functional and 
structural changes which were attenuated by FP and roflumilast but not GW274150F. As 
GW274150F proved ineffective in clinical trials, the data in this thesis suggests that chronic 
ovalbumin challenge animals are better pre-clinical models of asthma.
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CHAPTER 1
1.1 ASTHMA
1.1.1 DEFINITION
Asthma has proven to be frustratingly difficult to define in an accurate and precise 
manner. The first definition came from Hippocrates (460-377 BC) who used the Greek 
word ‘asthmaino’ meaning panting or gasping. However, a link between asthma and 
bronchospasm was not made until Galen (130-201 AD). A definition of asthma continued 
to evolve. The most commonly quoted definition of asthma comes from the National 
Asthma Education and Prevention Program Export Panel Report 2, which described 
asthma as:
A chronic inflammatory disorder o f the airways in which many cells and cellular 
elements play a role, in particular, mast cells, eosinophils, T lymphocytes, neutrophils, 
and epithelial cells. In susceptible individuals, this inflammation causes recurrent 
episodes o f wheezing, breathlessness, chest tightness, and cough, particularly at night 
and in the early morning. These episodes are usually associated with widespread but 
variable airflow obstruction that is often reversible either spontaneously or with 
treatment. The inflammation also causes an associated increase in the existing bronchial 
hyperresponsiveness to a variety o f stimuli. (1987)
However, this does not begin to describe the complexity of the disease and it is now 
known not to be completely accurate as several patients with asthma show extremely 
poor reversibility (Bousquet et al., 2000). It is believed that around 5.4 million Britons 
are receiving treated for asthma and there is a person with asthma in one of every five 
households (Asthma UK). It is estimated that the economic costs of asthma will exceed 
those of tuberculosis and HIV-AIDS combined (van Schalkwyk et al., 2005).
1.1.2 PATHOPHYSIOLOGY
Asthma can be classified into two different forms, intrinsic or extrinsic asthma (Wardlaw 
et al., 2002). Intrinsic, or non-atopic, asthma is triggered by something inside the body, 
not by an allergy. Respiratory infections, exercise, cold weather and certain drugs, such
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as non-steroidal anti-inflammatory drugs, can cause a reflex in the upper airways leading 
to asthmatic symptoms. This form of the disease is not caused by hypersensitivity to an 
antigen or allergen and levels of immunoglobulin E (IgE) remain normal in comparison 
to non-asthmatics.
In contrast, extrinsic, or atopic/allergic, asthma is IgE mediated. It is commonly 
diagnosed early in life and is a result of hypersensitivity to an inhaled antigen such as 
dust mites, pollen or ovalbumin. Individuals who suffer from extrinsic asthma become 
sensitive to the allergen; whenever they encounter the allergen again asthmatic symptoms 
occur. As a result extrinsic asthma is described as being caused by two phases, the 
sensitisation phase and the effector phase (figure 1).
Allergen
B cell
Plasma
Allergen
Vasoactive 
—amines
allergen
•2
Fc receptor 
for IgE
Degranulation
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Y y W
1 s /IT Allergen-
Sensitised 
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Figure 1 - Schematic diagram o f how sensitisation to an allergen occurs and the effect that a repeated 
exposure to the allergen has. Picture adapted from Goldsby et a l (2000). IgE = Immunoglobulin E; Th 
cell = T helper cell.
1.1.3 SENSITISATION PHASE
Circulating allergens can be recognised as foreign by antigen presenting cells (APC), 
such as macrophages, B cells and dendritic cells. IgE on the surface of the APC captures
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the antigen and causes it to be internalised by phagocytosis or endocytosis. The antigen is 
then proteolysed into peptides and part of it is displayed on the membrane bound major 
histocompatibility complex (MHC) class II on the surface of the APC (Banchereau & 
Steinman, 1998). The antigen is then recognised by naive T cells which then become 
activated. Once activated, the naive T cells will differentiate into T helper 1 (Thl) or T 
helper 2 (Th2) cells. This differentiation is triggered by interleukin-2 (IL-2). Naive T 
cells release IL-2 and at the same time develop surface receptors specific for it, once the 
receptor is active the differentiation occurs. Whether the cell becomes Thl or Th2 is 
dependent on the presence of the autocrine cytokines IL-12 and IL-4 respectively 
(Romagnani, 1997). The Thl response mainly activates certain T cells and macrophages 
through a cytokine profile that supports inflammation. The Th2 response activates B cells 
and immune responses dependent on antibodies (Goldsby et al., 2000). TheThl response 
is responsible for killing intracellular parasites and is more involved in autoimmune 
conditions (Berger, 2000). In asthmatic patients a trend is seen toward the differentiation 
of Th2 cells.
Active Th2 cells cause sensitisation to the allergen by releasing the cytokines IL-4 and 
IL-13. IL-4 and IL-13 stimulate the production of allergen-specific IgE from plasma 
cells. IL-4 also induces the expression of FceRI, or high affinity allergen-specific IgE, 
receptors on the surface of mast cells and basophils. Monovalent binding of IgE causes 
increased FceRI expression, increases mast cells resistance to apoptosis and can induce 
cytokine release (Knol, 2006). Once the allergen-specific IgE binds to these receptors 
sensitisation has occurred, therefore exposure to the same allergen would lead to an 
asthmatic response.
1.1.4 EFFECTOR PHASE
The asthmatic response following re-exposure of a specific allergen is two-fold. The first 
response is an immediate bronchoconstriction and is known as the early asthmatic 
response (EAR). The second bronchoconstriction does not occur until around seven hours 
after allergen exposure and is known as the late asthmatic response (LAR). The responses 
are a result of the re-exposed allergen binding to the membrane-bound IgE on the 
sensitised mast cells or basophils. The bound IgE interacts and cross-links with the IgE
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that bound to the mast cell or basophil during the sensitisation phase. Cross-linking of 
bound IgE leads to surface receptor clustering which induces a cascade of tyrosine 
phosphorylation events resulting in the activation of phospholipase Cy and ultimately 
causing degranulation of the mast cells or basophils (Knol, 2006). Mast cells and 
basophil degranulation occurs rapidly, within 60-300 seconds (Holmes 1999 referenced 
by John 2007). Mast cells contain many inflammatory mediators, including histamine, 
tryptase, prostaglandins, leukotrienes and cytokines, which are released when mast cells 
are degranulated. Some of these mediators, such as histamine, act on the local airway 
receptors causing the immediate bronchoconstriction or EAR. The LAR is caused by 
some of the other mediators chemoattracting inflammatory cells, such as macrophages, 
eosinophils, lymphocytes and neutrophils which in turn attract more inflammatory 
mediators and cause bronchoconstriction (Durham & Kay, 1985).
1.2 AIRWAY INFLAMMATION
Airway inflammation is one of the defining characteristics of asthma, it can be present 
even in mild asthma (Laitinen et al., 1996). Along with airway hyperresponsiveness, 
airway inflammation contributes to the common symptoms of asthma - chest tightness, 
wheezing, cough and shortness of breath. However, there are other mechanisms such as 
the activation of airway sensory nerves which can contribute to these symptoms, 
especially cough (Nasra & Belvisi, 2009). It has been established that the extent of 
inflammation correlates with the severity o f the disease (Walter & Holtzman, 2005). 
Elevation of the number of inflammatory cells in the airways of patients who die of an 
asthma attack (status asthmaticus) was observed by Barnes (1996). Although some 
inflammatory cells predominate in causing inflammation of the airways no single cell can 
account for the complex pathophysiology o f asthma. Inflammation is caused by a 
complex cascade of events involving various inflammatory cells and mediators.
1.2.1 MAST CELLS
As previously mentioned mast cells play a key role in the sensitisation and effector phase 
o f asthma. The number of mast cells found in the broncho-alveolar lavage (BAL) fluid of
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asthmatics is two- to six-fold higher than found in non-asthmatics (Hamid et al., 2003). 
The percentage of mast cells expressing the cytokines IL-4, IL-5 and tumour necrosis 
factor (TNF)-a is also increased in asthmatics (Bradding et al., 1994). These cytokines 
cause increased Th2/reduced Thl cell production, reduced apoptosis and bronchial 
hyperresponsiveness respectively (Barnes, 2002a).
Mast cells contain cytoplasmic granules in which mediators such as histamine, tryptase, 
prostaglandin D2 (PGD2) and leukotriene C4 (LTC4) (Barnes, 2002a). The 
glycosaminoglycan, heparin is also stored by mast cells (Rose & Page, 2004). These 
mediators are released when the mast cells become degranulated. Degranulation is caused 
by the binding of an allergen to the allergen-specific IgE bound to the mast cell or by 
other indirect stimuli, such as in intrinsic asthma (Barnes, 1996). The released mediators 
cause bronchoconstriction, increased vascular permeability and leukocyte recruitment 
and activation, (Galli, 2000) all of which contribute towards airway inflammation.
1.2.2 MACROPHAGES
Macrophages are derived from blood monocytes and are the most prominent cell found in 
the BAL fluid of both asthmatic and non-asthmatic patients (Hamid et al., 2003). As 
previously mentioned macrophages can act as an APC for presenting an allergen to a 
naive T cell. Macrophages have the ability to play a role in both increasing and 
decreasing airway inflammation. They are able to release cytokines, which induce 
epithelial cells and fibroblasts to release chemoattractants and growth factors. Some of 
these chemoattractants such as RANTES (regulated upon activation, normal T-cell 
expressed and secreted) and monocyte chemotactic protein (MCP)-l attract further 
macrophages and eosinophils. This would result in more macrophages acting as APCs 
and therefore inflammation would occur. On the other hand alveolar macrophages can 
have a suppressive effect on lymphocyte activity; however, this effect may be impaired 
after allergen exposure (Barnes, 1996; Hamid et al., 2003).
1.2.3 EOSINOPHILS
Eosinophils play a predominant role in the late asthmatic response (Goldsby et al., 2000). 
The number of eosinophils in the airways has been correlated to the severity of asthma
6
CHAPTER 1
(Hamid et al., 2003). In the bronchoalveolar lavage (BAL) fluid of sensitised and allergen 
challenged guinea pigs the number of eosinophils in the airways are shown to 
progressively increase after an hour until a peak of 24 hours (Toward & Broadley, 2004). 
This correlates with the late asthmatic response. Eosinophil recruitment is believed to 
occur by two exclusive pathways. The first is through the release of TNF-a by degraded 
mast cells, this acts on epithelial and endothelial cells causing the release of eosinophil- 
directed cytokines, such as granulocyte macrophage colony-stimulating factor (GM- 
CSF), and chemokines, such as eotaxin (Barnes, 2002a). The second pathway involves 
the release of IL-5 by recently activated naive T cells. IL-5 provides the signal for 
eosinophils to mobilise from the bone marrow and it also enhances the chemoattractant 
potential of tissue chemokines (Bames, 2002a). Once in tissue, eosinophils can amplify 
the inflammatory cascade by producing their own cytokines (Rothenberg, 1998). 
Eosinophils are not very phagocytic but contain granules that hold highly charged and 
basic proteins. IL-3, IL-5, GM-CSF, IL-lp and platelet activating factor can degranulate 
eosinophils (Chapoval et al., 1999) causing the release of the granule proteins. There are 
four types of granule proteins released from eosinophils; these are major basic protein 
(MBP), eosinophil cationic protein (ECP), eosinophil derived neurotoxin (EDN) and 
eosinophil peroxidase (EPO). MBP, ECP and EPO are all able to cause histamine release 
from mast cells. ECP is also able to damage target cells by causing voltage-insensitive, 
ion non-selective pores therefore allowing an influx of potentially damaging ions such as 
calcium (Rothenberg, 1998). MBP is believed to have a pathogenic role in asthma as it 
has been shown to cause damage to airway epithelial cells and levels of MBP in the 
airway decline in correlation with improved airway function (Bames, 2002a).
In addition to basic proteins, eosinophils can also produce LTC4, Platelet Activating 
Factor (PAF) (Chapoval et al., 1999), reactive oxygen species (ROS), transforming 
growth factor (TGF) a and p, TNF- a, IL-1, IL-3, IL-5, IL-6 and GM-CSF (Busse & 
Lemanske, 2001) all of which can contribute to airway inflammation via various 
mechanisms such as airway smooth muscle contraction, increased vascular permeability 
and mucus secretion. They are also able to chemoattract more inflammatory cells by 
releasing the chemokines, eotaxin, Macrophage Inflammatory Protein (M lP)-la and 
RANTES (Nickel et al., 1999). A role for eosinophils in airway remodelling may also
7
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exist as they produce fibrogenic growth factors, elastase and matrix metalloproteinases 
(MMP) (Bousquet et al., 2000).
1.2.4 T-LYMPHOCYTES
T-lymphocytes are essential in the asthmatic inflammatory response, they can be grouped 
depending whether they have a CD4 or CD8 surface cell marker. Generally CD4+ cells 
are T helper (Th) cells, whereas CD8+ are T cytotoxic (Tc) cells. It is the Th cells that are 
presented an allergen by an APC and as a result become active. As previously mentioned 
Th cells can be further divided into Thl and Th2 cells depending on the presence of 
various cytokines. Th2 cells are more frequently found in asthmatics and it is these cells 
that release IL-4 and IL-13 which lead to IgE release from plasma cells. The cytokines 
that T-lymphocytes release can also serve to attract and activated other cell types. 
Bronchial hyperresponsiveness and eosinophil number and activation has been shown to 
correlate with activated CD4+ lymphocytes (Robinson et al., 1993). Lymphocytes may 
play a role in airway remodelling as there is some evidence that they stimulate the 
synthesis of matrix proteins such as collagen I, III and fibronectin (Postlethwaite et al., 
1992; Postlethwaite & Seyer, 1991).
1.2.5 NEUTROPHILS
Neutrophils do not have a clear role in asthma. Some studies have shown a rapid influx of 
neutrophils into the airways following a stimulus challenge in asthma models (Fabbri et 
al., 1984; Matsumoto et al., 1999). This influx was associated with bronchial 
hyperresponsiveness suggesting there is a potential role for neutrophils. Evidence of a 
neutrophilic asthma, where neutrophils predominate over eosinophils, exists (Wardlaw et 
al., 2002) though results are controversial. Neutrophils contain reactive oxygen species 
and proteases, that are both capable of causing damage to the airways if released. 
Therefore, neutrophils have the potential to cause airway inflammation. In sensitised and 
allergen challenged guinea pigs airway neutrophils were shown to increase after an hour, 
peak at the end of the early asthmatic response and had subsided after 12 hours (Toward 
& Broadley, 2004) suggesting neutrophils may play a role in the early phase 
bronchoconstriction associated with asthma. There is a strong association between
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neutrophilic inflammation of the airways and severe asthma (Jatakanon et al., 1999; 
Wenzel et al., 1997), steroid resistant asthma (Pavord et al., 1999; Wenzel et al., 1999) 
and the sudden onset of fatal asthma (Sur et al., 1993).
1.2.6 DENDRITIC CELLS
The role of dendritic cells is primarily as APCs. As dendritic cells express high levels of 
MHC class II molecules they are more potent APCs than macrophages and B cells 
(Goldsby et al., 2000). There are several different subtypes of dentritic cells, however, 
the two that have the most prominent role in asthma are myeloid dentritic cells (mDC) 
and plasmacytoid dendritic cells (pDC) (Bames, 2002a). These cells are crucial in 
determining the outcome of allergen encounter in the lung (Lambrecht, 2008). Under 
normal conditions the outcome of inhalation of a harmless allergen would lead to 
immunological tolerance. The allergen would be taken up by both mDCs and pDCs. 
Under normal conditions the mDCs would be partly mature and the T-cell response they 
induce is characterised by cell division and not differentiation to effector cells (Bames, 
2002a) and therefore result in immunological tolerance. This process is regulated by 
pDCs, cyclooxygenase-2 derived prostaglandins and complement activation (Bames, 
2002a).
Th2 sensitisation to an allergen can also be caused by mDCs (Lambrecht, 2008). For this 
to occur it seems that mDCs need to be activated, or matured (Bames, 2002a). Several 
factors can cause this. Toll-like receptor agonists, such as endotoxin, adjuvants, viral 
infection, overexpression of GM-CSF and cigarette smoke have all been implicated in 
causing Th2 sensitisation through activation of mDCs (Bames, 2002a). Activation of 
mDCs can be direct, by factors such as low dose toll-like receptor agonists or adjuvants, 
or indirect (Bames, 2002a). Indirect activation can be caused by factors leading to 
epithelial activation, e.g. cigarette smoke, increasing the mDC/pDC balance, e.g. GM- 
CSF overexpression, or by the loss of pDC tolerogenic function, e.g. viral infection 
(Bames, 2002a).
Dendritic cells may also have a role in the effector phase of asthma as it appears that 
‘inflammatory’ dendritic cells are necessary and sufficient for secondary immune 
responses to the allergen (Bames, 2002a). The fact that dendritic cells have an
9
CHAPTER 1
inflammatory role in asthma has led to the development of novel anti-allergic compounds 
aiming to combat this inflammatory effect (Lambrecht, 2008).
1.2.7 CYTOKINES AND GROWTH FACTORS
Cytokines and growth factors play a huge role in asthma, one that goes way beyond the 
scope of this thesis. Some have a pro-inflammatory role in asthma whereas some have the 
opposite. Table 1 describes the roles of some of the more important pro-inflammatory 
cytokines and growth factors in asthma.
Cvtokine / Growth Factor Effect in Asthma Mechanism
IL-ip Enhances disease Increases inflammation
IL-4 Enhances disease Increases IgE production and 
number of Th2 cells
IL-5 Enhances disease Increases eosinophil number
IL-6 Enhances disease Increases inflammation
IL-9 Enhances disease Increases mast cell number
IL-10 Decreases disease Decreases inflammation
IL-12 Reduces disease Increases Th 1 number
IL-13 Enhances disease Increases IgE production and 
induces airway remodelling
IL-17 Enhances disease Increases neutrophil number
IL-18 Reduces disease Increases IFN-y release
IL-25 Enhances disease Increases Th2 number
EGF Enhances disease Induces mucus secretion
GM-CSF Enhances disease Increases eosinophil and 
neutrophil number
IFN-y Reduces disease Decreases Th2 number
NGF Enhances disease Increases AHR
TGF-p Enhances severe disease Increases fibrosis
TNF-a Enhances severe disease Increases inflammation
10
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TSLP Enhances disease Increases Th2 number
VEGF Enhances disease Induces angiogenesis
T a b le  1- A list o f cytokines and growth factors involved in asthma and the response they cause. Adapted from 
(Bames, 2008). IL = Interleukin; EGF = Epidermal growth factor; GM-CSF = Granulocyte-macrophage 
colony stimulating factor; IFN = Interferon; NGF = Nerve growth factor; TGF = Transforming growth factor; 
TNF = Tumour necrosis factor; TSLP = Thymic stromal lumphopoietin; VEGF = Vascular endothelial growth 
factor.
1.2.8 HISTAMINE
Histamine plays a fundamental role in causing airway inflammation and 
hyperresponsiveness in asthma. It is stored in, and then released from, mast cells through 
an IgE mediated pathway. Upon release, histamine constricts airway smooth muscle in 
the large and small airways, causes plasma exudation and bronchial vasodilation. 
Histamine mediates its effect through three subtypes of receptor, Hi, H 2  and H 3 .  Although 
all have been implicated in the airway response to histamine (Hill, 1990), it appears the 
main effect is through the Hi receptor as this is the receptor that causes contraction of 
airway smooth muscle when active. The activation of macrophages and enhancement of 
eotaxin-induced chemotaxis of eosinophils are suggested as roles for histamine (Das et 
al., 1997). More recently a histamine H4 receptor was identified and was suggested to 
have a role in the immune system (Zampeli & Tiligada, 2009). A H4 receptor antagonist, 
JNJ-7777120, has proved to be effective in animal models and is expected to enter 
clinical trials soon (Engelhardt et al., 2009).
1.3 AIRWAY HYPERRESPONSIVENESS (AHR)
Asthmatic airways are prone to increased responsiveness to a variety of stimuli (1987). 
These stimuli are known as direct and indirect stimuli. Direct stimuli are pharmacological 
agents administered exogenously and act directly on specific bronchiolar smooth muscle 
receptors to cause constriction (O'Byme et al., 2009). These agents include histamine and 
methacholine which act on histamine (Hi) and muscarinic receptors respectively. 
Eicosinoid mediators such as prostaglandins, thromboxanes and leukotrienes can also
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induce AHR (O'Byme et al., 2009). Indirect stimuli include natural stimulants such as 
cold air or exercise. Adenosine monophosphate (AMP) is also classified as an indirect 
stimulus. These stimulants indirectly cause a bronchoconstriction by causing the 
endogenous release of bronchoconstriction mediators from airway inflammatory cells 
(O'Byme et al., 2009). Direct and indirect stimuli contribute to the exacerbations of 
asthma by causing airway obstruction and bronchospasm. AHR is used as a test when 
diagnosing asthma. Subjects inhale a direct stimulus, such as histamine, and levels of 
bronchoconstriction are measured. Although non-asthmatics can respond to direct stimuli 
the dose required to elicit a response is far greater than would be required by asthmatics. 
The term AHR encompasses both airway hyperreactivity and airway hypersensitivity. 
Airway hyperreactivity is commonly used erroneously to mean increased responsiveness 
to a variety of stimuli whereas it actual means a greater degree of closure in the airways 
(O'Connor et al., 1999). Airway sensitivity is a decrease in the threshold of the airways to 
react to stimuli, therefore sensitive airways respond to a dose of stimuli that would have 
no effect on normal airways. Figure 2 demonstrates the shift to the left hypersensitive 
airways cause on a dose response curve and the increase in gradient that hyperreactive 
airways show. The figure of PC20 is the provocative concentration of the 
bronchoconstrictive agent required to cause 20% reduction in the forced expired volume 
over one second of expiration (FEVi) (O'Connor et al., 1999).
How AHR develops is not well known. There is evidence that an increased amount of 
MBP (released from eosinophils) leads to an increase in the number of damaged 
epithelial cells and an increase in AHR (Wardlaw et al., 2002). It is possible that damage 
to the epithelial cells could lead to a greater exposure of irritant receptors situated on the 
airway nerves meaning that the airways become hyperresponsive to stimuli as there are a 
greater number of receptors for the stimuli to activate. These receptors are those activated 
by direct stimuli such as histamine (Hi), muscarinic and leukotriene receptors whose 
activation results in bronchoconstriction of the airway smooth muscle.
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Figure 2 - Schematic diagram to demonstrate the differences between normal and asthmatic airways in 
response to an increasing dose o f bronchoconstrictor agent. Figure adapted from (Lotvall et al., 1998).
1.4 AIRW AY REiMODELLING
The long-term inflammation caused by repeated asthmatic episodes and subsequent repair 
mechanisms can cause irreversible structural changes in the airways commonly seen as 
an increase in airway wall thickness (Bousquet et al., 2000). Thickening has been 
observed in all layers of the asthmatic airway wall, a phenomenon known as ‘airway 
remodelling’ (Roberts, 1995). Hegele (2000) states that airway remodelling may 
exacerbate the chronicity and progression of asthma. This suggests that airway 
remodelling could be part of a vicious cycle that results in further thickening of the 
airway wall leading to more severe asthma.
The pathological changes of airway remodelling can be accounted for by four main 
changes in the airways (figure 3); subepithelial fibrosis, increased smooth muscle mass, 
goblet cell hyperplasia / metaplasia leading to excessive mucus secretion and
13
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angiogenesis / increased vascularity. The combination of these features leads to 
permanent thickening of the airways which results in increased resistance to airflow 
which is exacerbated during bronchial contraction and bronchial hyperresponsiveness 
(Bousquet et al., 2000). Goblet cell hyperplasia and subepithelial fibrosis has been 
observed in mild asthma, whereas increased smooth muscle mass appears to be mainly a 
feature of severe asthma (Woodruff & Fahy, 2002).
1.4.1 SUBEPITHELIAL FIBROSIS
Subepithelial fibrosis is defined as the thickening of the basement membrane caused by 
the deposition of extracellular matrix (ECM) proteins at the subepithelial space (Roche et 
al., 1989). The role of the ECM is to provide structural support and act as a physical 
barrier in the airways. It is comprised of various molecules including collagen type I, III, 
IV and V, elastin, microfibrils, proteoglycans, laminin and fibronectins. Collagen is the 
most abundant protein in the ECM, with type I predominating. Type I gives structural 
support to the alveolar, bronchial and vascular walls. This structural support is through 
fine fibres called fibrils. Type III collagen is essential for type I collagen fibrillogenesis 
(Bienkowski et al., 1990; Bradley et al., 1974; Hay, 1995; Leblond & Inoue, 1989). The 
role of type IV collagen is to act as a structural scaffold for binding laminin and 
proteoglycans, leading to the development o f the basement membrane (Leblond and 
Inoue 1989). Finally, the role of type V collagen in the lung is unclear.
Elastin causes the lungs to retain its shape after inspiration and expiration. It has been 
localised to the alveoli, pleural conducting airways and vascular tissues. Elastin can be 
degraded by the matrix metalloproteinases (MMP) 2 (gelatinase A), 9 (gelatinase B) and 
12 (macrophage elastase). This is essential for tissue remodelling and physiological 
development. However, upregulation of the MMPs is believed to occur during asthma 
(Locke et al., 2007), leading to decrease in lung structure but potentially preventing 
airway remodelling. Tissue inhibitor of metalloproteinases (TIMPs) breakdown 
metalloproteinases resulting in an increase in matrix proteins such as elastin. Whilst this 
is beneficial in a condition such as emphysema, in asthma an increase in TIMPs would 
cause an excess matrix accumulation in the asthmatic airways (Barnes, 2002a).
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Figure 3 - A schematic diagram to show the difference between normal lung structure (A.) and an asthmatic 
lung after repeated allergen exposures (B.). Mucus levels are increased, as are goblet cells. Epithelial shredding 
has occurred allowing the inflammatory cells to penetrate the subepithelial layer. Levels o f smooth muscle cells 
and blood vessels have increased whereas, elastin levels are dramatically reduced. A thickening o f the lamina 
reticularis is also observed. Diagram adapted from (Hu et a l,  2007).
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It is hypothesised that an imbalance between synthesis and degradation is what causes 
ECM protein deposition (Yamauchi, 2006) and as a result a 2-3 fold increase in the 
thickness of the lamina propria and reticularis (Brewster et al., 1990; Jeffery et al., 1989; 
Kuwano et al., 1993; Roche et al., 1989). Increased deposition of collagen types I, III and 
V, fibronectin, laminin, and elastin (Elias et al., 1999; Freyer et al., 2004; Freyer et al., 
2001; Laitinen et al., 1997) have been identified as some of the causative molecules of 
this thickening.
Upregulation of fibroblasts seems partly responsible for subepithelial fibrosis. Fibroblasts 
maintain the ECM by synthesising the ECM proteins such as collagen. Gizycki et al., 
(1997) suggest myofibroblasts, the intermediate between fibroblasts and smooth muscle 
cells, are responsible for matrix deposition in asthma as myofibroblast hyperplasia has 
been observed in the subepithelial layer of the airways. The increased level of fibroblasts 
in the airways appears to be a result o f overexpression of TGF-P and platelet-derived 
growth factor (PDGF) (Krymskaya et al., 2005). TGF-p can also cause the differentiation 
of fibroblasts into myofibroblasts and block matrix degradation by inhibiting proteolytic 
enzymes (Zhang et al., 1996)
Chetta (1997) demonstrated that the thickness o f the subepithelial layer is highly related 
to the severity of asthma but not related to the atopy or length of asthmatic history. 
However, Chu et al., (1998) reject the claim that there is a link between subepithelial 
thickness and asthma severity.
1.4.2 INCREASED SMOOTH MUSCLE MASS
Smooth muscle mass is increased in both the large and the peripheral asthmatic airways. 
This increased mass is a result of hyperplasia (increase in the number of cells) and 
hypertrophy (increase in the size of cells) (Munakata, 2006). Whether increased smooth 
muscle mass is caused mainly by hyperplasia or hypertrophy is controversial. Heard and 
Hossain (1973) suggested that the increase is predominately a result of hyperplasia. In 
contrast Ebina et al., (1993) describe two different observations. The first is increased 
muscle mass caused exclusively by hyperplasia restricted to the large airways, whereas 
the second is a result of smooth muscle thickening throughout the bronchial tree caused 
predominately by hypertrophy, with a small degree of hyperplasia in the large airways.
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The exact mechanism that leads to the increase of smooth muscle mass is unknown. 
Barnes (1996) suggests stimulation of airway smooth muscle cells could be a result of 
growth factors such as PDGF or endothelin-1. TGF-p has the ability to promote or inhibit 
smooth muscle growth (Cohen et al., 1997) suggesting that it could be involved. The 
factors that cause the increase of airway smooth muscle cause grand scale changes, with 
increases of 50-230% in fatal cases and 25-150% in nonfatal cases of asthma (James, 
1997).
1.4.3 GOBLET CELL HYPERPLASIA AND METAPLASIA
Goblet cell hyperplasia and metaplasia is commonly observed in mild, moderate and
severe asthma (Yamauchi, 2006). Ordonez et al., (2001) reported that a statistical 
increase in goblet cells and stored mucin was observed in the airways of asthmatics 
compared to non-asthmatics. When an increased number of goblet cells release mucus 
then bronchial obstruction occurs as a result o f the mucous plugging the airways. This is 
observed in the central and peripheral airways of sufferers of both chronic and severe 
asthma (Andoh et al., 1992).
Rogers (1994) proposed that metaplasia from epithelial cells into goblet cells is a result of 
mucus gene expression. This increased expression can be triggered by both 
environmental pollutants and host factors (Levine, 1995). A component in cigarette 
smoke, acrolein, has been shown to cause expression of the epithelial MUC5AC gene and 
therefore cause metaplasia in rat models (Borchers et al., 1999). Similarly, MUC5AC and 
MUC2 genes have been shown to be upregulated by IL-4, IL-9 and IL-13 using in vivo 
models (Temann et al., 1997). The upregulation of these genes and resultant goblet cell 
hyperplasia leads to hypersecretion of mucus, which is a serious issue in asthma as it can 
plug the airways contributing to airflow limitation, airway hyperresponsiveness and in 
severe cases, mortality (Morcillo & Cortijo, 2006).
1.4.4 ANGIOGENESIS AND INCREASED VASCULARITY
More vessels and a greater percentage area of vasculature are observed in the lamina
propria of asthmatics than there are in non-asthmatics (Orsida et al., 1999). Whether this 
is primarily a result of angiogenesis (the formation of new blood vessels) or
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microvasculature enlargement is unclear. The microenvironment in asthma has been 
shown to have the potential for angiogenesis and in fact Li and Wilson (1997) found 
changes suggesting new vessel formation in mild asthma. Several factors that are 
involved in angiogenesis have been identified, such as fibroblast growth factor 
(Montesano et al., 1986), hepatocyte growth factor (Nakamura et al., 1984) and PDGF 
(Ishikawa et al., 1989).
On the contrary, a study of the membrane bronchioles by Kuwano et al., (1993) suggests 
airway remodelling is a result of enlargement of the microvasculature. Whether 
angiogenesis or microvasculature enlargement predominate a correlation between number 
of airway wall blood vessels and asthma severity exists (Lazaar & Panettieri, 2003).
1.5 TREATMENT
Asthma therapeutics target inflammation, bronchoconstrictions and narrowing of the 
airways. Both symptom relievers and preventers are clinically available. The drugs used 
can be broadly classified as either bronchodilators or anti-inflammatories. Treatment is 
dependent on the severity of the disease, with mild asthma being treated with a short- 
acting bronchodilator whereas severe asthma is treated with oral steroids. Guidelines for 
the treatment of asthma were drawn up by the British Thoracic Society (Wu et al., 2008) 
(table 2).
Short acting p2 -adrenoreceptor agonists are administered to control mild asthma as they 
are bronchodilators. Beta-agonists are the most effective bronchodilators clinically 
available as they are effective at protecting against the bronchoconstriction caused by 
exercise, cold air and allergen (Bames, 1995). The binding of the agonists to the p2- 
adrenoreceptor causes activation of the receptor; this leads to the stimulation of the 
enzyme adenylyl cyclase, which converts adenosine trisphosphate (ATP) into cyclic 
adenosine monophosphate (cAMP). The formation of cAMP causes relaxation of the 
bronchial smooth muscle via downstream signals. Two types of p2-adrenoreceptor 
agonists are available, short acting and long acting. Short acting agonists, such as 
salbutamol, are used when required for symptom control, whereas long acting agonists, 
such as salmeterol, cause a prolonged bronchodilation for more than twelve hours
18
CHAPTER 1
(Boulet, 2004). However, there have been studies that cast doubt on the safety of long 
acting P2 agonists. It has been suggested that long acting P2 agonists such as salmeterol 
may increase the risk of asthma deaths (Salpeter et al., 2006). Recently concerns have 
been reduced as a result of reassuring data (Moore, 2009; Nelson et al., 2009).
STEP 1 Inhaled short acting p2 agonist
Mild Asthma e.g. salbutamol
STEP 2 + Low dose inhaled corticosteroid 
e.g. fluticasone propionate
STEP 3 + Increasing doses of inhaled corticosteroid + 
inhaled long acting P2 agonist 
e.g. salmeterol
STEP 4 + Oral steroids
Severe Asthma e.g. dexamethasone
Table 2 - Recommended guidelines for managing increasingly severe asthma in adults. Adapted from 
British Thoracic Society (Wu et a l 2008).
Another method to control the immediate bronchoconstriction in asthma is to target the 
muscarinic receptor. In the airways acetylcholine is released from vagus nerves, when 
this binds with the muscarinic receptor contraction of the smooth muscle and increased 
secretion of mucus occurs (Katzung, 2004). Muscarinic receptor antagonists, such as 
ipratropium bromide, competitively inhibit this acetylcholine effect. Ipratropium bromide 
is a non-selective muscarinic receptor and therefore blocks the Mi-, M2 - and M3 - 
receptors (Barnes, 2001). However, this is not efficient as the M3-receptor mediates the 
bronchoconstriction and is therefore the target, whereas the M2 -receptor inhibit 
acetylcholine release and is therefore beneficial (Bames, 2002a). Thus far, M3-selective 
anatagonists have proved difficult to develop (Maesen et al., 1993). The fact that M3-
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receptors can cause mucus secretion suggests that the inhibition of these receptors is 
beneficial when it comes to controlling airway remodelling.
Phosphodiesterase (PDE) is another target for asthma therapeutics. PDE enzymes 
decrease intracellular levels of cyclic adenosine monophosphate (cAMP) by catalysing its 
degradation to inactive AMP. Inhibiting PDE causes increased intracellular levels of 
cAMP which has several effects such as relaxing smooth muscle and inhibition of 
inflammatory cell activity. Methylxanthines, such as theophylline, are non-selective 
phosphodiesterase inhibitors. Through this inhibition of PDE, levels of cAMP increase 
and smooth muscle relaxation and anti-inflammatory actions can occur therefore 
attenuating the early phase bronchoconstriction associated with asthma. It is possible that 
theophylline works through another mechanism as it can inhibit cell surface adenosine 
receptors (Katzung, 2004). Adenosine has been shown to cause contraction of airway 
smooth muscle and to provoke histamine release from mast cells (Katzung, 2004). 
Therefore, inhibiting adenosine would also attenuate the early bronchoconstriction.
There is increasing evidence that theophylline has anti-inflammatory effects in asthma 
such as activation of histone deactylase (HDAC), which increases anti-inflammatory 
gene transcription, (Barnes, 2002a), increased eosinophil apoptosis (Barnes, 2002a), 
inhibition of mediator release (Orange et al., 1971) and inhibition of superoxide anion 
release from neutrophils (Nielson et al., 1988). Whether this action is mediated through 
cAMP activation, inhibition of adenosine cell surface receptors or through another 
mechanism is unclear. The side-effects of theophylline has led to limited usage as the 
combination of p2-agonists and corticosteroids has less detrimental effects (Barnes, 
2002a). Theophylline is a non-selective PDE inhibitor; more recent developments have 
been the introduction of selective inhibitors of the PDE subtypes such as the PDE4 
inhibitor, roflumilast (see chapter 6 for more information).
Some asthma therapeutics are effective at treating the late phase bronchoconstriction by 
having anti-inflammatory properties and are therefore also effective against AHR and 
cellular influx. The most powerful of this type of drug are the corticosteroids. 
Corticosteroids are the most commonly used drug in the treatment of asthma, their 
mechanism of action and effects in asthma are described in chapter 5. Another group of 
anti-inflammatory drugs focus on the inhibition of leukotrienes. Leukotrienes cause
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airflow obstruction and bronchoconstriction. The leukotriene antagonist, montelukast, 
blocks leukotriene D4 having a bronchoconstrictor response by binding to the Cysteinyl 
Leukotriene 1 (CysLTl) receptor on mast cells, smooth muscle and eosinophils, therefore 
attenuating the early asthmatic response (Finnerty et a l, 1992; Taylor et a l,  1991) and is 
in fact as effective as short acting p2 -agonists (Hui & Barnes, 1991; Reiss et a l,  1997) 
when administered orally. As well as a bronchoconstriction, CysLTl receptor activation 
causes eosinophil recruitment, mucus secretion and plasma exudation (Barnes, 2002a). 
Therefore montelukast is also effective at inhibiting the late asthmatic response (Bames, 
2002a).
The expanding knowledge of asthma mechanisms and pathology correlates with an 
increase in anti-asthma therapeutics. Many of the recently developed compounds are 
highly specific to a certain mediator shown to have a role in asthma, examples of such 
include tyrosine kinase inhibitors, adhesion molecule inhibitors and nuclear factor kappa- 
light-chain-enhancer of activated B cells (NF-kB) inhibitors (Bames, 2002a). Another 
class of potential anti-asthmatic drugs are inhibitors of inducible nitric oxide synthase 
(iNOS) which are described in chapter 7. Despite an increasing number of anti-asthmatic 
therapeutics, a combination of P2 agonists and corticosteroids is still the main treatment 
for asthma (Bames, 2002b) and it is believed that the current pharmacological treatment 
of asthma will not change for the next 10 years (Caramori et al,  2009).
1.6 MODELS OF ASTHMA
The use of animal models of asthma is no new phenomenon. Although no animals exhibit 
asthmatic symptoms spontaneously, certain horses, cats and Basenji-greyhound cross 
dogs show some features (Bames, 2002a). Consequently the most common method of 
developing a model of asthma is using allergen sensitisation and subsequent challenge. 
Several different allergens can be used to elicit an asthmatic condition, including house 
dust mite (Cates et a l ,  2007), short ragweed extracts (Chapoval et a l,  1999) and 
ovalbumin (Smith & Broadley, 2007).
Allergen sensitisation and exposure has led to the development of several animal models 
of asthma in guinea pigs, mice, rats, monkeys and dogs. The similarity between the
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pulmonary response and histological findings to antigen exposure in the airways of 
guinea pigs and humans led to the guinea pig being the model of choice (Nabe et a l , 
1997). However, studies that use mice as models of asthma are becoming more common 
(Kumar & Foster, 2002; McMillan & Lloyd, 2004; Wegmann et al., 2005). This is 
because mice are low cost, have a well-characterised immune system, knock-out mice are 
more achievable than other small species and antibodies for molecular studies in 
inflammatory mediators are readily available.
Several models of asthma concentrate on acute inflammation following antigen exposure 
(McMillan & Lloyd, 2004). These short-term models develop an inflammatory response 
which is limited to the proximal airways and as a result is not associated with the chronic 
pathological changes associated with airway remodelling (Wegmann et a l , 2005). Many 
studies also use anaesthetised animals (Johnson & Broadley, 1999; Underwood et a l , 
1995), however, the possibility exists that the anaesthetic may interfere with the vagal 
tone or sensory reflex (Toward & Broadley, 2004).
Clearly there are several advantages and disadvantages between species when it comes to 
using them as a model of asthma. The advantages and disadvantages of guinea pig and 
mouse models of asthma are discussed in greater detail in chapters 3 and 4, respectively. 
Ultimately no animal model can be completely perfect when it comes to representing 
human asthma; however, several models display many of the characteristics of asthma. 
Therefore, they have an important role as the first means of testing asthma therapeutics.
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1.7 AIMS
The overall aims of this thesis are as follows:
• Develop acute and chronic models of asthma in guinea pigs and mice, which 
demonstrate the features of human asthma -  early and late asthmatic responses to 
allergen challenge, airway hyperresponsiveness, airway inflammatory cell influx 
and changes in lung histology.
• Evaluate the effects of anti-inflammatory compounds belonging to the steroid, 
phosphodiesterase type IV inhibitor and inducible nitric oxide synthase inhibitor 
classes on these acute and chronic guinea pig and mouse models of asthma.
• Assess what effect acute and chronic ovalbumin challenges have on lung oedema 
in sensitised guinea pigs and whether corticosteroid treatment attenuates this by 
using magnetic resonance imaging.
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2.1 MATERIALS AND EQUIPMENT
A full list of materials and equipment used can be found in Appendix 1. Ovalbumin 
(OVA) was the allergen of choice to cause the sensitisation and effector phase of asthma.
2.2 ANIMAL EXPERIMENTS
2.2.1 ANIMAL WELFARE
All animals were obtained through the Joint Animal Service department of Cardiff 
University from Harlan UK Ltd. Upon arrival the animals were given one week to 
habituate to their surroundings before any experiments began. They were housed under 
conventional conditions with a twelve hour light/dark cycle, maintained room 
temperature of 20°C±2°C and a humidity of 50%. All experiments were carried out in 
accordance with the Animal Scientific Procedures Act 1986, under valid Home Office 
project and personal licences. Experienced technicians were in charge of the welfare of 
the animals. Before beginning any experiments the animals were exposed to the system 
that measures their airway function to ensure it was not a novel environment and the 
animals were habituated when readings were taken. The guinea pigs used in chapter 8 
were kept at GlaxoSmithKline, further details can be found in section 8.3.
2.2.1.1 GUINEA PIGS
Male Dunkin-Hartley guinea pigs (200-25Og) were used for all research involving guinea 
pigs. They received commercial guinea pig pellets, supplemented with ascorbic acid, and 
drinking water ad libitum. The guinea pigs were housed in grid-floor cages in groups of 
six and in order to enrich the environment, a cardboard tube and hay was supplied. An n 
of 6 was used for all experiments.
2.2.1.2 MICE
Male BALB/c mice (20-25g) were the breed used for all mouse studies. They were 
housed in groups of six in plastic cages, with a sawdust base, and a removable grid roof.
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Food and drinking water was supplied ad libtum. For environmental enrichment 
cardboard tubes were supplied. An n of 6 was used for all experiments.
2.2.2 SENSITISATION PROCESS
2.2.2.1 GUINEA PIGS
Guinea pigs in all studies were sensitised by an intraperitoneal injection of a mixture of 
OVA (100 pg) and aluminium hydroxide (Al(OH)3) (100 mg) in phosphate-buffered 
saline (PBS). The mixture was stirred for two hours prior to injection to ensure the OVA 
and Al(OH) 3  were completely dissolved. Al(OH)3  was used as an adjuvant to boost the 
immune response to OVA and promote the development of sensitization. 1 ml of the 
suspension was administered bilaterally to the guinea pigs on day 1 and day 5, all 
procedures then commenced on day 14. This method of sensitization was developed by 
Smith and Broadley (2007).
2.2.2.2 MICE
The sensitisation process for mice used the same OVA mixture as in guinea pigs. 
Intraperitoneal injections of 0.25 ml bilaterally were administered on days 1 and 5, with 
procedures commencing on day 14 (Femandez-Rodriguez et al., 2008).
2.2.3 MEASURING LUNG FUNCTION IN GUINEA PIGS
Throughout all studies non-invasive methods were employed using plethysmography, an 
airtight chamber, to measure airway function. For respiration to occur there must be a 
difference in pressure between the mouth or nose and the alveoli, this is known as the 
pressure difference. If the difference in pressure is divided by the airflow then the 
outcome is a measure of airway resistance (Raw)- However, airway conductance (Gaw) is 
regarded as a better measurement of airway function as this incorporates a change in 
transpulmonary pressure and lung tissue tension (Griffiths-Johnson et al., 1988). In 
asthma differences in the alveoli pressure occur and therefore changes in the volume of 
air in the lung, or thoracic gas volume (TGV), occur. Taking this into account a value of 
Gaw -  TGV is used for measuring airway function. This value is known as specific airway 
conductance (sGaw)-
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The plethysmograph allows sGaw to be calculated. The pressure in the sealed chamber, 
box pressure, will decrease and increase in line with the pressure changes between the 
mouth or nose and alveoli of the subject if the chamber is kept at a constant temperature 
(Boyle’s Law) (West, 2005). Airflow is measured through a mask placed over the 
subject’s mouth and nose. The full description of how sGaw is derived, taking the TGV 
into account is found in Appendix 2.
Guinea pigs are very docile and as a result they can be restrained and have a mask placed 
over their snout without much complaint. As previously mentioned to measure sGaw in 
guinea pigs a plethysmograph is used (figure 2.1). This is a perspex box with a removable 
endplate at one end. The guinea pig was placed in a neck restrainer, this slides into 
another restrainer that has high sides and therefore stops the guinea pig from moving its 
body. A perspex mask was attached to the full body restrainer; it was sealed to the snout 
of the guinea pig by means of a cut balloon. The restrainer was then placed into the 
plethysmograph and the endplate clamped shut making an airtight environment. The 
plethysmograph measures two variables, airflow and box pressure. Airflow was measured 
by using a mesh pneumotachograph that is inside the perspex mask. The mask is 
connected to a UP1 pressure transducer by means of a plastic tube. Box pressure 
measures the change in air pressure in the plethysmograph. It is connected to a UP2 
pressure transducer by means of a plastic tube.
The pressure transducers are connected to a Biopac data system that converts the airflow 
and box pressure data into waveforms; this is displayed on the computer by using 
Acqknowledge software. Acqknowledge allows the analysis of the waveforms by 
comparing the gradients of airflow and box volume where the flow of the wave tends 
towards 0. The result is a value of specific airway conductance (sGaw). One reading takes 
5 seconds to record and an average of 8 breaths are captured in this time. An example of 
the waveform data obtained from the plethysmograph is shown in figure 2.1.
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Figure 2.1 - A simplified schematic o f the whole body plethysmograph and acquisition packs used to 
measure specific airways conductance sGaw, in conscious, restrained guinea pigs. Flow rate is measured 
through a flow pressure transducer which is connected to the pneumotachograph found in the mask that is 
placed over the snout o f  the guinea pig. Changes in box pressure are also measured through a transducer. 
The two wave forms are captured using a Biopac amplifier, a value o f sGaw is then established using 
Acqknowledge software by comparing the gradients o f  flow rate (red) and box volume (blue) where the 
flow o f the wave tends towards 0.
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2.2.3.1 ACUTE CHALLENGE PROTOCOL
On days 14 and 16 guinea pigs were exposed to histamine to determine whether airway 
hyperresponsiveness was occurring, this is explained in greater detail in section 2.7.1. 
The effector phase of asthma was triggered by an allergen challenge on day 15. The 
guinea pigs were exposed to either OVA (0.01%) or a control solution (saline). Exposure 
was carried out in a stainless steel exposure chamber (40 cm diameter, 15 cm height) with 
a Wright nebuliser attached. The nebuliser delivered the OVA or saline at an air pressure 
of 20 lb p.s.i. and at a rate of 0.3 ml/min. The guinea pigs remained in the chamber for 1 
hour, however, if they appeared to be distressed they were immediately removed from the 
chamber and exposure was considered complete. On day 16 following the second 
histamine challenge the guinea pigs were killed and a lavage was carried out. This 
allowed for total and differential cell counts to be obtained, following this the lungs were 
stored for histological analysis.
An additional group following the same protocol as the antigen-challenged group was 
run, however, this group was left for 72 hours after the test day before the second 
histamine challenge and lavage was performed. The purpose of this group was to observe 
whether any recovery occured in terms of airway hyperresponsiveness and cellular influx 
and histology when compared to the antigen-challenged group that had the lavage 
immediately after the final histamine exposure. Figure 2.2 highlights the various stages of
the acute protocol for guinea pigs. Ovalbumin (0.01%) 
or saline exposure
Lavage
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
----------v ---------
Ovalbumin
Sensitisation
Injections
 v
Histamine 
(1 mMol) 
Exposure
J  t
Histamine 
(1 mMol) 
Exposure + 
lavage for 
72 hour 
recovery
Figure 2.2 - A diagram to represent the protocol for acute ovalbumin and saline challenged guinea pigs. 
Lung function measurements are recorded on day 15 immediately following the OVA or saline exposure.
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2.23.2 CHRONIC CHALLENGE PROTOCOL
Exposure for the chronic model was carried out using the same equipment. Once again, 
all exposures lasted 1 hour unless the guinea pig appeared distressed. Day 15 was the first 
exposure day for each protocol, the control group was exposed to nebulised saline, 
whereas the antigen-challenged group was exposed to OVA (0.01%). Further exposures 
occurred every 48 hours from day 17 to day 29, once again this was saline for the control 
group. However, the antigen-challenged group was exposed to a higher dose of OVA 
(0.1%), 30 minutes prior to this exposure the group were given an intraperitoneal 
injection of the histamine Hi receptor antagonist, mepyramine (30 mg/ml). This protected 
against the fatal anaphylaxis that would be caused by massive histamine release as a 
result of the high level of OVA inhaled. The reason the high dose of OVA was used is 
because the guinea pigs would rapidly become tolerant to the lower dose and therefore 
the structural changes in the airways would be less likely to occur (John 2007).
Day 31 was the final exposure day and the day in which readings assessing lung function 
were taken. The control group were exposed to saline. The antigen-challenged group 
were exposed to OVA (0.1%), however, they had developed a tolerance to the high dose 
and therefore did not need mepyramine. In a similar way to the acute protocol a group 
was introduced that was allowed 72 hours to recover following the OVA challenge before 
the final histamine exposure and lavage were carried out. Figure 2.3 shows the chronic 
protocol for guinea pigs.
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Ovalbumin (0.01%) 
or saline exposure
Histamine (1 mMol) 
Exposure* Lavage
I
1 2 3 4 5 //14  15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Histamine 
(1 mMol) 
Exposure
Ovalbumin
Sensitisation
Injections
Ovalbumin (0.1%) + 
mepyramine (30 mg/ml) or 
saline exposures every 48 
hours
Ovalbumin 
(0.1%) or saline 
exposure -  test 
day
Histamine (1 
mMol) Exposure + 
lavage for 72 hour 
recovery groups
Figure 2 3  - A diagram to represent the protocol for chronic ovalbumin and saline challenged guinea pigs. 
Lung function is measured on day 30.
2.2.4 MEASURING LUNG FUNCTION IN MICE
As mice cannot be easily restrained an alternative method to sGaw must be used to 
measure airway function. Generally, enhanced pause (Penh) is the method of choice for 
measuring airway function in mice. As recording Penh does not involve restraint the 
mouse is allowed to move freely around the airtight chamber. This is advantageous over 
sGaw in the respect that as no restraint is involved stress is reduced and normal breathing 
patterns occur. Despite this, mice still need a great deal of habituation and as a result they 
were introduced to the chamber several weeks before any experiments began.
There is great controversy whether Penh should be used as a measurement for airway 
function as it may not necessarily represent a change in the lower respiratory tract 
(Nakaya et al., 2006). Hamelmann et al., (1997) supports the use of Penh by 
demonstrating that it correlates well with the pulmonary resistance measured with
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conventional two-chamber plethysmography in anaesthetised animals under mechanical 
ventilation. However, using Penh as a measurement of lung resistance is described as 
inappropriate by Adler et al, (2004). The use of Penh is described in section 9.1.4. 
Although the use of Pcnh is widely debated it prevents using a method of forced restraint 
on a mouse. The method by which Penh is derived is explained fully in Appendix 3. The 
chamber (height - 8 cm; diameter - 8 cm) is part of a system designed by Buxco for 
measuring airway function in mice, giving a value of enhanced pause (Penh). Figure 2.4 
shows the Buxco chamber.
Pneumotachograph
Main inlet for 
aerosol, controlled 
by valve
Main chamber
Reference chamber
Inlet for water bottle
Outlet to remove 
carbon dioxide
Inlet for calibration
Figure 2.4 - A photograph o f the Buxco chamber in which mice have free run whilst Penh is being measured. 
Diagram taken from The Jackson Laboratory (http://pga.jax.org/images/buxco2.jpg).
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2.2.4.1 ACUTE CHALLENGE PROTOCOL
In order to elicit the effector phase associated with asthma, mice were exposed to 
ovalbumin (0.5%) on day 15. On the previous day and day 16 the mice were challenged 
with methacholine (30 mg/ml) to determine the responsiveness of the airways. Like the 
guinea pig protocol, the OVA or saline challenge lasted for one hour. However, one OVA 
challenge is not sufficient to provoke an asthma-like inflammatory response in mice 
(Ohkawara et al., 1997), consequently another hour-long challenge occurred four hours 
after the start of the first challenge. Exposures were carried out in a perspex box (38 cm 
length; 20 cm width; 20 cm height) using the same nebuliser as in the guinea pig 
protocols. The acute protocol for mice is summarised in figure 2.5.
Ovalbumin (0.5%) or 
saline exposure x2
T
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Ovalbumin
Sensitisation
Injections
Methacholine 
(30 mg/ml) 
Exposure
Figure 2.5 - A diagram to represent the protocol for acute ovalbumin and saline challenged mice.
2.2.4.2 CHRONIC CHALLENGE PROTOCOL
The chronic challenge protocol for mice was very different to the guinea pig protocol. 
After sensitisation (days 1 and 5) and the first methacholine exposure (10 mg/ml) (day 
14), the mice were challenged three times a week for six weeks. They were challenged 
with OVA (2%) for 30 minutes, no protective drug, such as mepyramine, was needed as 
the mice could withstand the high dose of OVA immediately but did not become tolerant 
to it over time. The final challenge occurred on the first day of the seventh week (day 57)
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and lasted for one hour, readings were taken on this day. Unlike the acute group only one 
challenge was needed on the test day. The same protocol was followed using saline for a 
control group. Figure 2.6 shows the chronic allergen challenge protocol for mice.
Methacholine 
(10 mg/ml) 
Exposure
Ovalbumin (2%) or 
saline exposure -  test 
day
* I
1 2 3 4 5 // 14 15 & every 48hrs for 6 weeks // 57 58
t
 v ---------
Ovalbumin
Sensitisation
Injections
Ovalbumin (2%) or 
saline exposure
Methacholine 
(30 mg/ml) 
Exposure and 
Lavage
Figure 2.6 - A diagram to represent the protocol for chronic ovalbumin and saline challenged mice.
2.2.5 RECORDING EARLY AND LATE ASTHMATIC RESPONSES
2.2.5.1 GUINEA PIGS
Values for sGaw were taken 0, 15, 30, 45 and 60 minutes after antigen exposure, then 
hourly until 12 hours with a final reading being taken at 24 hours. Before exposure a 
baseline value was recorded. The other sGaw values at the different time-points were 
expressed as a percentage of baseline. If the percentage value was negative this signifies 
a trend towards bronchoconstriction whereas if it was positive it signifies 
bronchorelaxation.
The early asthmatic response (EAR) occurs within the first hour, however, it can often 
take up to 6 hours until the sGaw values returns to baseline levels. To allow for variability 
in guinea pigs, a value of maximum bronchoconstriction between 0 and 6 hours was used. 
The same principles apply for the late asthmatic response (LAR), as a result maximum
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bronchoconstriction values between 7 to 12 hours were used, to ensure the LAR is 
analysed correctly.
2.2.5.2 MICE
Prior to allergen challenge, baseline values of Penh were recorded. In the opposite way to 
sGaw, if a percentage change in Penh values was positive this would signify 
bronchoconstriction, whereas negative values were bronchorelaxation. Values of Penh 
following allergen challenge were recorded at 0, 20, 40, 60, 90 and 120 minutes, then 
hourly until 10 hours followed by a final reading at 19 hours for the acute protocol (24 
hours after first challenge) or 24 hours for the chronic protocol. The EAR of mice does 
not peak until around 2 hours after exposure, whereas the LAR tends to occur at around 7 
hours (Femandez-Rodriguez et al., 2008). In order to ensure maximum 
bronchoconstriction was being observed and to minimise variation between each mouse, 
a value of maximum percentage change in Penh between 0-6 hours and 7-10 hours was 
used for analysis.
2.2.6 RECORDING AIRWAY RESPONSIVENESS
2.2.6.1 GUINEA PIGS
AHR was also measured by using plethysmography. Whether AHR occurs or not was 
determined by the airway responses to 1 mMol of histamine. 1 mMol of histamine was 
used as this is considered the subthreshold dose; the guinea pig should not show any 
reaction to it before OVA exposure but if there is AHR there should be a response (figure 
2.7).
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2 0 - i
Omins 5mins
1 mMol 
-o- 3 mMol 
10 mMol-«o-
*=P<0.05 significantly di£farent from baseline 
-M-l (One-way Analysis of Variance followed by Durmett post test).
Figure 2.7 - A histamine dose o f  lm m ol is not significantly different from baseline values as seen with higher 
doses. Therefore 1 mMol is the best dose to use to induce airway hyperresponsiveness in antigen challenged 
guinea nigs.
Guinea pigs were given histamine by using a Wright nebuliser, instead of using a 
chamber the guinea pig was exposed using a plastic pipe (figure 2.8). The end of the 
nebuliser with the aerosol is attached to a J-bend at one end of the pipe; the other end 
leads out to an air filtration system, so as not to expose the surrounding environment to 
histamine. The pipe has a hole within three inches of the aerosolised end with a 
diaphragm over it by means of a balloon. The guinea pigs’ snout was placed into this hole 
while the nebuliser was running and they are exposed to the histamine for 20 seconds. A 
baseline value, measured as sGaw, was recorded before the histamine exposure and all 
other values were taken as a percentage of this. The time-points used were 0, 5 and 10 
minutes after histamine exposure.
The histamine exposures occurred 24 hours pre-OVA or saline exposure (day 14) and 24 
hours post-OVA or saline exposure (day 16) in acute models. In the chronic model 
histamine exposures occurred 24 hours pre-first exposure (day 14) and 24 hours post- 
final exposure (day 32). The purpose of performing a histamine exposure pre- and post­
ovalbumin or saline exposure was two-fold. Firstly, if there was a significant 
bronchoconstriction pre-ovalbumin or saline exposure when comparing values to the
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baseline reading then the guinea pig was already exhibiting some form of airway 
hyperresponsiveness and should not be used. Secondly, by comparing pre- and post­
ovalbumin or saline exposure it was possible to determine whether ovalbumin or saline 
causes airway hyperresponsiveness.
Exposure tunnel
Wright nebuliser
Nosepiece
Air filtration
Tubing
Figure 2.8 -  A schematic diagram to show how guinea pigs are exposed to histamine. The Wright nebuliser causes 
1 mMol histamine to be aerosolised through the exposure tunnel. The guinea pig is held with the nosepiece over its
snout for 20 seconds. Any excess histamine exits through the air filtration system.
2.2.6.2 MICE
Hyperresponsiveness in mice was measured using methacholine (10 mg/ml or 30 mg/ml). 
30 mg/ml was used for measuring hyperresponsiveness in the acute model and 10 mg/ml 
was used for the chronic model. These doses were used as they have previously been 
shown to cause a response in OVA challenged mice but not in saline challenged mice 
(Fernandez-Rodriguez et al., 2008). The higher dose would cause fatal anaphylaxis in the 
chronic model mice hence 10 mg/ml was used. The exposures were carried out in the
same Buxco chambers that were used to measure lung function.
The mice were challenged with methacholine both pre- and post-challenge. If a 
significant response to methacholine was observed pre-challenge then the animal exerting 
the response was removed from the experiment. The second methacholine challenge 
occurred after the final OVA challenge. The Buxco set up allowed the mice to be exposed 
to the methacholine whilst in the chamber. The protocol began with five minutes of 
baseline readings of which an average was taken. This was followed by one minute of
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intermittent methacholine exposure (one second exposure followed by five seconds 
without exposure on a continuous cycle). Finally, another five minutes of readings were 
recorded and averaged. The mean for the post-methacholine value was then expressed as 
a percentage of baseline. When the results were graphed post-challenge, 
hyperresponsiveness was shown as a significant increase in percentage change in Penh 
when compared to pre-challenged results.
2.2.7 MEASURING CELLULAR INFLUX
2.2.7.2 GUINEA PIGS
After the second histamine exposure the guinea pigs were killed by a lethal overdose of 
sodium pentobarbitone (Euthatal 400 mg/kg) by an intra-peritoneal bilateral injection. An 
incision into the neck was then made. Subsequently, the trachea was cannulated using a 5 
cm length of intravenous polypropylene cannula. The lungs were then completely 
removed from the guinea pig. Saline solution (1 ml/100 g guinea pig weight) was 
instilled into the lungs through the cannula and then recovered three minutes later. This 
process was repeated and the two amounts of recovered lavage fluid were combined. The 
lungs were inflated with 10% buffered formaldehyde solution (2 ml/100 g guinea pig 
weight) via the cannula and then submerged in 10% buffered formaldehyde. They were 
stored ready for further histological studies.
In order to measure the level of cellular influx two different counts were carried out on 
the lavage fluid. Firstly, the total number of cells (per ml of lavage fluid) were counted 
using a Neubauer haemocytometer under a light microscope at 100 x magnification. 10 pi 
of bronchoalveolar lavage (BAL) fluid was pipetted beneath the coverslip on the 
haemocytometer, capillary action enabled the fluid to be evenly distributed. When 
viewed under a microscope two grids of 25 squares can be observed on the 
haemocytometer. The number of cells in 5 of the squares was counted, always using the 
same squares (top left, top right, middle, bottom left and bottom right), and the total 
figure was multiplied by 5 to give an estimated amount of cells in 25 averaged. This was 
repeated for the other grid on the haemocytometer and an average was taken. As each of 
the squares measure 0.04 mm2 and 25 were counted, a figure of number of cells per 1 
mm2 was established. However, the depth of the chamber was 0.1 mm, therefore giving a
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number of cells per 0.1 mm3. As the number of cells per 1 ml (1 cm3) was required, the 
cell count figure was multiplied by 104.
The second count was a differential count. 100 pi of the lavage solution was centrifuged 
at 1000 rpm for 7 minutes onto a glass slide using a cytospin. The slide was then stained 
using 0.15% Leishman’s solution in 100% methanol. After 7 minutes it was removed 
from the solution and allowed to air-dry over night. Once dry, 200 cells were counted 
under a light microscope at 1000 x magnification to determine which leukocytes were 
present in the lavage fluid. The leukocytes counted were macrophages, eosinophils, 
lymphocytes and neutrophils (figure 2.9). Once all the cells had been counted the 
leukocyte populations were calcuated as a ratio of total cells in 1 ml.
Macrophage NeutrophilEosinophil Lymphocyte
Figure 2.9 - Photographs o f the four subtypes o f leukocytes, stained with Leishman’s solution, counted in a 
differential count. Diagram taken from (Gude et al., 1982)
Macrophages are the most common inflammatory cells found in the BAL fluid (Hamid et 
a l , 2003). Macrophages are the largest cells found in the BAL fluid with a diameter of 
15-20 pm (Gude et al., 1982). Eosinophils are easily definable as they have a bi-lobed 
nucleus which stains blue. The cytoplasm is full of red/pink stained granules. They are 
not as big as macrophages, measuring 10-14 pm in diameter (Gude et al., 1982). 
Lymphocytes, like macrophages, are mononuclear. They can vary in size from small (6-8 
pm), medium (8-10 pm) and large (10 pm or more) (Gude et al., 1982). However, the 
majority of them are small. As figure 2.10 shows they have a large spherical nucleus that 
stains a dark purple and a small blue cytoplasm. Neutrophils have a diameter measuring 
around 9-12 pm (Gude et al., 1982). The nucleus stains dark purple and is multi-lobed,
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made up of around two- to three-lobes. The cytoplasm contains granules that are smaller 
in size than those found in eosinophils, they stain a dark purple/pink colour.
2 2 ,1 2  MICE
As mice have a trachea with such a small diameter the tracheal internal wall was 
frequently damaged when cannulating causing the release of red blood cells and therefore 
contaminating the BAL fluid. Consequently, total cell counts were not carried out. 
Differential cell counts could still be undertaken and the method of retrieving the BAL 
fluid was the same as in guinea pigs with the exception that the mouse lungs were not 
removed until the BAL fluid was withdrawn. To prepare the slide for the differential 
count 200 pi of each sample of BAL fluid was centrifuged for 7 minutes at 1000 rpm at 
room temperature. After air drying, the slides were stained using Leishman’s stain 
(0.15% in 100% methanol) for 20 minutes then rinsed with distilled water.
The same inflammatory cells were counted as in the guinea pig protocol (figure 2.9). 
Once again 200 cells were counted and expressed as a percentage of inflammatory cell. 
However, as no total cell count occurred then estimating total number of inflammatory 
cell types in 1 ml was not possible.
2.2.8 QUANTIFICATION OF SERUM IMMUNOGLOBULIN G LEVELS 
USING AN ENZYME-LINKED IMMUNOSORBENT ASSAY
This is described fully in section 3.3.6
2.2.9 HISTOLOGICAL ANALYSIS OF GUINEA PIG AND MOUSE 
LUNGS
The lungs were removed from the guinea pigs or mice following cellular analysis and 
they were stored in formaldehyde. Once enough samples were collected to carry out 
histological analysis a 3-5 mm section from the superior left lobe was cut 1 mm below 
the bronchus from each sample and stored in histology cassettes. To process the sections 
they were put through the following protocol:
50% industrial methylated spirit (IMS) -  1 hour
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70% IMS -  1 hour 
90% IMS -  1 hour 
100% IMS -  1 hour 30 minutes 
100% IMS -  1 hour 30 minutes 
100% IMS -  1 hour 30 minutes 
50% IMS:50% chloroform -  overnight 
Chloroform -  1 hour 30 minutes 
Chloroform -  1 hour 30 minutes 
Paraffin wax -  6 hours
To embed the lung samples in wax the processed samples were placed in metal histology 
moulds, molten paraffin wax was then poured into the moulds and then they were left to 
set on a cold plate. A microtome was used to cut 3-5 pm sections of the embedded lung 
samples and the sections were subsequently fixed to glass slides and allowed to dry 
overnight. Once dry the slides were stained with one of the following protocols:
Haematoxylin & Eosin for general morphology
Xylene -  5 minutes
100% IMS -  5 minutes
100% IMS -  5 minutes
90% IMS -  5 minutes
70% IMS -  5 minutes
Distilled water -  5 minutes
Mayer’s Haematoxylin -  3 minutes
Rinse in distilled water
Running tap water -  5 minutes
Acid ethanol -  dip 8-12 times to destain
Running tap water -  2 minutes
Distilled water -  2 minutes
Eosin -  30 seconds
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90% IMS -  15 minutes 
100% IMS -  15 minutes 
Xylene -  45 minutes
Smooth muscle
Epithelium
Subepithelial
layer
Blood vessel
Figure 2.10 -  A chronic ovalbumin challenged guinea pig bronchiole that has been stained with haematoxylin and 
eosin to show general morphology (lOOOx magnification).
Picrosirius red stain for collagen
Xylene -  5 minutes
100% IMS -  5 minutes
100% IMS -  5 minutes
90% IMS -  5 minutes
70% IMS -  5 minutes
Distilled water -  5 minutes
0.5 g sirius red in 500 ml picric acid -  60 minutes
0.01 M hydrochloric acid -  2 minutes
Rinse in distilled water
Mayer’s haematoxylin -  30 seconds
Running tap water -  5 minutes
70% IMS -  5 minutes
90% IMS -  5 minutes
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100% IMS -  5 minutes 
100% IMS -  5 minutes 
Xylene -  5 minutes
Picrosirius red 
stained 
subepithelial layer 
showing collagen
Figure 2.11 -  A GW274150F treated chronic ovalbumin challenged mouse bronchiole that has been stained with 
picrosirius red to show collagen deposition (lOOOx magnification).
Alcian blue/periodic acid Schiff stain for goblet cells/presence of mucus
Xylene -  5 minutes 
100% IMS -  5 minutes 
100% IMS -  5 minutes 
90% IMS -  5 minutes 
70% IMS -  5 minutes 
Distilled water -  5 minutes
1% Alcian blue dissolved in 3% aqueous acetic acid (pH 2.5) -  5 minutes
Running tap water -  5 minutes
Periodic acid (0.5%) -  5 minutes
Running tap water -  5 minutes
Distilled water -  5 minutes
Schiffs reagent -  10 minutes
Running tap water -  10 minutes
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W
Mucin associated 
goblet cells
Figure 2.12 -  A GW274150F treated chronic ovalbumin challenged mouse bronchiole that has been stained with 
alcian blue/periodic acid SchifF to show mucin associated goblet cells (lOOOx magnification). Goblet cells stain 
bright pink as shown in the zoomed in picture.
Mayer’s haematoxylin -  20 seconds
Running tap water -  5 minutes
70% IMS -  5 minutes
90% IMS -  5 minutes
100% IMS -  5 minutes
100% IMS -  5 minutes
Xylene -  5 minutes
Alcian blue / periodic 
acid SchifF stained 
epithelium
Following each of the staining protocols a drop of DPX mountant medium was added to 
the slide and a coverslip was placed on top ensuring no air bubbles were trapped 
underneath the slip. Once dry photographs of the slides were then taken using a
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microscope at lOOOx magnification and a digital camera with 3 times optical zoom. The 
purpose of including haematoxylin & eosin stain was for qualitative and semi- 
quantitative analysis. Firstly it showed the general morphology of the bronchiole and as a 
result enabled easy differentiation between different treatment groups. Secondly a semi- 
quantitative method was applied to score the number of inflammatory cells present in the 
peribronchiolar area (the periphery of the small airways). Each of the individual slides 
from each treatment protocol was assessed by eye at random using a scale which 
recorded the number of cells as absent (0), minimal (1), slight (2), moderate (3), marked 
(4), or severe (5) (Barends et al., 2004).
Inflammatory cells
Figure 2.13 -  A semi-quantitative scoring method is used for assessing inflammatory cell influx in the lung 
tissue. Image A shows a naive guinea pig bronchiole that would be scored ‘1-minimal’. Image B shows a 
bronchiole from a chronic OVA challenged guinea pig that would be scored ‘4-marked’. The bronchioles have 
been stained with haematoxylin and eosin to show general morphology. Photographs o f the images were taken at 
lOOOx magnification. ImageJ software allows closer analysis o f the bronchioles by increasing the magnification.
Picrosirius red stain is used to enable analysis of the amount of collagen found around the 
bronchiole. This method enabled further comparisons between acute and chronic OVA 
challenged animals and respective drug treatments and also helped determine whether 
airway remodelling had occurred. The sections of picrosirius red and AB/PAS stained 
bronchioles were both analysed using ImageJ software. To measure the percentage of
45
CHAPTER 2
collagen in the bronchiole the lumen (including the epithelium) was drawn around as was 
the total bronchiole as shown in figure 2.13. The following formula was then applied:
Bronchiolar Collagen = 100 -  [(Lumen area Total bronchiole area) x 100]
Figure 2.14 -  To determine levels o f bronchiolar collagen firstly the lumen area (including the epithelium) is 
drawn around, then the total bronchiole area. They are divided by each other and multiplied by 100. The value is 
then subtracted from 100. The bronchiole is that o f a GW274150F treated chronic ovalbumin challenged mouse 
(lOOOx magnification).
Staining with AB/PAS identifies goblet cell associated mucin. As goblet cell hyperplasia 
is a feature of airway remodelling this staining protocol would also help determine the 
presence of the structural changes in the airways associated with chronic asthma. To 
measure the number of mucin-associated goblet cells in the epithelium a click/count 
method was applied using Image J. This involved counting each of the bright purple- 
stained mucin containing cells. Firstly the epithelium area was calculated by drawing 
around the lumen including and excluding the epithelium (figure 2.15) and using the 
following formula:
Epithelial area = Lumen including epithelium -  lumen excluding epithelium
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Figure 2.15 -  The area o f the epithelium is determined by drawing around the lumen (including the epithelium) 
then subtracting the lumen area (excluding the epithelium). The bronchiole is that o f a GW274150F treated 
chronic OVA challenged mouse (lOOOx magnification).
Although this method will enable any differences between acute and chronic challenges 
to be observed it does not distinguish whether the differences were caused by goblet cell 
hyperplasia or hypertrophy or whether epithelial shedding is contributing. Therefore, the 
AB/PAS positive points were counted (figure 2.16) and the following formula was 
applied to determine the mucin-associated goblet cells per 10000 epithelial pixels:
Mucin per 10000 = (Number of AB/PAS+ points + Epithelial area) x 10000
The outcome of this formula enabled any differences in goblet cell hyperplasia to be 
recorded.
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Figure 2.16 -  Each goblet cell (shown as a yellow dot) is counted to ensure the differences in mucin associated 
goblet cells is a result o f goblet cell hyperplasia not hypertrophy or epithelial shedding. The bronchiole is that o f  a 
GW274150F treated chronic OVA challenged mouse (lOOOx magnification).
2.2.10 MRI ANALYSIS
This is described fully in chapter 8
2.2.11 DRUG ADMINISTRATION
The effects that corticosteroids, a PDE4 inhibitor and an iNOS inhibitor have on acute 
and chronic models of asthma have been evaluated throughout this thesis. The drugs used 
were fluticasone propionate, dexamethasone, roflumilast and the iNOS inhibitor 
(GW274150F). Each of the drugs were administered 24 hours and 0.5 hours pre­
ovalbumin challenge and 6 hours post-ovalbumin challenge. The methods of 
administration, dose and vehicle for each drug are detailed in table 2.1.
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Drug Method of 
Administration
Dose Vehicle
Fluticasone
Propionate
Nebulised 
Inhalation 
(15 minutes)
0.51 mg/ml Saline -  40% 
DMSO -  30% 
Ethanol -  30%
Dexamethasone Intraperitoneal 20 mg/kg Saline -  50% 
DMSO -  50%
Roflumilast Oral 
(Gavage Needle)
1 mg/kg Methyl Cellulose 
(10mg in 10ml o f  sterile
h 2o >
INOS inhibitor 
(GW274150F)
Oral 
(Gavage Needle)
5 mg/kg Methyl Cellulose 
(lOmg in 10ml o f  sterile
h 2o >
Table 2.1 - List o f  the compounds used, administration route, dose and vehicle.
The fluticasone propionate vehicle of saline (40%): DMSO (30%): Ethanol (30%) was 
selected because there was difficulty in getting the drug to dissolve in saline and DMSO 
alone. Previous work in the laboratory had identified the saline:DMSO:ethanol mix as a 
vehicle for budesonide (Nevin & Broadley, 2004) and it was shown to have minimal 
side-effects whilst also ably dissolving the drug. Dexamethasone dissolved easily in 
saline (50%): DMSO (50%) (Toward & Broadley, 2004) as a result of which there was 
no need to introduce ethanol. Methyl cellulose was used as a vehicle as it is a viscous 
material that the drugs dissolved in easily. As a result of the viscosity the guinea pigs and 
mice took the drugs without any complaint or noticeable side-effects.
Fluticasone propionate was administered by inhalation to match the clinical route of 
administration (Barnes and Adcock, 2003). Clearly guinea pigs or mice cannot be given 
an inhaler so a 15 minute inhalation using a Wright nebuliser connected to a Perspex box 
measuring (38 cm length; 20 cm width; 20 cm height) was used. Dexamethasone was 
administered via the IP route because previous data had shown this route to inhibit 
successfully some of the features of asthma (Toward & Broadley, 2004). Roflumilast was 
given as an oral dose to match the clinical trial setting (Spina, 2008) and although limited
49
CHAPTER 2
clinical work has been carried out on GW274150F it was agreed that the oral route would 
be the best option (Nials, personal communication).
2.3 STATISTICAL ANALYSIS
In all studies that were comparing two points a two-tailed t-test was used for statistical 
analysis. If three or more groups were being compared a one-way analysis of variance 
(ANOVA) followed by a Bonferroni post test was used. All results were plotted as 
mean±SEM and a P value of <0.05 was considered significant. Figures 3.2b and 4.1b 
show raw data. However these graphs do not take variations in baseline calibration values 
into account, therefore % change from baseline graphs were used elsewhere with raw 
values shown in the legends. As guinea pigs and mice have slight variations in when they 
have an EAR and LAR, three methods were used to assess these parameters. Firstly, 
values of sGaw were plotted as a time course graph as % change from baseline, secondly, 
maximum bronchoconstriction values between 0-6 hours and 7-12 hours were recorded to 
account for the EAR and LAR, respectively. These were plotted as a histogram on the 
same graph as the time course plot. T Finally, area under the curve (AUC) analysis was 
carried out on the time course graph, assessing total AUC, EAR AUC (0-6 hours) and 
LAR AUC (6-24 hours). This allowed %.h to be measured and therefore offered another 
statistical approach. Graphs were drawn using GraphPad Prism 5 and results were 
analysed using GraphPad Instat 3.
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3.1 INTRODUCTION
3.1.1 GUINEA PIG MODELS OF ASTHMA
Guinea pigs have been used as models of pulmonary hypersensitivity for more than 100 years 
(Karol, 1994); however, the development of animal models of asthma is a more recent 
phenomenon (Cates et al., 2007). In 1983 it was shown that guinea pigs that were exposed to 
the organic chemical toluene diisocyanate demonstrated both early and late phase 
bronchoconstrictions, hyperreactivity towards cholinergic agonists and production of 
hypersensitivity antibodies (Karol, 1983). This was an early model of occupational asthma.
Although guinea pigs have proved an important model of asthma like all other animal disease 
models their effectiveness in representing human conditions has to be carefully considered. 
There are several advantages of using guinea pigs for models of asthma compared to larger 
species such as sheep and dogs. Guinea pigs are reasonably inexpensive and are therefore a 
relatively cost efficient model. They are also small in size and therefore easy to use. Guinea 
pigs also have advantages over other small animal models such as rats and mice. As they are 
so docile they can be restrained and therefore accurate measurements of airway function can 
be recorded without a need for anaesthesia. They also readily respond to histamine in a 
similar manor to humans (Zosky & Sly, 2007).
There are also several disadvantages in using guinea pigs as models of asthma. A major 
criticism in using all small animal models is that they do not develop an asthma-like 
condition naturally and therefore usually require an adjuvant in order to have an immune 
response (Zosky and Sly 2007). It is argued that using an adjuvant neglects the fact that 
humans are generally exposed at the respiratory mucosa by aeroallergens and as a result this 
could have immunological consequences (Cates et a l , 2007). Although Nabe et al., (1997) 
developed an aerosol sensitisation model an adjuvant was still required and sensitisation took 
4 weeks.
Guinea pigs are also sometimes overlooked as models because of the poor availability of 
species-specific reagents. Therefore the role of genetics in asthma cannot be as well defined 
in this model as it can be in mice where there is a vast availability of species-specific reagents 
(Zosky and Sly 2007). One of the main fundamental differences between guinea pigs and
52
CHAPTER 3
humans is that the main antibody present during a type 1 hypersensitivity reaction in guinea 
pigs is immunoglobulin (Ig) G1 whereas in humans it is IgE. Despite these disadvantages 
guinea pigs are still an important tool in understanding the mechanisms of asthma and in drug 
discovery and development.
3.1.2 GUINEA PIG OVALBUMIN MODELS
The majority of models of asthma use ovalbumin (OVA) as the allergen to provoke an 
immune response (Cates et al., 2007). OVA models have been developed in both conscious 
(Smith & Broadley, 2007) and anaesthetised (Johnson & Broadley, 1999) guinea pigs, 
however, it is possible that anaesthetic may interfere with the vagal tone or sensory reflex 
(Toward & Broadley, 2004). The availability of whole-body plethysmographs means that 
lung function can easily be measured in conscious restrained guinea pigs using specific 
airway conductance (sGaw) as a parameter (Griffiths-Johnson et al., 1988).
Several studies have shown that sensitising and challenging a guinea pig with OVA results in 
reproducible airway constriction responses similar to those observed in human asthma (Smith 
and Broadley 2007; Nabe et al., 1997, Karol 1994). Ideally a good model of asthma should 
display an early and late asthmatic response, airway hyperresponsiveness and cellular influx 
into the lungs (Smith and Broadley 2007). However, the chronic nature of asthma needs to be 
considered and the majority of guinea pig studies use only acute inflammation (Zosky and 
Sly 2007).
Studies that demonstrate chronic airway changes in the guinea pig airways after OVA 
challenge are rare, in fact Zosky and Sly (2007) state that there is no model in smaller 
laboratory animals that demonstrates both chronic remodelling and long-term airway 
hyperresponsiveness. It was not until recently that chronic OVA guinea pig models of asthma 
started appearing. Studies using multiple OVA challenges were shown to cause smooth 
muscle remodelling (Gosens et al., 2005) and goblet cell hyperplasia (Bos et al., 2007) but 
other features of asthma were not measured. More recently Bazan-Perkins, Sanchez-Guerrero 
(2009) showed airway remodelling, airway hyperresponsiveness and increased levels of 
cellular influx in the airways in a chronic guinea pig model, however, early and late asthmatic 
responses were not measured and airway hyperresponsiveness peaked around a third of the 
way through the study. Currently it seems there is a lack of guinea pig models which displays
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early and late phase bronchoconstriction, airway hyperresponsiveness, cellular influx into the 
lungs and airway remodelling.
The reason for the lack of chronic guinea pig models of asthma could be because of the issue 
of tolerance. Sensitised animals that are chronically exposed to an allergen can develop 
tolerance and therefore have a reduced allergic response (Schramm et al., 2003). Tolerance is 
somewhat of a double-edged sword. Studies have shown that exposure to cat dander during 
childhood can reduced the incidence of asthma in adulthood (de Meer et al., 2004; Roost et 
a l , 1999). However, if an animal model develops tolerance to repeated allergen exposure, 
then it would make chronic changes in remodelling more difficult to establish. Increasing the 
dose of allergen used could go some way in preventing tolerance, though measures must be 
taken to prevent the anaphylaxis that a higher dose could cause in the animal models.
3.1.3 REQUIRED FEATURES OF ACUTE AND CHRONIC GUINEA PIG
MODELS OF ASTHMA
As previously mentioned a good model of asthma should display early and late asthmatic 
responses, airway hyperresponsiveness, cellular influx into the airways and airway 
remodelling. These are all common features of human asthma and therefore if they can be 
replicated in a consistent manner the model could prove effective at investigating the 
mechanisms of asthma and potential therapeutics.
For more than 30 years it has been known that early and late phase bronchoconstrictions after 
a single dose of allergen have been observed in humans with atopic asthma (Pepys & 
Hutchcroft, 1975).The early phase bronchoconstriction, also known as early asthmatic 
response (EAR), occurs within 10 minutes, reaches a maximum after 30 minutes and recovers 
around 3 hours in human asthmatics (Gauvreau & Evans, 2007). A second 
bronchoconstriction known as the late phase bronchoconstriction or late asthmatic response 
(LAR) occurs between 4-8 hours in human asthmatics (Booij-Noord et al., 1971). Therefore a 
model of asthma should show these responses during the same time points as seen in human 
asthma.
Airway hyperresponsiveness (AHR) is a key feature of asthma (Hargreave et al., 1981) 
therefore it is extremely important that an animal model is able to display some form of 
AHR. A role for monitoring AHR in the long-term management of asthma was suggested by
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Sont et al., (1999), as a result it can be classified as one of the defining features of an 
asthmatic response. AHR is characterised by an increased sensitivity of the airways to a 
variety natural or pharmacological stimuli such as histamine and methacholine (Booij-Noord 
et al., 1971). Therefore a sensitised and allergen exposed model of asthma should have an 
enhanced bronchoconstriction response when challenged with histamine or methacholine.
As asthma is a pulmonary inflammatory disorder an increase in inflammatory cells should be 
observed in the lungs. Macrophages, eosinophils, lymphocytes and neutrophils are among 
several different inflammatory cells that play a role in asthma and can therefore be found in 
the airways of asthmatics (Barnes, 1996). Lavaging the lungs is a method that has been used 
to analyse lung inflammatory cell levels in both humans (Calhoun et al., 1991) and animals 
(Smith & Broadley, 2007), for that reason a good model of asthma should show increased 
inflammatory cell levels when it is lavaged. However, the number of inflammatory cells in 
the lavage fluid do not necessarily reflect the number of cells in lung tissue therefore some 
studies use histology as a method for assessing cell number (Barends et al., 2004).
As mentioned, asthma is a chronic disorder but the majority of animal models are acute 
(Zosky and Sly 2007). These acute models do not show the same levels of airway 
remodelling that is observed in an asthmatic lung such as collagen deposition and goblet cell 
hyperplasia. Therefore if a model is going to give us a better understanding of the 
mechanisms of asthma and prove a better model for drug discovery and development it is 
clearly important that airway remodelling is present.
In order to ensure complete sensitisation has occurred and to confirm a hypersensitivity 
reaction it is worthwhile to quantifiably measure the levels of the hypersensitivity antibody in 
the serum of the animal model. In guinea pigs this is IgGl but it is IgE in humans. Therefore 
running an enzyme-linked immunosorbant assay (ELISA) to evaluate guinea pig serum levels 
of IgGl would be beneficial in improving the quality of the model.
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3.2 AIMS AND OBJECTIVES
3.2.1 AIMS
The aim of this chapter was to assess early and late phase bronchoconstriction, airway 
hyperresponsiveness, cellular influx and lung histology in OVA sensitised acute and chronic 
guinea pig models of asthma. By measuring these characteristics, a comparison can be drawn 
between both models and in subsequent chapters the effects of anti-asthmatic compounds will 
be examined on these asthmatic features. The level of IgG in both acute and chronic models 
was assessed to ensure adequate sensitisation.
3.2.2 OBJECTIVES
• To investigate the effect that a single exposure of OVA or saline has on sensitised 
guinea pigs by measuring lung function, responsiveness to histamine and cellular 
influx.
• To investigate the effects of multiple exposures of OVA or saline on the same 
parameters mentioned in the previous point.
• To analyse the level of blood IgG found in naive, saline challenged and OVA 
challenged guinea pigs by using an enzyme-linked immunosorbent assay.
• To assess bronchiole structure, collagen deposition and goblet cell hyperplasia by 
utilising histological techniques.
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3.3 METHODS
The methods that were used are described in full detail in chapter 2; the following is a brief 
overview. For each study in this chapter six male Dunkin-Hartley guinea pigs (Harlan, UK) 
weighing 200-250 g were used. An n of six was used for each experimental group.
3.3.1 SENSITISATION
Guinea pigs were sensitised by an intra-peritoneal, bilateral injection of a suspension 
containing OVA (100 pg) and Al(OH) 3  (100 mg) in 1 ml of PBS on days 1 and 5.
3.3.2 OVALBUMIN CHALLENGES
Ovalbumin challenges for both acute and chronic groups were carried out in a stainless steel 
chamber with a Wright nebuliser attached. Exposures lasted 1 hour, however, if the guinea 
pig appeared distressed it was removed and exposure was considered complete.
3.3.2.1 ACUTE PROTOCOL
On day 15 (14 days subsequent to the first sensitisation injection), guinea pigs following the
acute protocol were challenged with a single exposure of OVA (0.01%) or saline (see figure
2 .2).
3.3.2.2 CHRONIC PROTOCOL
Guinea pigs that were following the chronic protocol were also challenged with an exposure 
of OVA (0.01%) or saline on day 15. Every 48 hours from days 17-29 guinea pigs were then 
challenged with an exposure of OVA (0.1%), this was preceded by 30 minutes with an intra- 
peritoneal, bilateral injection of mepyramine (30 mg/kg). On day 31 the guinea pigs were 
once again challenged with an exposure of OVA (0.1%), however, this time no mepyramine 
protection was required. Over the same period the control group of sensitised guinea pigs 
were challenged with 1 hour long saline exposures (see figure 2.3).
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3.3.3 LUNG FUNCTION MEASUREMENTS
Lung function measurements were achieved by using conscious guinea pigs restrained in a 
whole-body plethysmograph. This allowed values of sGaw to be obtained. Lung function 
measurements were acquired in the same way for both the acute and chronic challenged 
groups. On day 14 (prior to any OVA exposures) baseline values of sGaw were recorded. 
Following the final OVA exposure, day 15 for acute groups and day 31 for chronic groups, 
further values were recorded. The time points were 0, 15 minutes, 30 minutes, 45 minutes 
and 60 minutes post-exposure, then hourly until 12 hours and a final reading at 24 hours. As 
the maximum bronchoconstriction of the LAR occurred at different times in each animal, the 
peak bronchoconstrictions between 7 and 12 hours were recorded. These were displayed 
along with the peak of the early phase (0-6 hours) as a histogram next to the time course plot.
Whole-body plethysmography in conscious guinea pigs was used to evaluate AHR. The 
response of the guinea pig to a nose-only nebulised solution of histamine (1 mMol for 20 
seconds) determined the presence of AHR. Values of sGaw were recorded prior to the 
histamine challenge and 0, 5 and 10 minutes post-challenge. The histamine response was 
assessed 24 hours before the first OVA challenge (day 14) and 24 hours after the final OVA 
challenge on day 16 for acute groups and day 32 for chronic groups.
To investigate the recovery rates of both the acute and chronic challenged groups two further 
groups were introduced. The first group followed the acute protocol but the final histamine 
challenge did not occur until 72 hours after the OVA challenge (day 18). The second group 
followed the chronic protocol and once again the final histamine challenge did not occur until 
72 hours after the last OVA challenge (day 34).
Following the final histamine challenge the guinea pigs were administered a lethal dose of 
sodium pentobarbitone, the lungs were then removed and lavaged. Using the BAL fluid
3.3.4 AIRWAY HYPERRESPONSIVENESS MEASUREMENTS
3.3.5 TOTAL AND DIFFERENTIAL CELL COUNTS
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recovered total and differential cell counts were then carried out using the methods described 
in chapter 2. A naive, non-sensitised, group of guinea pigs were introduced at this stage as a 
reference to establish the normal cell counts in a guinea pig.
3.3.6 HISTOLOGICAL ANALYSIS OF GUINEA PIG LUNGS
Histological techniques for the lungs are detailed in chapter 2. Briefly, 3-5 mm thick portions 
of the left superior lobe sliced 1 mm below the bronchus were processed into wax blocks. 
6pm sections were then sliced using a microtome and fixed onto a glass slide. The slices were 
stained using either the haematoxylin and eosin, picrosirius red or AB/PAS protocols. The 
purpose of haematoxylin and eosin staining was two-fold. Firstly, the staining shows the 
general morphology of the bronchiole allowing for any structural changes to be easily 
observed. Secondly, the stain allowed the assessment of the number of inflammatory cells in 
the peribronchiolar space of the lung tissue by using a semi-quantifiable scoring method. The 
parameters for scoring were absent (0), minimal (1), slight (2), moderate (3), marked (4), or 
severe (5) (Barends et al., 2004). For the sections stained with picrosirius red or AB/PAS 
protocols the mean % of collagenous or AB/PAS positive area of the bronchiolar epithelium 
was determined respectively. ImageJ software was used to quantify the results.
3.3.7 QUANTIFICATION OF SERUM IMMUNOGLOBULIN G LEVELS 
USING AN ENZYME-LINKED IMMUNOSORBENT ASSAY
In order to ensure that sensitisation had occurred and to determine the differences in 
Immunoglobulin G (IgG) levels between the acute and chronic groups 1ml of blood was 
removed directly from the heart of the guinea pig following the administration of sodium 
pentobarbitone. The blood was left to coagulate overnight and then centrifuged at 18000g for 
15 minutes at a temperature of 2°C. Serum was removed and stored at -80°C. Once enough 
samples were collected an anti-guinea pig OVA specific IgGl enzyme-linked immunosorbent 
assay (ELISA) (figure 3.1) was run using the serum.
The ELISA plate was coated with 100 pg/well of OVA (10 pg/ml in phosphate buffered 
saline) and left overnight at room temperature. The following day the unbound antigen was 
washed off using phosphate buffered saline with tween (PBST) buffer three times. The plate
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was then blocked using 1% non fat milk powder in PBST for 30 minutes, following this the 
plate was once again washed three times with PBST. 100 pl/well of serum (diluted 1:1000 in 
PBST) were added to the plate and left for 90 minutes. In order to monitor background colour 
change some wells had PBST containing no serum added.
ELISA plate
Anti-Guinea Pig IgGl
Serum IgG
HRP
Ovalbumin
RP
OPD substrate
HRP
Ovalbumin
RP
Figure 3.1 - A schematic o f the indirect ELISA used to detect levels o f IgGl in the guinea pig serum. 
Ovalbumin binds to the ELISA plate and in turn is bound by the serum IgG. The enzyme-linked anti-guinea pig 
IgGl antibody reacts with the serum IgG. An o-phenylenediamine dihydrochloride (OPD) substrate is added 
which causes a colour change when it binds the enzyme-linked antibody. IgG = Immunoglobulin G; HRP = 
Horse Radish Peroxidase.
Following the 90 minute period the plate was washed three times with PBST and then 50 
pl/well of 1:500 dilution of the Horse Radish Peroxidase (HRP)-anti guinea pig IgGl 
antibody was added and left for 60 minutes. After a final three washes with PBST, 50 pl/well 
of an o-phenylenediamine dihydrochloride (OPD) substrate was added. This comprised of 
12.15 ml 0.1 M citric acid; 12.85 ml 0.2 M sodium phosphate; 25 ml distilled water; OPD 
(0.1 M citrate-phosphate buffer pH 5.0). OPD is a substrate for the peroxidise enzyme and as 
a result it yielded a yellow-brown colour when it reacted with the HRP conjugated to the anti-
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guinea pig IgGl antibody. As soon as the change had developed sufficiently 50 pl/well of 
sulphuric acid was added to stop the colour changing further (after around 15-20 minutes). 
Using a spectrophotometer the absorbance at 490 nm was determined for each of the samples. 
The more IgG detected by the ELISA the higher the colour changing unit.
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3.4 RESULTS
3.4.1 EFFECT OF AN ACUTE OVALBUMIN CHALLENGE ON LUNG
FUNCTION
Figure 3.2a represents the mean time course changes in sGaw that sensitisation followed by a 
single OVA (0.01%) or saline challenge cause. In OVA sensitised and challenged guinea pigs 
a significant bronchoconstriction was observed immediately (-68.8±8.7%), this did not 
resolve to saline challenged levels until 5 hours following the OVA challenge. This 
bronchoconstriction was the EAR. 7 hours following the challenge a second significant 
bronchoconstriction was observed (-19.8±5.7%), the LAR, which recovered to saline 
challenged levels by 8 hours.
The mean of the peak early and late asthmatic responses are also represented in figure 3.2 as 
a histogram. An early phase bronchoconstriction was demonstrated in OVA challenged 
guinea pigs shown by a significant decrease in sGaw compared to saline challenged guinea 
pigs (-71.2±6.5% compared to -8.9±1.5% respectively). This was also the case for levels of 
late phase bronchoconstriction (-25.2±6.7% compared to -1.3±0.8% respectively).
Figure 3.3 represents area under the curve analysis for both saline and OVA challenged 
sensitised guinea pigs. Throughout the whole time course OVA challenged showed a 
significantly greater area under the curve than saline challenged (977.3±111.8%.hr compared 
to 63.8±18.0%.hr). This was also true for the EAR time points (853.3±103.6%.hr compared 
to 55.2±18.9%.hr) and LAR time points (134.4±29.6%.hr compared to 4.2±1.5%.hr).
3.4.2 EFFECT OF AN ACUTE OVALBUMIN CHALLENGE ON AIRWAY
RESPONSIVENESS TO HISTAMINE
Figure 3.4 demonstrates the effect of challenging sensitised guinea pigs with histamine (1 
mMol for 20 seconds) before and after a saline or OVA exposure. Following a saline 
challenge guinea pigs show no significant bronchoconstriction when compared to the sGaw 
values prior to the saline challenge. In the OVA exposed group there was a significant 
bronchoconstriction immediately after the histamine challenge when compared to the sGaw
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values taken prior to the OVA challenge (-18.8±2.4% compared to -3.4±5.3% respectively). 
This bronchoconstriction was still present 5 minutes after the histamine challenge (-6.8±0.6% 
compared to 1.7±3.0% respectively). By 10 minutes the guinea pigs had recovered to pre- 
OVA exposure levels.
In order to determine how long AHR lasts in acute challenged guinea pigs a group was added 
that followed the same protocol as the OVA (0.01%) challenged guinea pigs, but instead of 
the histamine challenge being carried out 24 hours after OVA exposure this group had the 
histamine challenge at 72 hours. Figure 3.5 shows that no AHR was present in guinea pigs 
that were given a longer recovery period.
3.4.3 EFFECT OF CHRONIC OVALBUMIN CHALLENGES ON LUNG
FUNCTION
Figure 3.6 represents mean time course changes in sGaw for OVA sensitised guinea pigs that 
had received nine challenges with OVA at 48 hour intervals. Saline controls received 
repeated saline exposures at the same intervals. Changes in sGaw were assessed after the final 
OVA or saline exposure (day 31). The guinea pigs challenged with repeated OVA exposures 
showed an immediate bronchoconstriction of -71.6±2.6% which was significant when 
compared to saline challenged values. This bronchoconstriction did not resolve for 5 hours. A 
second significant bronchoconstriction occurred at 7 hours (-22.4±2.0%) this recovered to 
saline challenged levels at 9 hours.
When comparing mean of the peak bronchoconstriction values an early asthmatic response 
was observed in the OVA challenged group observed as a significantly greater 
bronchoconstriction than the saline challenged group (-71.6±2.6% compared to -5.7±0.8% 
respectively). This significantly greater decrease in sGaw was again seen between 7-12 hours 
demonstrating that the OVA challenged group had a late asthmatic response (-22.4±2.0% 
compared to -1.3±0.5% respectively).
When area under the curve analysis was applied to both groups (figure 3.7) the OVA 
challenged group showed a significantly greater area than the saline challenged group overall 
(875.3±57.1%.hr compared to 32.0±8.9%.hr). This was also seen for the early asthmatic time 
period (691.4±29.4%.hr compared to 29.6±9.1%.hr) and the late asthmatic time period 
(187.3±31.5%.hr compared to 4.2±1.8%.hr).
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3.4.4 EFFECT OF CHRONIC OVALBUMIN CHALLENGES ON AIRWAY
RESPONSIVENESS TO HISTAMINE
Figure 3.8 highlights the changes in sGaw from baseline following a histamine challenge (1 
mMol for 20 seconds) preceding and following multiple saline or OVA exposures. No 
response to histamine was observed in saline challenged guinea pigs. An immediate 
significant bronchoconstriction was seen in guinea pigs that had received multiple OVA 
exposures compared to sGaw values before they had been exposed to nebulised OVA (- 
40.5±0.8% compared to 1.5±0.8% respectively). This bronchoconstriction remained in place 
5 (-33.0±1.5% compared to 0.7±0.8% respectively) and 10 (-10.0±3.1% compared to 
1.4±1.6% respectively) minutes after the histamine challenge.
In figure 3.9 the level of recovery at 72 hours following the histamine challenge and the 
recovery at 24 hours is shown. There was still a significant bronchoconstriction immediately 
following the histamine at the 72 hour recovery point compared to before they received any 
OVA (-25.4±5.1% compared to -1.5±4.4% respectively). Despite the fact that AHR was still 
present at 72 hours it was not as severe as it was at 24 hours.
3.4.5 EFFECT OF ACUTE AND CHRONIC OVALBUMIN CHALLENGES
ON TOTAL AND DIFFERENTIAL CELL COUNTS
Figure 3.10 represents the number of cells recovered in the BAL fluid of naive, saline 
challenged and OVA challenged guinea pigs. A single and multiple OVA exposures caused a 
significant increase in the total number of BAL cells, as well as increase in macrophage, 
eosinophil, lymphocyte and neutrophil number compared to their respective saline challenged 
group. Multiple OVA exposures resulted in a significantly greater number of BAL cells than 
a single exposure (1 l.l±0.3xl06 compared to 8.8±0.6xl06 respectively). This was also true 
for macrophage number (4.4±0.2xl06 compared to 2.9±0.3xl06 respectively) and eosinophil 
number (6.3±0.1xl06 compared to 5.2±0.3xl06 respectively). Despite the increase in 
inflammatory cells that multiple OVA exposures cause the BAL levels of neutrophils are 
slightly higher, though not significantly, in the acute model than the chronic model.
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Figure 3.11 compares acute and chronic OVA challenged guinea pigs that were lavaged at 
either 24 hours or 72 hours. The total cell numbers between single challenged OVA guinea 
pigs was significantly greater than in the 24 hour recovery group compared to the 72 hour 
group (8.8±0.6xl06 compared to 3.3±0.2xl06 respectively). This was also the case in 
macrophage number (2.9±0.3xl06 compared to 1.8±0.1xl06 respectively), eosinophil number 
(5.2±0.3xl06 compared to 1.4±0.1xl06 respectively) and neutrophil number (0.5±0.1xl06 
compared to 0.01±0.01xl06 respectively).
A significant increase in total cell numbers was also observed in the chronic OVA challenged 
group that had 24 hours recovery compared to the 72 hour recovery group (11.1 ±0.3x106 
compared to 6.8±0.7xl06 respectively). Again this was true for the numbers of macrophages 
(4.4±0.2xl06 compared to 2.8±0.2xl06 respectively), eosinophils (6.3±0.1xl06 compared to 
3.9±0.3xl06 respectively) and neutrophils (0.3±0.05xl06 compared to 0.03±0.03xl06 
respectively).
3.4.6 EFFECT OF ACUTE AND CHRONIC OVALBUMIN CHALLENGES
ON LUNG HISTOLOGY
Figures 3.12 (A-E) shows a bronchiole stained with haematoxylin and eosin for a naive, acute 
saline challenged, acute OVA challenged, chronic saline challenged and chronic OVA 
challenged guinea pig. These pictures highlight the general morphology of each of the 
bronchioles. The bronchioles of the naive, acute saline challenged, acute OVA challenged 
and chronic saline challenged are all relatively similar with a small amount of smooth 
muscle, if any, a thin lamina propria and a small epithelial layer. The chronic OVA 
challenged guinea pig bronchiole shows a much greater level of airway smooth muscle, a 
thicker lamina propria and a larger epithelium compared to the other protocols.
Figure 3.13 shows the mean pathological scores for the number of inflammatory cells in the 
peribronchiolar space of naive, acute saline challenged, acute OVA challenged, chronic saline 
challenged and chronic OVA challenged guinea pigs. Multiple exposures of OVA cause a 
significantly greater level of inflammatory cells in the lung tissue compared to repeated saline 
exposures (4.8±0.3 compared to 1.0±0.4 respectively). However, this increase in 
inflammatory cells is not a result of an OVA exposure. Repeated exposures are required for 
an increased score to be observed as shown by the significantly greater level of inflammatory
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cells in the chronic OVA challenged guinea pigs compared to the acute OVA challenged 
guinea pigs (4.8±0.3 compared to 1.8±0.3 respectively).
Figure 3.14 (A-E) show picrosirius red stained bronchioles from the five protocols. The 
naive, acute saline challenged, acute OVA challenged and chronic saline guinea pig 
bronchioles show limited red stained collagen. However, the chronic OVA challenged group 
show collagen throughout the lamina propria and smooth muscle. Figure 3.15 represents the 
percentage of bronchiolar collagen in naive, saline and OVA challenged guinea pigs. No 
significant difference was observed between a single saline or OVA challenge. Multiple 
challenges of OVA caused a significantly greater percentage of bronchiolar collagen than 
multiple challenges of saline (58.1±5.0% compared to 19.7±3.5% respectively). When 
comparing both OVA challenges the chronic group had a significantly greater percentage of 
bronchiolar collagen than the acute group (58.1±5.0% compared to 16.9=1=1.7%).
Alcian blue and periodic acid Schiff stained guinea pig bronchioles are shown in figure 3.16 
(A-E). The epithelial cells stain a dark purple whereas mucin associated goblet cells are a 
brighter pink colour. The naive, acute saline challenged, acute OVA challenged and chronic 
saline guinea pig bronchioles have a very dark purple epithelium whereas the chronic OVA 
challenged group have a brighter pink epithelium suggesting the presence of goblet cells. 
Figure 3.17 shows the number of mucin associated goblet cells per 10,000 epithelial pixels 
for the same groups, again no significant differences were observed between acute challenged 
guinea pigs. Guinea pigs following a chronic OVA challenge protocol showed a higher 
number of mucin associated goblet cells per 10,000 epithelial pixels than those following a 
chronic saline challenge protocol (9.4±1.9 compared to 1.9±0.2 respectively). Chronic OVA 
challenged guinea pigs also show a higher number of mucin associated goblet cells per 
10,000 epithelial pixels than acute OVA challenge guinea pigs (9.4±1.9 compared to 
2.5±0.5%).
3.4.7 EFFECT OF ACUTE AND CHRONIC OVALBUMIN CHALLENGES
ON BLOOD IgGl LEVELS
Figure 3.18 represents the results of an anti-guinea pig OVA specific IgGl ELISA in level of 
colour changing units measured at 490nm. All groups had an increase in intensity that was 
significantly greater than naive guinea pigs. The acute OVA challenged group had a
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significantly greater intensity than acute saline challenged (0.5±0.008 compared to 0.2±0.01 
respectively). An even greater increase in colour changing units was observed between 
chronic OVA and chronic saline (2.2±0.06 compared to 0.7±0.04 respectively). The ELISA 
also demonstrated that repeated OVA challenges had a significantly greater effect on the 
colour intensity than a single OVA dose.
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Figure 3.2a -  Mean time-course values o f sGaw in OVA sensitised guinea pigs that were challenged with saline or 0.01 
% OVA. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 24 hours. 
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represents a bronchoconstriction. ^significantly different from saline challenged guinea pigs; A significant difference 
between saline and OVA challenged guinea pigs. Two-tailed T-test (P<0.05; n=6).
1 J1  -i
OjB -
0.7 -
0.8
0. 05 
S
* 0A- □  = Acute saline challenged
■  = Acute OVA challenged
0 2  -
0.1 -
0.0
71*llr
Figure 3.2b -  Mean time-course raw values o f sGaw in OVA sensitised guinea pigs that were challenged with saline or 
0.01 % OVA. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 24 
hours. Raw OVA sGaw values (cm/H20) -  Base (0.85±0.04), 0-6 hours (0.25±0.07), 7-12 hours (0.68±0.06) and 24 
hours (0.88±0.04). Raw control sGaw values (cm/H20) -  Base (0.77±0.08), 0-6 hours (0.70±0.08), 7-12 hours 
(0.76±0.08) and 24 hours (0.78±0.06).
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Figure 3.3 -  Area under the curve analysis comparing OVA sensitised guinea pigs challenged with a single dose o f  saline 
or 0.01% OVA. Only negative peaks are considered, any peaks that have a positive value o f sGaw are excluded. Total 
includes all negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR includes from 6-24 hours. Area under 
the curve is measured in %.hour. * significantly different from saline challenged guinea pigs. Two-tailed T-test (P<0.05; 
n=6).
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Figure 3.4. -  Response o f the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs challenged with saline or OVA (0.01%). Values were recorded 24 hours before saline or OVA challenge and 
again 24 hours post-saline or OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. percentage change 
from baseline where a negative value represents a bronchoconstriction. * significantly different from pre-challenge values 
of sGaw. Two-tailed T-test (P<0.05; n=6).
69
CHAPTER 3
2 0 -i
10 -
I
o
£  - 10-  
S)
|  -20- 
o
-3 0 -
5min
A  = Acute OVA challenged (pre-challenge)
□  = Acute OVA challenged (post-challenge)
A  = Acute OVA challenged -  72hr (pre-challenge)
□  = Acute OVA challenged -  72hr (post-challenge)
-4 0 -
-50 J
Figure 3.5 -  Response o f the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs challenged OVA (0.01%). Values were recorded 24 hours before saline or OVA challenge and again 24 or 72 
hours post- OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from baseline where 
a negative value represents a bronchoconstriction. * significantly different from pre-challenge values o f sGaw. Two-tailed 
T-test (P<0.05; n=6).
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Figure 3.6 -  Mean time-course values o f sGaw in OVA sensitised guinea pigs that had nine challenges at 48 hour 
intervals o f saline or OVA . The histogram represents maximum bronchoconstriction values during baseline, EAR, 
LAR and 24 hours. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from baseline where a 
negative value represents a bronchoconstriction. * significantly different from saline challenged guinea pigs; A 
significant difference between saline and OVA challenged guinea pigs. Two-tailed T-test (P<0.05; n=6). Raw OVA 
sGaw values (cm/H20) -  Base (0.72±0.01), 0-6 hours (0.21±0.02), 7-12 hours (0.56±0.01) and 24 hours (0.75±0.01). 
Raw control sGaw values (cm/H20) -  Base (0.71±0.06), 0-6 hours (0.67±0.06), 7-12 hours (0.70±0.06) and 24 hours 
(0.72±0.06).
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Figure 3.7 -  Area under the curve analysis comparing OVA sensitised guinea pigs challenged with a chronic dosing o f  
saline or OVA. Only negative peaks are considered, any peaks that have a positive value o f sGaw are excluded. Total 
includes all negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR includes from 6-24 hours. Area under 
the curve is measured in %.hour. * significantly different from saline challenged guinea pigs. Two-tailed T-test (P<0.05; 
n=6).
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Figure 3.8 -  Response o f the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs chronically challenged with saline or OVA. Values were recorded 24 hours before saline or OVA challenge 
and again 24 hours post-final saline or OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. percentage 
change from baseline where a negative value represents a bronchoconstriction. *significantly different from pre-challenge 
values o f sGaw. Two-tailed T-test (P<0.05; n=6).
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Figure 3.9 -  Response o f the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs challenged with multiple doses o f OVA. Values were recorded 24 hours before saline or OVA challenge and 
again 24 or 72 hours post-final OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. percentage change 
from baseline where a negative value represents a bronchoconstriction. * significantly different from pre-challenge values 
o f sGaw. Two-tailed T-test (P<0.05; n=6).
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Figure 3.10 -  The number o f total cells, macrophages, eosinophils, lymphocytes and neutrophils found in the 
bronchoalveolar fluid o f naive (non-sensitised), saline challenged (acute and chronic) and OVA challenged (acute and 
chronic) guinea pigs. Results are expressed as mean±S.E.M. * significantly different from acute saline; #significantly 
different from chronic saline; Significant difference between acute and chronic OVA challenged guinea pigs. One-way 
Analysis o f Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 3.11 -  The number o f total cells, macrophages, eosinophils, lymphocytes and neutrophils found in the 
bronchoalveolar fluid o f  naive (non-sensitised), and OVA challenged (acute and chronic) guinea pigs 24 or 72 hours post- 
final challenge. Results are expressed as mean±S.E.M. Asignificantly different from acute OVA challenged (72 hours) 
guinea pigs; #significantly different from chronic OVA challenged (72 hours) guinea pigs. One-way Analysis o f  Variance 
followed by a Bonferroni post-test (P<0.05; n=6).
A -  Naive non-sensitised guinea pig
Epithelium
Alveoli
Blood vessel
|100pm
73
CHAPTER 3
B -  Acute saline challenged guinea pig
Epithelium
C -  Acute OVA challenged guinea pig
Smooth muscle
Lamina propria
Epithelium,
|100tjmj
Smooth muscle
Lamina propria
D -  Chronic saline challenged guinea pig
Smooth muscleEpithelium
Lamina propria
|100 i^m
74
CH APTER 3
E -  Chronic OVA challenged guinea pig
Epithelium Smooth muscle
Lamina propria
Figure 3.12 (A-E) -  Bronchioles o f naive, saline challenged (acute and chronic) and OVA challenged (acute and chronic) 
guinea pigs stained with haematoxylin and eosin to display general morphology (lOOOx magnification)
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Figure 3.13 -  The mean pathology score o f cells found in the peri-bronchiolar space o f naive, saline challenged (acute and 
chronic) and OVA challenged (acute and chronic) guinea pigs Results are expressed as mean±S.E.M. * significantly 
different from chronic saline; Significantly different from acute OVA challenged guinea pigs. One-way Analysis o f 
Variance followed by a Dunnett post-test (P<0.05; n=4).
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Figure 3.14 (A-E) -  Bronchioles o f naive, saline challenged (acute and chronic) and OVA challenged (acute and chronic) 
guinea pigs stained with picrosirius red to display collagen (lOOOx magnification)
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Figure 3.15 -  Effect o f saline (acute or chronic) or OVA (acute or chronic) challenge on percentage bronchiolar collagen 
in guinea pigs. Results are expressed as mean±S.E.M. * significantly different from chronic saline; Asignificantly different 
from acute OVA challenged guinea pigs. One-way Analysis o f  Variance followed by a Dunnett post-test (P<0.05; n=4).
78
CHAPTER 3
A -  Naive non-sensitised guinea pig
Epithelium
B -  Acute saline challenged guinea pig
Epithelium
j100pm
C -  Acute OVA challenged guinea pig
1 0 0 |jm |
Epithelium
79
CH APTER 3
D -  Chronic saline challenged guinea pig
Epithelium
E -  Chronic OVA challenged guinea pig
Epithelium 
containing 
goblet cells
Figure 3.16 (A-E) -  Bronchioles o f naive, saline challenged (acute and chronic) and OVA challenged (acute and chronic) 
guinea pigs stained with alcian blue and periodic acid SchifF to display goblet cells (lOOOx magnification).
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Figure 3.17 -  Effect o f saline (acute or chronic) or OVA (acute or chronic) challenge on number o f mucin associate 
goblet cells per 10,000 epithelial pixels. Results are expressed as mean±S.E.M. * significantly different from chronic 
saline; Asignificantly different from acute OVA challenged guinea pigs. One-way Analysis o f Variance followed by a 
Dunnett post-test (P<0.05; n=4).
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Figure 3.17 -  Levels o f IgGl in the serums of naive, saline (acute and chronic) and OVA (acute and chronic) challenged 
guinea pigs determined by ELISA. Results values o f colour changing units measured at 490nm and are expressed as 
mean±S.E.M. *significantly different from acute saline; #significantly different from chronic saline; Asignificantly 
different from acute OVA challenged guinea pigs; Ssignificantly different from naive. One-way Analysis o f Variance 
followed by a Bonferroni post-test (P<0.05; n=6).
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3.5 DISCUSSION
3.5.1 EARLY AND LATE ASTHMATIC RESPONSES IN ACUTE AND 
CHRONIC OVALBUMIN CHALLENGED GUINEA PIGS
When sensitised guinea pigs were given a single or repeated saline challenges no features of 
asthma were recorded except for an increase in levels of IgG in the chronic saline model. 
Guinea pigs that were sensitised and then challenged with OVA showed evidence of 
bronchoconstriction. A single and the last of a series of OVA exposures cause an immediate 
decrease in sGaw representing the early asthmatic response. This recovers 4 hours after the 
exposure in the acute group and 5 hours in the chronic group. A second bronchoconstriction 
was observed after 7 hours in both groups which is consistent with the late asthmatic 
response time period. As with the early phase bronchoconstriction this response takes 1 hour 
longer to recover to control levels in the chronic group than the acute group.
Observing an EAR and LAR in acute challenged guinea pigs sensitised with 100 pg 
ovalbumin is consistent with what is seen in the literature (Smith & Broadley, 2007; Smith & 
Johnson, 2005). The fact that the chronic OVA model had a similar decrease in sGaw during 
the EAR and LAR as the acute OVA model despite being exposed to a higher dose of OVA 
suggests that a degree of tolerance to the allergen has occurred. However, this tolerance was 
overcome by administering the higher dose with mepyramine protection. It is possible that if 
the chronic model was extended further then tolerance to the higher dose of OVA would 
occur.
3.5.2 AIRWAY HYPERRESPONSIVENESS IN ACUTE AND CHRONIC 
OVALBUMIN CHALLENGED GUINEA PIGS
AHR was observed in both acute and chronic OVA exposed guinea pigs that were challenged 
with a direct stimulus but not in the saline challenged groups suggesting that sensitisation 
alone does not cause AHR. A dose of 1 mMol histamine, which is sub-threshold for naive 
guinea pigs (figure 2.7) and before OVA challenge, caused a response 24 hours post-OVA 
challenge in the acute group, however, when AHR was assessed after 72 hours it was not 
present. This proves that an acute challenge does not replicate the chronic nature of asthma.
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In the chronic OVA challenged groups AHR was observed after 24 hours and AHR was still 
present after 72 hours. The chronic nature of AHR is something which is observed in asthma 
(Khor et al., 2007). It has been suggested that persistent AHR is caused by airway 
inflammation and airway remodelling (O'Byme et al., 2009). However, Crimi et al., (1998) 
state that the link between persistent AHR and inflammation is unclear and suggest it may be 
that airway remodelling or autonomic dysfunction are the main causes.
As the mechanisms that cause AHR are not well known it is possible that because the degree 
of AHR in the chronic OVA model was greater than the acute OVA model that this was the 
reason AHR was still present after 72 hours in the chronic model. However, although features 
that were present in both models, such as eosinophils, have been implicated in AHR 
(Wardlaw et al., 2002) other factors that were only present in the chronic model, such as 
increased airway wall thickness, have been suggested to exacerbate AHR (Kasahara et al., 
2002). Therefore it is possible that these factors cause the delay in AHR recovery.
3.5.3 CELLULAR INFLUX IN ACUTE AND CHRONIC OVALBUMIN
CHALLENGED GUINEA PIGS
Acute and chronic OVA challenge caused a mass influx of inflammatory cells into the 
airways as demonstrated in BAL fluid samples. This is understandable as inflammatory cell 
influx is a feature of human asthma (Barnes 1996). A great influx was observed in chronic 
challenged guinea pigs compared to acute which corroborates similar findings shown by 
Bazan-Perkins et al., (2009). An increase was observed in macrophage number compared to 
control guinea pigs. Although macrophage number in control guinea pigs were at a greater 
level than eosinophils the opposite was true for the OVA challenged group. This is partly 
contradictory to findings in humans where macrophages were the most prominent cell in both 
asthmatics and non-asthmatics (Hamid et al., 2003).
A mass increase in airway eosinophils was observed in both OVA challenged groups. This is 
consistent with human findings as patients with allergen-induced late-phase reactions had a 
significant increase in BAL eosinophil number (Diaz et al., 1989). Eosinophils are believed 
to be involved in the development of the LAR (De Monchy et al., 1985; Diaz et al., 1989). 
This would explain why the numbers were so high 24 hours after challenge and could explain
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the conflicting data with the Hamid et al., (2003) study as it does not state at which point 
BAL samples were taken from asthmatics.
Lymphocytes are activated in response to an acute allergen challenge and produce high levels 
of cytokines which contribute to the asthmatic response (Barnes, 2008). This would explain 
why an increased level is seen in the BAL fluid of acute and chronic OVA challenged guinea 
pigs compared to vehicle. Neutrophil levels are also increased in OVA challenged guinea 
pigs compared to vehicle, however, they are not one of the prominent cell types. It seems 
unlikely that neutrophils have a prominent role in the LAR as a response can still be observed 
even after depletion of neutrophils (Hutson et al., 1990). Toward and Broadley (2004) 
showed almost non-existent levels of neutrophils in the BAL fluid following an acute OVA 
exposure in sensitised guinea pigs after 24 hours but showed the peak neutrophil influx was 
during the EAR. This could explain why lower levels in neutrophils were observed in the 
chronic OVA model compared to the acute OVA model. The influx of neutrophils is likely to 
be maximal during the first EAR and diminish with each challenge.
When comparing the levels of cellular influx between 24 hour and 72 hour lavage time points 
there are significant reductions throughout all leukocyte subtypes except lymphocytes. In 
chronic OVA challenged guinea pigs the levels of eosinophils is still high, this goes someway 
in confirming the theory of Wardlaw et al., (2002) that major basic protein released from 
eosinophils lead to an increase in damaged epithelial cells and AHR. The fact that the levels 
of cells have not completely returned to baseline after 72 hours suggests that complete 
recovery takes some time to occur and therefore these cells could be exacerbating asthma and 
making it the chronic condition it is.
3.5.4 HISTOLOGICAL CHANGES IN ACUTE AND CHRONIC
OVALBUMIN CHALLENGED GUINEA PIGS
A vast difference was seen in chronic OVA challenged guinea pig bronchioles compared to 
the other protocols bronchioles. An increase in amount of smooth muscle, thickness of lamina 
propria and epithelium (possibly a result of goblet cell hyperplasia) was observed. These 
findings are similar to those by Bazan-Perkins et al., (2009) who showed increased fibrosis in 
the guinea pig lung following nine OVA challenges. The number of inflammatory cells found 
in the lung tissue corroborated with the total cells counts observed in the BAL fluid. The
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influx of these inflammatory cells, especially eosinophils, are likely to be the cause of the 
airway remodelling observed in the chronic OVA model.
When assessing the lamina propria for fibrosis a much greater percentage of bronchiolar 
collagen was observed in the chronic OVA challenged guinea pigs. This was also the case 
when assessing the number of mucin associated goblet cells. Goblet cell hyperplasia has 
occurred in the chronic OVA model. This model shows airway remodelling has occurred and 
is therefore a much more clinically relevant model of asthma than the acute OVA model.
3.5.5 IgG PRODUCTION IN ACUTE AND CHRONIC OVALBUMIN
CHALLENGED GUINEA PIGS
An increase in IgGl levels compared to naive guinea pigs was observed in all models except 
the acute saline challenged guinea pigs suggesting that sensitisation to OVA occurred. The 
guinea pigs challenged with OVA had higher levels of IgGl especially the chronic model. 
Although the OVA challenge would cause cross-linking of the antibodies and subsequent 
degranulation of the mast cells and cleavage of the antibody (Rauter et al., 2008) at the same 
time the sensitisation process would also be reoccurring and thus new antibodies being 
created. The acute OVA challenged group had significantly greater levels of IgGl than the 
acute saline challenged group suggesting that after an OVA exposure a greater level of 
antibodies may be produced than degraded. The chronic OVA exposed guinea pigs had 
significantly greater levels of IgGl than all the other groups and this is likely to be a result of 
repeated stimulation of the immune system with each exposure of the allergen. If with each 
exposure more antibodies were produced than degraded then there would be an accumulation 
of antibodies. It was also possible that the higher dose of OVA that the chronic group receive 
caused the production of more IgGl antibodies. A much greater level of IgGl was observed 
in the chronic OVA group than the other groups suggesting that this model may be a better 
representation of human asthma than the acute OVA group although it is important to 
consider that IgE is the allergic antibody in humans.
85
CHAPTER 3
3.5.6 GENERAL CONCLUSIONS
From these data it is clear that although the acute OVA guinea pig model displays several of 
the features of asthma it does not demonstrate airway remodelling. It seems that the chronic 
OVA guinea pig model is the first model to display EAR, LAR, long-term AHR, cellular 
influx and airway remodelling backed up by the statement by Zosky and Sly (2007) that 
stated there is no model in smaller laboratory animals that demonstrates both chronic 
remodelling and long-term airway hyperresponsiveness. It would seem that the chronic OVA 
model developed in this chapter has several advantages over other guinea pig models and 
indeed larger animal models as a pre-clinical model as it is cost effective and takes a 
relatively short time to develop. However, as previously mentioned all models of asthma 
must take into account the fact that it is not completely representative of human asthma. The 
chronic OVA model is sensitised then challenged nine times over the period of a month. 
Many asthmatics have suffered with asthma for years and the levels of airway remodelling 
are likely to be far more severe than observed in the chronic OVA model. Despite this, the 
chronic OVA model would enable more accurate research into asthma mechanisms and 
potential therapy than the acute OVA model.
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4.1 INTRODUCTION
4.1.1 MOUSE MODELS OF ASTHMA
In recent years mice models of asthma have become the most popular animal for modelling 
allergic airway responses (Zosky & Sly, 2007). This is because mice have several advantages 
over other models of asthma. The size of mice can be an advantage compared to larger 
models of asthma as they are easy to house together and therefore reduce cost. However, as 
mice are not as docile as guinea pigs they are not as easy to handle and as a result non­
restrained measurements of lung function are employed. The main reasons why murine 
models have become so popular in asthma research is the availability of species-specific 
reagents (Karol, 1994) and transgenic mice (Hausding et al., 2008). These allow further 
research into the mechanisms of asthma at both the immunological and genetic level 
respectively. The fact that IgE is the major anaphylactic antibody (Karol, 1994), as this is also 
the case in humans, serves as another advantage over guinea pigs where IgG is the prominent 
antibody.
Despite the advantages of mice models of asthma they have drawbacks. Mice are different to 
humans when it comes to mast cell degranulation. The primary mediator in human mast cell 
degranulation is histamine whereas in mice it is serotonin (Canning, 2003), as a result mice 
respond poorly to histamine (Zosky and Sly 2007). There is huge variation in the pattern of 
allergic inflammation between different strains of mice (Kumar et al., 2008). For example, 
Shinagawa and Kojima (2003) found that A/J mice exhibited more marked changes after 
chronic intranasal challenges compared to BALB/c and C57BL/6 mice.
There are large anatomical differences between mice and humans. The fact that mice, and 
guinea pigs, are quadrupeds means the difference in posture compared to humans could 
influence the way the lung responds to flow limitation and therefore may have an impact on 
aerosol deposition (Zosky and Sly 2007). In addition to this, mice have poorly developed 
airway smooth muscle compared to humans (Karol 1994). Mice, like guinea pigs, generally 
require an adjuvant along with OVA to induce sensitisation. Although adjuvant-free protocols 
exist they require many injections to achieve sensitisation (Kumar et a l , 2008). This is 
because like most models of asthma they do not develop allergy naturally and therefore do
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not completely represent human asthma. Despite these drawbacks mice have proved an 
excellent tool at investigating the mechanisms of asthma and will continue to do so.
4.1.2 MOUSE OVALBUMIN MODELS
Despite increasing studies that use house dust mite (Kim et al., 2006), olive pollen (Batanero 
et al., 2002) and Aspergillus fumigatus extract (Baelder et al., 2005), ovalbumin is still the 
allergen of choice to provoke an immune response in the majority of studies modelling 
asthma (Cates et al., 2007). Although using ovalbumin is sometimes criticised for not being 
as clinically relevant as other allergens, such as house dust mite, the fact that it can induce a 
consistent and robust inflammatory response leads to it being used extensively (Cates et al., 
2007).
The method of ovalbumin sensitisation and subsequent challenge differs greatly between 
different study groups and species (Kumar et al., 2008). The dose of ovalbumin used to 
sensitise mice ranges from 1 pg to 8000 jig and varies between the route of administration 
used (Kumar et al., 2008). With so much variation between sensitisation and exposure 
methods and, on top of this, strain variation it is no surprise that the key features observed 
vary dramatically. An example of this is how the differences in protocols alter the time of the 
early asthmatic response (EAR) can be shown by comparing the studies by Cieslewicz et al., 
(1999) and Femandez-Rodriguez et al., (2008). An early and late phase bronchoconstriction 
was observed in ovalbumin sensitised and challenged mice in both studies, however, in the 
Cieslewicz et al., (1999) study the EAR peaks at 15 minutes whereas in the Femandez- 
Rodriguez et al, (2008) study it did not peak until 2 hours. Variation needs to be carefully 
considered when developing and assessing a mouse model of asthma, as a result strain and 
protocol will be kept consistent throughout this thesis.
When developing a chronic model of a disease the issue of tolerance must be considered. As 
a result of tolerance the majority of inhaled challenges are short-term, which results in 
eosinophil accumulation and airway hyperresponsiveness (Kumar et al., 2008). However, 
these models are associated with features that are not characteristics of human asthma such as 
perivascular and parenchymal inflammation of the lungs (Cohn, 2001). To ensure that 
tolerance to inhaled ovalbumin does not occur some models have been developed in which 
ovalbumin was delivered intermittently following sensitisation (Henderson et al., 2002; Leigh
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et al., 2002; Tanaka et al., 2001; Temelkovski et al., 1998). However, this approach does not 
completely inhibit tolerance as down-regulation of inflammation, airway 
hyperresponsiveness and structural airway changes were observed following repeated antigen 
exposure (Jungsuwadee et al., 2004; Palmans et al., 2000; Yiamouyiannis et al., 1999).
Previous work in our laboratory developed a chronic mouse model that maintained a 
consistent dose of ovalbumin throughout and showed limited tolerance (Femandez-Rodriguez 
et al., 2008). Sensitisation followed by six weeks of ovalbumin challenges three times a week 
led to early and late asthmatic responses, airway hyperresponsiveness and cellular influx. 
However, this model required a higher dose of ovalbumin than the acute model to provoke 
asthma-like responses. Histological analysis will help determine the appropriateness of this 
model as a model of human asthma.
4.1.3 REQUIRED FEATURES OF ACUTE AND CHRONIC MOUSE
MODELS OF ASTHMA
Models of asthma should be able to consistently replicate most, if not all, of the key features 
of asthma. These are early and late asthmatic responses (Pepys & Hutchcroft, 1975), airway 
hyperresponsiveness (Hargreave et al., 1981), increased airway cellular influx (Bames, 1996) 
and airway remodelling (McMillan & Lloyd, 2004). The model developed by Femandez- 
Rodriguez et al., (2008) demonstrated four of these features in both acute and chronic 
ovalbumin challenged mice. Airway remodelling was not assessed in their study. Airway 
remodelling has been observed in many mouse models of asthma (Blyth et al., 2000; 
McMillan & Lloyd, 2004; Temelkovski et al., 1998; Xisto et al., 2005). However, these 
studies did not assess all of the other features of asthma. It appears that currently there is no 
chronic model of asthma that can demonstrate all the hallmarks of asthma.
The model by Femandez-Rodriguez et al., (2008) has also assessed the levels of IgE, the 
antibody involved in asthma, and ovalbumin-specific IgG in the serum of acute and chronic 
ovalbumin challenged mice. The study showed that sensitisation followed by ovalbumin 
challenge caused a significant increase in serum IgE compared to naive mice and that 
sensitisation alone was enough to cause a significant increase in ovalbumin-specific IgG. 
Currently this model appears to demonstrate more hallmarks of asthma than any other mouse
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model, therefore the protocol developed in the Femandez-Rodriguez et al, (2008) model will 
be used in this chapter.
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4.2 AIMS AND OBJECTIVES
4.2.1 AIMS
The aim of this chapter was to sensitise mice to ovalbumin (OVA) and subsequently 
challenge them with acute or chronic exposures of OVA or saline. The response to the final 
OVA challenge was assessed by measuring early and late phase bronchoconstrictions, airway 
hyperresponsiveness, cellular influx and lung histology. The development and comparison of 
acute and chronic OVA mouse models allows for the assessment of potential asthmatic 
therapies in subsequent chapters.
4.2.2 OBJECTIVES
• To investigate the effect that an acute exposure of OVA or saline has on sensitised 
mice by measuring lung function, response to methacholine and percentage cellular 
influx.
• To investigate the effect that multiple exposures of OVA or saline has on the same 
parameters mentioned in the previous point.
• To assess bronchiole structure, collagen deposition and goblet cell hyperplasia in both 
acute and chronic challenged mice by utilising histological techniques.
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4.3 METHODS
Chapter 2 describes the methods used in detail and the following is a brief overview. Male 
BALB/c mice (20-25g) were used for all mouse studies. Six mice were used per experimental 
group.
4.3.1 SENSITISATION
The sensitisation process for mice was OVA (100 pg) and Al(OH) 3  (100 mg) in phosphate 
buffered saline (PBS). Intraperitonael injections of 0.25 ml bilaterally were administered on 
days 1 and 5, with procedures commencing on day 14.
4.3.2 OVALBUMIN CHALLENGES
Mice were exposed to aerosolised OVA in a Perspex box (38 cm length; 20 cm width; 20 cm 
height). If a mouse appeared distressed during the exposure it was removed from the box and 
exposure was considered complete.
4.3.2.1 ACUTE PROTOCOL
The mice were exposed to two 1 hour OVA (0.5%) or saline inhalation challenges on day 15, 
there was a 4 hour gap between exposures.
4.3.2.2 CHRONIC PROTOCOL
Mice were challenged three times a week for six weeks with nebulised OVA (2%) or saline 
for 30 minutes. A final hour long challenge occurred on the first day of the seventh week (day 
57).
4.3.3 LUNG FUNCTION MEASUREMENTS
The method for measuring lung function in mice is covered in chapter 2. Briefly, values of 
the lung function of unrestrained mice were measured as Penh using a Buxco system. Values 
of Penh following allergen challenge were recorded at 0, 20, 40, 60, 90 and 120 minutes, then
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hourly until 10 hours followed by a final reading at 19 hours for the acute protocol (24 hours 
after first challenge) or 24 hours for the chronic protocol.
4.3.4 AIRWAY HYPERRESPONSIVENESS MEASUREMENTS
Airway hyperresponsiveness in mice was measured using methacholine. A 1 minute 
intermittent exposure of 30 mg/ml methacholine (one second exposure followed by five 
seconds without exposure) was used in the acute challenged mice and a 10 mg/ml dose over 
the same time period was used in the chronic model. Prior to the challenge 2 minutes of 
baseline readings were taken and subsequent to the challenge 5 minutes of readings were 
taken. The percentage change in Penh from baseline was calculated. Methacholine challenges 
were carried out before the first ovalbumin exposure and 19 or 24 hours after the final 
ovalbumin exposure.
4.3.5 DIFFERENTIAL CELL COUNTS
As previously described in chapter 2 it was not possible to carry out a total cell count on mice 
BAL fluid, however, a differential cell count of macrophages, eosinophils, lymphocytes and 
neutrophils was obtained. Non-sensitised naive mice were included as a reference only.
4.3.6 HISTOLOGICAL ANALYSIS OF MOUSE LUNGS
The techniques for histological analysis are described in chapter 2. Briefly, sections of the left 
superior lung measuring 3-5 mm were cut 1 mm below the bronchus and processed into wax 
blocks. Sections measuring 6 pm were then cut using a microtome and fixed onto a glass 
slide. The slices were stained with either the haematoxylin and eosin, picrosirius red or 
AB/PAS protocols. The haematoxylin and eosin staining shows the general morphology of 
the bronchiole allowing for any structural changes to be easily observed. Secondly, the stain 
allowed the semi-quantifiable analysis of the number of inflammatory cells in the 
peribronchiolar space of the lung tissue. The parameters for scoring were absent (0), minimal 
(1), slight (2), moderate (3), marked (4), or severe (5) (Barends et al., 2004). The sections 
stained with picrosirius red or AB/PAS protocols allowed the analysis of the mean % of
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collagenous or AB/PAS positive areas respectively of the bronchiolar epithelium using 
ImageJ software.
CHAPTER4
4.4 RESULTS
4.4.1 EFFECT OF AN ACUTE OVALBUMIN CHALLENGE ON LUNG 
FUNCTION
Mice that were sensitised with OVA (100 pg) and challenged with saline showed no 
significant changes in lung function. However, if the sensitised mice are challenged with 
OVA (0.5%) changes were observed. A significant increase versus saline challenged mice 
was seen after 1 hour, this peaks after 2 hours (64.6±2.7%) and had recovered by 4 hours. A 
second increase in Penh was observed at 7 hours (55.8±3.7%) which recovered by 8 hours. 
This is equivalent to an EAR and LAR and is shown in figure 4.1a. When comparing peak 
Penh values, OVA challenged mice showed a significant increase in Penh compared to saline 
challenged mice (64.6±2.7% compared to 20.4±5.0% respectively) suggesting the OVA 
challenged mice had an early phase bronchoconstriction. This was also true for the late phase 
bronchoconstriction time period (7-12 hours) (55.8±3.7% compared to 21.5±3.8% 
respectively).
Area under the curve analysis (figure 4.2) highlights the differences in %.hour between the 
sensitised mice challenged with an acute saline or OVA exposure. OVA mice showed a 
greater area than saline mice throughout the whole curve (1611.5±200.4%.hr compared to 
677.9±199.2%.hr respectively). This was also the case when the area under the curve for the 
EAR time period (0-6 hours) (1024.5±151.8%.hr compared to 346.8±117.1%.hr respectively) 
and the LAR time period (7-12 hours) (550.2±62.9%.hr compared to 260.6±76.3%.hr 
respectively) was taken.
4.4.2 EFFECT OF AN ACUTE OVALBUMIN CHALLENGE ON AIRWAY 
RESPONSIVENESS TO METHACHOLINE
The response of mice after a single OVA challenge to 30 mg/ml methacholine (1 minute) is 
shown in figure 4.3. Saline challenged mice showed no significant difference post-saline 
challenges compared to pre-saline challenges. AHR was present in the OVA challenged mice 
post-OVA exposures as Penh values were significantly greater when compared to pre­
challenge levels (1203.9±115.6% compared to 2.2±3.3% respectively).
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4.4.3 EFFECT OF CHRONIC OVALBUMIN CHALLENGES ON LUNG
FUNCTION
Figure 4.4 represents the effects that multiple exposures of saline or OVA (2%) have on the 
lung function of mice sensitised with OVA (2%). Saline challenges have no significant effect 
on lung function, however, this is not the case for chronic OVA challenges. A significant 
bronchoconstriction was observed 1 hour after the final OVA challenge, which peaked at 2 
hours (55.8±7.8%) and decreased almost to saline challenged levels at 4 hours. A second 
bronchoconstriction occurred after 6 hours, which peaked at 7 hours (47.5± 10.1%) and 
recovered after ten hours. These two bronchoconstrictions represent the EAR and LAR 
respectively.
Peak Penh values highlighted a significant increase in OVA challenged mice compared to 
saline challenged mice at the early phase (55.8±7.8% compared to 23.1±8.5% respectively) 
and late phase (47.5± 10.1% compared to 1.7±4.3% respectively) bronchoconstriction time 
points. Area under the curve analysis is shown in figure 4.5. A significantly greater area was 
observed in chronic OVA challenged mice compared to chronic saline challenged mice 
throughout (1720.7±427.4%.hr compared to 236.6±150.5%.hr respectively) and also at the 
EAR (1132.4±282.3%.hr compared to 216.1±150.5%.hr respectively) and LAR 
(588.3±153.8%.hr compared to 23.4±17.5%.hr respectively) time points.
4.4.4 EFFECT OF CHRONIC OVALBUMIN CHALLENGES ON AIRWAY
RESPONSIVENESS TO METHACHOLINE
Figure 4.6 shows that repeatedly challenging OVA sensitised mice with saline did not cause 
any hyperresponsiveness. However, following multiple OVA challenges, a response to 10 
mg/ml methacholine (1 minute) was recorded in mice compared to the response pre-OVA 
challenge (362.6±16.1% compared to -10.3±2.2% respectively). Therefore, AHR was 
observed in sensitised mice following a chronic OVA exposure protocol.
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4.4.5 EFFECT OF ACUTE AND CHRONIC OVALBUMIN CHALLENGES 
ON DIFFERENTIAL CELL COUNTS
Figure 4.7 represents the percentage of cells present in the BAL fluid of naive, saline 
challenged and OVA challenged mice. More eosinophils were seen in acute OVA mice than 
in saline challenged mice (15.7±0.7% compared to 0.4±0.2% respectively). However, a 
significantly smaller percentage of macrophages were observed in acute OVA challenged 
mice compared to saline challenged (72.1±1.5% compared to 84.0±2.9% respectively), this is 
probably a result of the fact that there was a significantly greater percentage of eosinophils. A 
similar result was observed in chronically challenged mice with a greater percentage of 
eosinophils observed in the OVA challenged (12.5±1.0% compared to 0.2±0.1% 
respectively) and a lower percentage of macrophages seen in OVA challenged compared to 
saline challenged (72.8±1.9% compared to 89.3±1.8% respectively). No significant changes 
were observed in lymphocyte and neutrophil percentage influx.
4.4.6 EFFECT OF ACUTE AND CHRONIC OVALBUMIN CHALLENGES 
ON LUNG HISTOLOGY
Figure 4.8 (A-E) shows a bronchiole from a mouse in each of the five study groups in this 
chapter, naive, acute saline, chronic saline, acute OVA and chronic OVA. The bronchioles 
have been stained with haematoxylin and eosin to show general morphology. Considerable 
structural changes were observed in the chronic OVA challenged mice compared to the other 
groups most noticeably an increase in epithelium thickness and the increased presence of 
smooth muscle. From the haematoxylin and eosin stained slides the number of inflammatory 
cells in the lung tissue can be assessed semi-quantifiably, shown in figure 4.9. A single OVA 
challenge caused a greater score of inflammatory tissue cells than a single saline challenge 
(2.0±0.0 compared to 0.8±0.3 respectively). However, when mice received nineteen OVA 
challenges the number of inflammatory cells in the lung tissue was significantly greater than 
a single OVA challenge (4.8±0.3 compared to 2.0±0.0 respectively). Chronic OVA 
challenged mice also had a greater number of lung tissue inflammatory cells than chronic 
saline challenged mice (4.8±0.3 compared to 1.0±0.4 respectively).
Bronchioles for the same five groups that were stained with picrosirius red to show collagen 
are shown in figure 4.10 (A-E). The chronic OVA challenged mice had a greater level of
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collagen in the lamina propria than the other groups. The quantitative analysis of these 
bronchioles is shown in figure 4.11. This represents the percentage of bronchial collagen for 
each group. No significant change was observed between OVA and saline when a single 
challenge occurred. However, multiple OVA challenges caused an increase in percentage 
bronchiolar collagen compared to multiple saline challenges (51.5±5.2% compared to 
14.2±4.4% respectively). When comparing the two OVA groups multiple challenges caused a 
significant increase compared to a single challenge (51.5±5.2% compared to 13.9±2.2% 
respectively).
Alcian blue / periodic acid Schiff stain bronchioles are shown in figure 4.12 (A-E). The 
epithelium of the naive, acute saline, chronic saline and acute OVA mice was dark purple in 
colour suggesting the presence of mainly epithelial cells. However, the chronic OVA 
challenged mice had more bright purple stained cells in their bronchiolar epithelium 
suggesting the presence of mucin associated goblet cells. Figure 4.13 compares the number of 
mucin associated goblet cells per 10,000 epithelial pixels between naive, acute saline, chronic 
saline, acute OVA and chronic OVA. Chronic OVA challenges caused a significant increase 
in the number of mucin associated goblet cells compared to acute OVA challenges (13.6=1=2.6 
compared to 2.5±0.8 respectively) and chronic saline challenges (13.6=1=2.6 compared to 
2.8±0.7 respectively). No significance was observed between both acute challenge groups.
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Figure 4.1a -  Mean time-course values o f P enh in OVA sensitised mice that were challenged twice with saline or 0.5% 
OVA 4 hours apart. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 19 
hours (24 hours after first exposure). Mean changes in Penh are expressed as mean±S.E.M. percentage change from 
baseline where a positive value represents a bronchoconstriction. * significantly different from saline challenged mice; A 
significant difference between saline and OVA challenged mice. Two-tailed T-test (P<0.05; n=6).
0.7-1
Figure 3.2b -  Mean time-course raw values o f Penh in OVA sensitised mice that were challenged with saline or 0.01 % 
OVA. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 24 hours. Raw 
OVA P ^  values (AU) -  Base (0.38±0.02), 0-6 hours (0.62±0.03), 7-12 hours (0.59±0.03) and 24 hours (0.40±0.03). 
Raw control Penh values (AU) -  Base (0.35±0.03), 0-6 hours (0.42±0.02), 7-12 hours (0.42±0.02) and 24 hours
(0.37±0.02).
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Figure 4.2 -  Area under the curve analysis comparing OVA sensitised mice challenged with a two doses o f saline or 0.5% 
OVA. Only positive peaks are considered, any peaks that have a negative value o f P enh are excluded. Total includes all 
negative peaks from 0-19 hours, EAR includes from 0-6 hours and LAR includes from 6-19 hours. Area under the curve is 
measured in %.hour. *significantly different from saline challenged mice. Two-tailed T-test (P<0.05; n=6).
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Figure 4.3 -  Response o f the airways to a 60 second intermittent dose o f methacholine (30 mg/ml) in OVA sensitised 
mice challenged with saline or OVA (0.5%). Values were recorded 24 hours before saline or OVA challenge and again 24 
hours post-saline or OVA challenge. Mean changes in POTh are expressed as mean±S.E.M. percentage change from 
baseline where a positive value represents a bronchoconstriction. * significantly different from pre-challenge values o f Penh. 
Two-tailed T-test (P<0.05; n=6).
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Figure 4.4 -  Mean time-course values o f Penh in OVA sensitised mice that were challenged repeatedly with saline or 
2% OVA three times a week for six weeks. The histogram represents maximum bronchoconstriction values during 
baseline, EAR, LAR and 24 hours. Mean changes in Penh are expressed as mean±S.E.M. percentage change from 
baseline where a positive value represents a bronchoconstriction. * significantly different from saline challenged mice; A 
significant difference between saline and OVA challenged mice. Two-tailed T-test (P<0.05; n=6). Raw OVA Penh 
values (AU) -  Base (0.34±0.02), 0-6 hours (0.52±0.02), 7-12 hours (0.49±0.03) and 24 hours (0.31±0.01). Raw control 
Penh values (AU) -  Base (0.45±0.01), 0-6 hours (0.54±0.04), 7-12 hours (0.45±0.01) and 24 hours (0.39±0.02).
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Figure 4.5 -  Area under the curve analysis comparing OVA sensitised mice challenged with repeated doses o f saline or 
2% OVA. Only positive peaks are considered, any peaks that have a negative value o f Penh are excluded. Total includes all 
negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR includes from 6-24 hours. Area under the curve is 
measured in %.hour. *significantly different from saline challenged mice. Two-tailed T-test (P<0.05; n=6).
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Figure 4.6. -  Response o f the airways to a 60 second intermittent dose o f methacholine (10 mg/ml) in OVA sensitised 
mice challenged repeatedly over 7 weeks with saline or OVA (2%). Values were recorded 24 hours before the first saline 
or OVA challenge and again 24 hours post-final saline or OVA challenge. Mean changes in P^h are expressed as 
mean±S.E.M. percentage change from baseline where a positive value represents a bronchoconstriction. *significantly 
different from pre-challenge values o f Penh. Two-tailed T-test (P<0.05; n=6).
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Figure 4.7 -  The percentage o f macrophages, eosinophils, lymphocytes and neutrophils found in the bronchoalveolar fluid 
of naive (non-sensitised), saline challenged (acute and chronic) and OVA challenged (acute and chronic) mice. Results are 
expressed as mean±S.E.M. *significantly different from acute saline; #significantly different from chronic saline; One­
way Analysis o f Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 4.8 (A-E) -  Bronchioles o f naive, saline challenged (acute and chronic) and OVA challenged (acute and chronic) 
mice stained with haematoxylin and eosin to display general morphology (lOOOx magnification).
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Figure 4.9 -  The mean pathology score o f cells found in the peri-bronchiolar space of nai ve, saline challenged (acute and 
chronic) and OVA challenged (acute and chronic) mice. Results are expressed as mean±S.E.M. #significantly different 
from acute saline; *significantly different from chronic saline; Asignificantly different from acute OVA challenged mice. 
One-way Analysis o f Variance followed by a Dunnett post-test (P<0.05; n=4).
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Figure 4.10 (A-E) -  Bronchioles o f naive, saline challenged (acute and chronic) and OVA challenged (acute and chronic) 
mice stained with picrosirius red to display collagen (lOOOx magnification).
108
CHAPTER 4
100n
8 0 -
o
O  6 0 -
&_
o
!co
Eo
i -
4 0 -
m
S5 20-
i i
ChrSal AcOva ChrOvaNaive AcSal
Figure 4.11 -  Effect o f saline (acute or chronic) or OVA (acute or chronic) challenge on percentage bronchiolar collagen 
in mice. Results are expressed as mean±S.E.M. *significantly different from chronic saline; Asignificantly different from 
acute OVA challenged mice. One-way Analysis o f Variance followed by a Dunnett post-test (P<0.05; n=4).
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Figure 4.12 (A-E) -  Bronchioles o f naive, saline challenged (acute and chronic) and OVA challenged (acute and chronic) 
mice stained with alcian blue and periodic acid Schiff to display goblet cells (lOOOx magnification).
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Figure 4.13 -  Effect o f saline (acute or chronic) or OVA (acute or chronic) challenge on number o f mucin associate 
goblet cells per 10,000 epithelial pixels. Results are expressed as mean±S.E.M. * significantly different from chronic 
saline; Significantly different from acute OVA challenged mice. One-way Analysis o f Variance followed by a Dunnett 
post-test (P<0.05; n=4).
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4.5 DISCUSSION
4.5.1 EARLY AND LATE ASTHMATIC RESPONSES IN ACUTE AND
CHRONIC OVALBUMIN CHALLENGED MICE
Saline challenges in sensitised mice did not cause bronchoconstriction indicating that there 
was no contamination of the saline or exposure chamber with OVA. However, in the groups 
challenged with OVA a biphasic response was observed. There was little difference observed 
between the two OVA challenge protocols when assessing EAR and LAR. The acute and 
chronic OVA challenged mice both had an EAR, which peaked at 2 hours, and LAR, which 
peaked at 7 hours. The fact that the EAR took 2 hours to peak is in contrast to the study by 
Cieslewicz et al., (1999), who showed a peak at 15 minutes, but correlates with the study by 
Femandez-Rodriguez et al., (2008), upon which protocol the present study was based. The 
reason for the difference between this study and the Cieslewicz et al., (1999) study could be a 
result of a number of factors. Firstly this study used male BALB/c mice obtained from 
Harlan, UK, the Cieslewicz et al., (1999) study used female BALB/c mice obtained from The 
Jackson Laboratory, USA. It is possible that there could be differences between sex when it 
comes to the EAR in mice, also there could be differences between the strain of BALB/c 
mice as they were bred in different countries. There are also differences in the protocols and 
amounts of OVA used which could explain the differences.
It is unclear which study better reflects the true situation, however, a study by Choi et al, 
(2005) also displayed a delayed EAR. There are explanations as to why the EAR could be 
delayed. As serotonin and not histamine is the primary mediator in mouse mast cell 
degranulation (Cannings 2003) and a relatively high dose of serotonin is require to cause a 
bronchoconstriction (Unpublished observations -  Femandez-Rodriguez et al.) it is possible 
that it takes longer for the levels of serotonin to reach a peak than histamine. Another 
explanation is that there could be a delay in the release of mediators that provoke mast cell 
degranulation (Femandez-Rodriguez et al., 2008). Mice have poorly developed airway 
smooth muscle compared to humans (Karol 1994) this may also be a factor in causing a 
delay. The fact that this model has a delay before the EAR and this is not seen in human 
asthma means that this model is a poor representation of the mechanisms of early phase 
bronchoconstriction in humans.
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4.5.2 AIRWAY HYPERRESPONSIVENESS IN ACUTE AND CHRONIC
OVALBUMIN CHALLENGED MICE
Hyperresponsiveness of the airways was assessed by using the non-selective muscarinic 
receptor agonist methacholine. A dose of 30 mg/ml was used in acute OVA and saline 
challenged mice. Previous experiments have shown using this dose in chronic OVA 
challenged mice causes a severe bronchoconstriction response which was difficult to record 
(Femandez-Rodriguez et al., 2008); as a result a dose of 10 mg/ml was used. In both the 
acute and chronic saline challenged mice no difference was observed between pre- and post­
saline challenge.
In the acute OVA challenged mice there was evidence of AHR following a methacholine 
challenge. Levels of Penh increased by over 1,000 percent post-OVA challenge. AHR was 
also observed in the chronic OVA challenged mice. An increase in Penh of almost 400 percent 
was observed after a methacholine challenge following the final OVA exposure. The fact that 
a lower dose of methacholine must be used in the chronic group suggests that the repeated 
challenges have increased the risk of bronchoconstriction occurring because of the increased 
hyperresponsiveness of the airways. The chronic OVA group may be more susceptible to the 
higher dose of methacholine because repeated OVA challenges will cause the loss of 
epithelial cells and therefore reduce the protection they give the airway wall.
4.5.3 CELLULAR INFLUX IN ACUTE AND CHRONIC OVALBUMIN 
CHALLENGED MICE
After the final methacholine challenge the mice were euthanised and the trachea cannulated. 
As the mouse trachea is small it is difficult to insert the cannula without damage and 
subsequent contamination of the BAL fluid with red blood cells. When carrying out a total 
cell count it would be difficult to distinguish between red and white blood cells meaning the 
results would be inaccurate, because of this no total cell count was carried out. The drawback 
of not having a total cell count is that the BAL data must be presented as percentage of 
leukocytes. This is not an ideal measurement as an increased influx in one leukocyte subtype 
could mean that a smaller percentage of another leukocyte subtype is counted but this does 
not necessarily mean there is a decrease in the number of that subtype.
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The issue of having no total cell count limits the effectiveness of the model as there could 
potentially be major changes in cell number which are not being observed. There are ways to 
overcome the issue of the trachea size. The mouse lung tissue was used to obtain a semi- 
quantifiable score of the total inflammatory cells in the lung tissue using histological analysis, 
unfortunately sections are not clear enough to distinguish the leukocyte subtypes.
A significant increase in the percentage of eosinophils present in the BAL fluid of acute and 
chronic OVA challenged mice was observed. This is to be expected as eosinophils drive the 
LAR which was observed in both models. Zosky and Sly (2007) reviewed models of asthma 
and stated that a drawback of mouse models is that they can have a massive influx of 
eosinophils, up to 60% of BAL fluid cells, and this is more reminiscent of allergic alveolitis. 
The fact that this model does not have the same magnitude of eosinophil influx strengthens 
the claim than it is more representative of human asthma that other mouse models. In both 
acute and chronic OVA treated mice a significantly decreased level of macrophages were 
observed compared to the respective saline challenged group. As mentioned this may not 
necessarily mean that there is a decrease in absolute number, but just a relative fall compared 
to the large increase in another subtype. In reality an increase in macrophage number would 
be expected.
4.5.4 HISTOLOGICAL CHANGES IN ACUTE AND CHRONIC
OVALBUMIN CHALLENGED MICE
Airway remodelling was observed in chronic OVA challenged mice but no other groups. It is 
clear to see from the haematoxylin and eosin stained sections that there is a vast increase in 
the thickness of the bronchiole wall of the chronic OVA challenged group compared to the 
other protocols. The scoring of the peribronchiolar inflammatory cells confirms that chronic 
OVA challenge caused increased influx of inflammatory cells into the lung. It is likely that 
these inflammatory cells contribute to the airway remodelling observed. Following staining 
with picrosirius red a large increase in bronchiolar collagen was observed both qualitatively 
and quantitatively in the repeated OVA challenged group. Evidence of airway remodelling 
was also observed in the alcian blue / periodic acid Schiff stained chronic OVA bronchioles 
where goblet cell hyperplasia was observed. These findings are also present in other studies 
following different OVA protocols (McMillan & Lloyd, 2004; Xisto et al., 2005). The fact
115
CHAPTER4
that airway remodelling was observed in the chronic OVA model but not the acute OVA 
model suggests that the chronic model is a far better representation of human asthma.
4.5.5 GENERAL CONCLUSIONS
Models of asthma tend to have positive and negative features and this model is no exception. 
Firstly, there are limitations in using mice such as the fact that they respond poorly to 
histamine, there is huge variation between strains and anatomically they are very different to 
humans. However, species-specific reagents are available, transgenic mice are also readily 
available and IgE is the major-anaphylactic antibody making mice advantageous for models 
of asthma. As long as the limitations are considered when testing potential asthma 
therapeutics on mice then they can prove an excellent tool for asthma research.
This model was able to replicate the key features of the Femandez-Rodriguez et al, (2008) 
model. EAR, LAR, AHR and cellular influx, in the form of eosinophil recruitment, was 
observed. The fact that airway remodelling occurred in the chronic OVA model but not in the 
acute OVA model supports the method of chronic OVA challenging to develop a model of 
asthma as opposed to the commonly used single or double OVA challenge. Although the 
chronic model has a more time-consuming protocol it ultimately proves more efficient. 
Following a literature search it appears that this chronic OVA model is the only mouse model 
that displays changes in lung function, AHR, cellular influx and airway remodelling. The 
effect that current and potential asthma therapeutics has on the chronic OVA model and the 
acute OVA model will be assessed in the forthcoming chapters.
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5.1 INTRODUCTION
5.1.1 CORTICOSTEROIDS
Corticosteroids, administered via inhalation, are recommended as the first-line therapy in 
treating persistent symptoms of asthma. Firstly a low dose is administered; if this does not 
relieve the symptoms then the dose is increased until control is achieved. Fluticasone 
propionate, budesonide and beclometasone are all examples of inhaled corticosteroids that 
have been used to relieve airway inflammation. However, in cases where asthma is severe 
and inhaled corticosteroids do not prove effective then orally administered steroids, such as 
dexamethasone, betamethasone and prednisolone, have been used (Wu et al., 2008).
Corticosteroids can also reduce the number of the main inflammatory cells involved in the 
asthmatic reaction. Eosinophil apoptosis is increased when corticosteroids are administered 
(Meagher et al., 1996) resulting in a decreased amount of circulating eosinophils. Viegas et 
al., (2008) state that corticosteroids can also induce apoptosis in T-lymphocytes; this would 
result in the release of less cytokines such as IL-4, which play an important role in the 
exacerbation of the asthmatic response. The number of mast cells are reduced by 
corticosteroids during asthma (Jeffery et al., 1992). Alveolar macrophages secrete 
chemokines and cytokines to chemoattract more macrophages to the airways resulting in 
increased inflammation. Corticosteroids can reduce this secretion (John et a l , 1998). 
Whether corticosteroids have an effect on neutrophils is debatable, it may be a case of 
reduced neutrophil number in severe asthma only (Belvisi, 2004). Kamei et al,. (1996) show 
that corticosteroids reduce the number of dendritic cells in the airways. The role of dendritic 
cells is to act as an antigen-presenting cell. Therefore reducing dendritic cell numbers leads to 
a reduction in the immune response.
Corticosteroids do not have their role exclusively on inflammatory cells. They are also able to 
inhibit mucus secretion in the airways possibly by inhibiting the expression of the mucin 
genes MUC2 and MUC5AC (Liu et al., 2004). This would reduce the occlusion of the 
airways caused by excess mucus release and thus make breathing easier. Epithelial cells 
release a vast amount of inflammatory mediators and hence are an excellent target for 
therapeutics. Figure 5.1 shows some of the mediators released by epithelial cells and how 
corticosteroids are able to reduce the secretion of these mediators. This all results in a marked
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decrease in airway inflammation and as a result airway hyperresponsiveness is reduced 
(Barnes, 1990).
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Figure 5.1: Schematic diagram to highlight the multiple roles that corticosteroids have on combating an 
asthmatic response. IL-1[3 = Interleukin 1(3; IL-6 = Interleukin 6; GM-CSF = Granulocyte-Macrophage Colony 
Stimulating Factor; RANTES = Regulated upon Activation, Normal T Cell Expressed, and Secreted; M IP-la = 
Macrophage Inflammatory Protein - la; INOS = Inducible Nitric Oxide Synthase; COX-2 = Cyclooxygenase-2; 
cPLA2 = Cytoplasmic Phospholipase A2; ET-1 = Endothelin-1; ICAM-1 = Intercellular adhesion molecule-1. 
Diagram adapted from Barnes (2002).
Corticosteroids do not have bronchodilator properties and as a result do not alleviate the EAR 
to allergen inhalation. To overcome this problem corticosteroids are often administered in
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combination with inhaled P2-agonists which are bronchodilators. The long-term 
administration of p2-adrenergic receptor agonists causes downregulation and uncoupling of 
P2-adrenoreceptors. This is overcome by administering the agonist in combination with 
corticosteroids (Mak et al., 2002; Mak et al., 1995). Corticosteroids also cause an increase in 
the expression of p2-adrenergic receptors in the lung (Adcock et al., 1996). The synergistic 
and complementary effect that these two drug classes have renders them arguably the most 
effective way to control asthma (Barnes, 2002).
Generally corticosteroids do not cause many harmful side effects. Dysphonia, hoarseness of 
the voice, and thrush are some of the more common complaints, which occur after taking 
inhaled corticosteroids. Some more severe systemic effects can occur such as osteoporosis 
and glaucoma but these are rare. One problem some asthmatics face is corticosteroid-resistant 
asthma; this means they do not respond to high doses of inhaled corticosteroids (McLeod et 
al., 1985; Szefler & Leung, 1997). Reduced responsiveness to corticosteroids is a much more 
common problem; much higher doses must be used to treat airway inflammation (Barnes et 
a l , 2009).
5.1.2 MECHANISM OF ACTION
Corticosteroids are the only currently available therapy that can suppress the inflammation in 
asthmatic airways (Barnes & Adcock, 2003). This is done via two main mechanisms, 
transactivation and transrepression. Transactivation occurs when a high dose of corticosteroid 
is administered resulting in the formation of anti-inflammatory protein. The corticosteroid is 
able to cross the cell membrane of the target cell and bind to a cytosolic glucocorticoid 
receptor (GR). The binding causes structural changes in the receptor which causes transport 
of the receptor-corticosteroid complex to the nucleus. The complex then dimerises and binds 
to DNA at specific sequences known as the glucocorticoid response elements (GRE). The 
receptor-corticosteroid complex also interacts with coactivator molecules such as cyclic 
adenosine monophosphate response element-binding protein (CREB) -  binding protein 
(CBP). CBP has intrinsic histone acetyltransferase (HAT) activity which is activated by the 
interaction of the complex. The result of the receptor-corticosteroid complex binding to both 
the GRE and CBP is an increase in gene transcription of anti-inflammatory genes. This leads 
to an increase in anti-inflammatory protein synthesis producing such proteins as interleukin-
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10 and the a form of inhibitor of nuclear factor kappa B (NF-kB), inhibitor of kappa B-a 
(IicBa). A schematic diagram of transactivation is shown in figure 5.2.
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Figure 5.2: A high dose o f corticosteroid passes through the cell membrane and binds with a glucocorticoid 
receptor causing the translocation o f the complex to the nucleus. Here it dimerises and binds to GRE or CBP 
resulting in the increased transcription o f anti-inflammatory genes. GRE = Glucocorticoid response elements; 
CBP = CREB (Cyclic adenosine monophosphate response element binding protein) -  binding protein; HAT = 
Histone acetyltransferase; N F -kB  = Nuclear factor kappa B; IkB -o = Inhibitor of kappa B - a  Diagram adapted 
from Barnes and Adcock (2003).
If transactivation can be thought of as the switching on of anti-inflammatory genes then 
transrepression is the switching off of inflammatory genes. Transrepression occurs when a 
lower dose of corticosteroid is administered. Originally an inflammatory stimulus such as 
tumour necrosis factor-a (TNF-a) causes activation of inhibitor of IkB  kinase-2 (IKK2) 
which in turn activates N F -k B . This causes the translocation of two N F -k B  proteins, p50 and 
p65, to the nucleus where they bind to CBP. As CBP has intrinsic HAT activity the outcome
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is increased gene transcription of inflammatory genes such as granulocyte-macrophage 
colony stimulating factor (GM-CSF) shown in figure 5.3.
Corticosteroids are able to inhibit this increase in gene transcription. Once administered the 
corticosteroids pass through the cell membrane and bind to the GR, like in transactivation, 
this causes the newly formed complex to transport to the nucleus and bind to the CBP. After 
binding the corticosteroid is able to prevent the formation of inflammatory genes by either 
directly inhibiting HAT activity or by recruiting histone deacetylase-2 (HDAC2) which 
causes gene repression by deacetylation. These two processes are shown in figure 5.3.
5.1.3 USE IN ASTHMA MODELS
Treatment with the corticosteroid fluticasone propionate (FP) was shown to have no effect on 
the EAR in both humans (Palmqvist et al., 2005) and ovalbumin challenged guinea pigs 
(Lawrence et al., 1998). This is expected as corticosteroids do not have bronchodilator 
properties. However, FP was able to inhibit the LAR in the same two studies. This inhibition 
is most likely a consequence of eosinophil apoptosis which is increased when corticosteroids 
are administered (Meagher et al., 1996). In humans FP was also shown to decrease sputum 
levels of eosinophils and airways hyperresponsiveness to methacholine (Palmqvist et al., 
2005). This was also observed in ovalbumin sensitised and challenged guinea pigs that were 
treated with FP (Lawrence et al., 1998). Treatment with the orally-administered 
corticosteroid dexamethasone has shown inhibition of eosinophil influx, LAR and AHR in 
sensitised guinea pigs that were exposed to ovalbumin (Toward & Broadley, 2002).
Corticosteroids potentially have a role in alleviating the structural airway remodelling 
observed in chronic asthma. A study by Feltis et al., (2007) showed evidence of inhaled 
corticosteroids downregulating angiogenic remodelling in humans. It has also been shown 
that FP can increase the ratio of sputum metalloproteinase 9 (MMP-9) compared to tissue 
inhibitor of metalloproteinase-1 (TIMP-1) (Vignola et al., 1998). MMP-9 is involved in the 
breakdown of extracellular matrix proteins, the build up of which leads to subepithelial 
fibrosis. Therefore an increase in MMP-9 over TIMP-1 results in the increased breakdown of 
extracellular matrix proteins and potential reduction in subepithelial fibrosis. However, a 
study in rats by Vanacker et al., (2002) showed that FP had no measurable effect on airway 
remodelling at a clinically relevant dose and only when a higher dose, which caused systemic 
side-effects, was used then airway remodelling was inhibited.
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By assessing the effect FP has on asthmatic parameters shown in both the acute and chronic 
guinea pig and mouse models developed in earlier chapters then it is possible to gain a better 
understanding of whether these models mimic the human response to a corticosteroid.
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(e.g. IL-1J3, TNF-a)
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NF-Kp
Acetylation
Inflammatory gene
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Figure 5.3: An inflammatory stimuli causes activation o f IKK2 resulting in the translocation o f p65 and p50 NF- 
kB  dimers to the nucleus. This causes increased gene transcription of inflammatory genes. A low dose o f  
corticosteroid passes through the cell membrane and binds with a glucocorticoid receptor causing the translocation 
of the complex to the nucleus. Here it binds to CBP causing inhibition o f HAT activity. The complex can also bind 
to HDACs resulting in deacetylation and inflammatory gene repression. CRP = Cyclic adenosine monophosphate 
response element binding protein (CREB) -  binding protein; HAT = Histone acetyltransferase; N F -kB = Nuclear 
factor kappa B; HD AC = Histone Deacetylase; IL-1(3 = Interleukin-113; TNF-a = Tumour Necrosis Factor-a; IKK2 
= Inhibitor o f IkB Kinase 2; GM-CSF = Granulocyte-Macrophage Colony Stimulating Factor Diagram adapted 
from Bames and Adcock (2003)
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5.2 AIMS AND OBJECTIVES
5.2.1 AIMS
The aim of this chapter was to assess the effect of fluticasone propionate treatment compared 
to vehicle treatment on acute and chronic OVA challenged guinea pigs and mice. The 
parameters investigated were early and late phase bronchoconstriction, airway 
hyperresponsiveness, cellular influx and lung histology. This chapter will give an indication 
of how well the guinea pig and mouse models represent human asthma.
5.2.2 OBJECTIVES
• To investigate the effect that FP treatment has on acute OVA exposed guinea pigs and 
mice by measuring lung function, response to histamine and cellular influx compared 
to vehicle treatment.
• To investigate the effect that FP treatment has on chronic OVA exposed guinea pigs 
and mice by measuring lung function, response to histamine and cellular influx 
compared to vehicle treatment.
• To assess bronchiole structure, collagen deposition and levels of goblet cell 
hyperplasia in FP treated chronic OVA challenged guinea pigs and mice compared to 
vehicle.
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5.3 METHODS
The methods for this chapter are covered in greater detail in chapter 2. Briefly, six male 
Dunkin-Hartley guinea pigs weighing 200-250 g and six male BALB/c mice weighing 20-25 
g were used for each test group.
5.3.1 SENSITISATION
Both guinea pigs and mice were sensitised by an intra-peritoneal, bilateral injection of a 
suspension containing OVA (100 pig) and Al(OH) 3  (100 mg) in PBS on days 1 and 5. Guinea 
pigs were administered 1 mg/kg and mice 0.25 mg/kg.
5.3.2 OVALBUMIN CHALLENGES
Guinea pig OVA challenges for both acute and chronic groups were carried out in a stainless 
steel exposure chamber (40 cm diameter, 15 cm height) with a Wright nebuliser attached. The 
same nebuliser was used for challenging mice but they were exposed in a perspex box (38 cm 
length; 20 cm width; 20 cm height). The nebuliser delivered the OVA or saline at an air 
pressure of 20 lb p.s.i. and at a rate of 0.3 ml/min. Both animals were removed from the 
chamber and exposure was considered complete if they appeared to be distressed during the 
challenge.
5.3.2.1 ACUTE PROTOCOL -  GUINEA PIGS
Guinea pigs were challenged with OVA (0.01%) on day 15 (14 days subsequent to the first 
sensitisation injection) for an hour.
5.3.2.2 CHRONIC PROTOCOL -  GUINEA PIGS
To provoke a response to chronic OVA challenges the guinea pigs were intially challenged 
with an hour long OVA (0.01%) exposure on day 15. On days 17-29, every 48 hours, 
mepyramine (30 mg/kg) was administered then 30 minutes later an hour long challenge of
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OVA (0.1%) occurred. Finally on day 31 OVA (0.1%) was administered for an hour without 
mepyramine. Lung function measurements were recorded immediately after this challenge.
5.3.2.3 ACUTE PROTOCOL -  MICE
Two OVA (0.5%) challenges lasting an hour, separated by 4 hours, were used to provoke an 
acute response.
5.3.2.4 CHRONIC PROTOCOL -  MICE
OVA (2%) was used throughout the chronic protocol. To begin with the mice were 
challenged with this dose for 30 minutes three times a week for six weeks. On the first day of 
the seventh week the exposure lasted an hour and lung function measurements were recorded 
after this.
5.3.3 LUNG FUNCTION MEASUREMENTS
Baseline values of sGaw were recorded before the final OVA exposure and all subsequent 
results were taken as a percentage of these values. The results were obtained by using whole- 
body plethysmography. Following the final challenge values were taken after 0, 15, 30, 45 
and 60 minutes, then hourly until 12 hours with a final reading taken at 24 hours.
To record lung function in mice an unrestrained system (Buxco), which calculates Penh was 
used. Values were recorded 0, 20, 40, 60, 90 and 120 minutes post challenge, then hourly 
until 10 hours with a final recording at 19 hours (for acute) or 24 hours (for chronic). Prior to 
the challenge, baseline values of Penh were taken and the subsequent results were taken as a 
percentage of this.
5.3.4 AIRWAY HYPERRESPONSIVENESS MEASURMENTS
5.3.4.1 GUINEA PIGS
Airway responses to histamine were assessed pre-OVA exposure and post-final OVA 
exposure. It was assessed by recording baseline sGaw values, then exposing the guinea pigs to 
histamine (1 mMol for 20 seconds) and finally recording further sGaw values 0, 5 and 10 
minutes subsequent to the histamine exposure.
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5.3.4.2 MICE
AHR was assessed in mice by evaluating their response to methacholine (30 mg/ml for acute, 
10 mg/ml for chronic). 2 minutes of baseline values were recorded, followed by a minute of 
methacholine then finally 5 minutes of readings. The response to methacholine was recorded 
as a percentage of baseline. AHR was assessed on day 14 after the final OVA exposure.
5.3.5 TOTAL AND DIFFERENTIAL CELL COUNTS
5.3.5.1 GUINEA PIGS
After the final histamine challenge was complete the guinea pigs were euthanised and the 
trachea was cannulated. Following this the lungs were removed and saline was pumped into 
them and then removed to obtain BAL fluid. This was used to carry out a total and 
differential cell count.
5.3.5.2 MICE
BAL fluid was obtained from mice in the same way as guinea pigs. As the trachea was 
damaged when cannulated blood contaminated the BAL fluid meaning a total cell count 
could not be carried out. A differential cell count was still done using the BAL fluid.
5.3.6 DRUG ADMINISTRATION
FP was delivered at a dose of 0.51 mg/ml dissolved in saline (40%), DMSO (30%) and 
ethanol (30%). A 15 minute inhalation of the solution was administered 24 hours and 30 
minutes before the final OVA exposure and 6 hours post-exposure.
5.3.7 HISTOLOGICAL ANALYSIS OF GUINEA PIG AND MOUSE LUNGS
3-5 mm thick portions of the left superior lobe sliced 1 mm below the bronchus were 
processed into wax blocks. 6pm sections were then sliced using a microtome and fixed onto a 
glass slide. The slices were stained with either the haematoxylin and eosin, picrosirius red or
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AB/PAS protocols. This allowed staining for general morphology, collagen and mucin 
associated goblet cells, respectively. ImageJ software was used to quantify these results. The 
peribronchiole, periphery of the small airways, of sections that were stained with 
haematoxylin and eosin was scored for number inflammatory of cells present to evaluate 
whether the number of inflammatory cells differed in the lung tissue of various treatment 
groups. The parameters for scoring were on a semi-quantitative scale as absent (0), minimal 
(1), slight (2), moderate (3), marked (4), or severe (5) (Barends et al., 2004).
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5.4 RESULTS
5.4.1 LUNG FUNCTION OF ACUTE CHALLENGED GUINEA PIGS AND
MICE 
5.4.1.1 GUINEA PIGS
Figure 5.4 demonstrates that in guinea pigs that were administered the FP vehicle (saline- 
40%;DMSO-30%;ethanol-30%) an early phase bronchoconstriction was observed 
immediately following a single OVA challenge (-54.7±7.0%). FP treatment had no effect on 
this bronchoconstriction as an immediate decrease in sGaw was observed in this group also (- 
65.9±2.2%). In fact no significant difference was observed between the two groups until the 7 
hour time point. A late phase bronchoconstriction was present in the vehicle treated group (- 
25.5±5.1%) but FP treatment significantly reduced this (-1.2±3.2%).
When assessing the peak bronchoconstriction values between 0-6 hours no difference is seen 
between the two groups, however, between 7-12 hours FP treated guinea pigs had a 
significantly reduced value of sGaw compared to vehicle treated (-4.5±2.0% compared to - 
26.0±4.9% respectively). Area under the curve analysis showed no difference in total or EAR 
area between the groups but as expected a significantly reduced area was seen after FP 
treatment compared to vehicle in LAR area (24.1 ±7.2%.hr compared to 163.8±45.4%.hr 
respectively) (figure 5.5).
5.4.1.2 MICE
Figure 5.6 represents the lung function of acute OVA challenged mice treated with vehicle or 
FP. An early phase bronchoconstriction seen as an increase in Penh was observed for both 
vehicle treated (53.9±2.9%) and FP treated (53.6±4.0%) after 2 hours. This steadily 
recovered back to baseline. At 7 hours the vehicle treated group had a second 
bronchoconstriction (46.1±4.3%), however, FP treatment significantly reduced this 
(7.7±2.6%). FP continued to cause a significant reduction at 8  hours. When comparing peak 
bronchoconstrictions no difference was observed at the EAR time point. During the LAR 
time point FP treatment caused a significant reduction in the response to OVA compared to 
vehicle (11.8±1.9% compared to 46.6±4.2% respectively).
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Area under the curve analysis is shown in figure 5.7. No significant variation was observed 
between the groups throughout the whole curve and during the EAR. However, FP treatment 
caused a significantly lower area under the curve compared to vehicle during the LAR 
(195.6±58.0%.hr compared to 555.9±101.1%.hr respectively).
5.4.2 AIRWAY HYPERRESPONSIVENESS OF ACUTE CHALLENGED
GUINEA PIGS AND MICE 
5.4.2.1 GUINEA PIGS
Assessment of AHR in acute OVA challenged guinea pigs treated with vehicle or FP is 
shown in figure 5.8. Vehicle treatment does not prevent AHR as a significant decrease in 
sGaw after histamine inhalation was observed post-OVA challenge compared to pre-OVA 
challenge at both 0 (-40.4±9.4% compared to -0.7±0.7% respectively) and 5 (-16.4±7.3% 
compared to 0.1±1.1% respectively) minutes following histamine challenge. Treatment with 
FP caused complete inhibition of AHR as a response to histamine was observed pre- or post- 
OVA challenge.
5.4.2.2 MICE
The responses of acute OVA challenged mice treated with FP or vehicle to methacholine 30 
mg/ml is shown in figure 5.9. The vehicle treated group show a significantly greater increase 
of percentage change in Penh from baseline value post-OVA compared to pre-OVA challenge 
(1461.8±131.0% compared to 5.5±6.4% respectively). This was not the case for the FP 
treated mice as no significant difference was observed post-OVA challenge compared to pre- 
OVA challenge (5.9±4.4% compared to -9.2±4.4% respectively). FP treatment caused a 
significantly less value of Penh post-OVA than vehicle treatment (5.9±4.4% compared to 
1461.8±131.0% respectively).
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5.4.3 LUNG FUNCTION OF CHRONIC CHALLENGED GUINEA PIGS
AND MICE 
5.4.3.1 GUINEA PIGS
Following the final OVA challenge an immediate bronchoconstriction was observed in both 
FP (-47.8=1=7.4%) and vehicle (-54.3=1=10.8%) treated guinea pig as shown in figure 5.10. After 
these resolved a second bronchoconstriction was observed at 7 hours in the vehicle treated 
guinea pigs, however, FP treatment caused significant inhibition of this bronchoconstriction 
(-19.8=1=6.2% compared to -0.8±1.5% respectively). The maximum sGaw values recorded 
between the EAR time point showed no significant difference between the two treatments, 
however, during the LAR time point FP treatment caused a significant decrease in sGaw 
compared to vehicle (-3.1±1.0% compared to -28.1±2.6% respectively). Area under the curve 
analysis, displayed in figure 5.11, showed that the only difference seen between the two 
treatments was during the LAR, when the FP treated guinea pigs had a significantly smaller 
area than the vehicle treated (30.0±3.9%.hr compared to 252.3±20.4%.hr respectively).
5.4.3.2 MICE
Figure 5.12 represents the percentage change in Penh values from baseline in chronic OVA 
challenged mice that were treated with FP or vehicle. A peak bronchoconstriction was 
observed after 2 hours in both the FP (64.8=1=4.5%) and vehicle (61.6±6.7%) treated groups. 
Although this steadily decreased a second bronchoconstriction was observed after 7 hours in 
the vehicle treated group, which was significantly inhibited by FP treatment (58.5=1=5.0% 
compared to 6.6±3.0% respectively). Maximum bronchoconstriction values show that FP was 
only significantly effective at reducing the level of the LAR compared to vehicle (13.1=1=1.8% 
compared to 58.5=1=5.0% respectively). Area under the curve analysis, shown in figure 5.13, 
highlights a significant difference in area between FP and vehicle throughout the whole curve 
(1261.2±65.3%.hr compared to 1934.0=i=220.0%.hr respectively) and at the LAR time point 
(210.2=1=38.6%.hr compared to 778.6±104.7%.hr respectively).
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5.4.4 AIRWAY HYPERRESPONSIVENESS OF CHRONIC CHALLENGED
GUINEA PIGS AND MICE 
5.4.4.1 GUINEA PIG
Figure 5.14 represents the effect of histamine challenge on chronic OVA exposed guinea pigs 
treated with FP or vehicle. In the vehicle treated guinea pigs a significant bronchoconstriction 
was observed post-exposure compared to pre-exposure at both 0 (-38.4±9.0% compared to 
2.6±4.7% respectively) and 5 (-18.1±5.6% compared to 0.9%±3.0%) minutes after the 
histamine challenge. However, FP treatment effectively prevented this AHR as no significant 
difference was observed between sGaw values taken pre- and post-OVA exposure.
5.4.4.2 MICE
The response of chronic OVA challenged mice that have been treated with vehicle or FP to 
methacholine (10 mg/ml) is shown in figure 5.15. The vehicle treated group show a 
significant increase in Penh post-OVA challenge compared to pre-OVA challenge 
(374.4±31.2% compared to 7.9±4.1% respectively) suggesting AHR. FP treated mice had no 
significant difference post-challenge compared to pre-challenge (11.7±2.2% compared to - 
4.7±2.9% respectively). The effectiveness of FP at reducing Penh after a histamine challenge 
was seen as a significant reduction compared to vehicle Penh values post-OVA challenge 
(11.7±2.2% compared to 374.4±31.2% respectively).
5.4.5 CELL COUNTS IN ACUTE AND CHRONIC CHALLENGED GUINEA
PIGS AND MICE
5.4.5.1 GUINEA PIG
Figure 5.16 represents the number of cells in BAL fluid of naive and OVA challenged guinea 
pigs treated with vehicle or FP. The total number of cells in FP treated acute OVA challenged 
guinea pigs was significantly reduced compared to vehicle treated guinea pigs (4.1±0.2xl06 
compared to 6.2±0.6xl06 respectively). The same was true for FP treatment in chronic OVA 
challenged guinea pigs (3.8±0.2xl06 compared to 15.1±0.6xl06 respectively). When 
comparing cellular subtypes a significant decrease was observed in eosinophil number when
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the treatment was FP instead of vehicle in both acute (1.7±0.1xl06 compared to 3.9±0.1xl06  
respectively) and chronic (1.5±0.1xl06 compared to 7.3±1.9xl06 respectively) OVA 
challenged guinea pigs. The only difference between the two FP treated groups was in 
neutrophil number, the chronic group showed a significantly lower level compared to the 
acute group (0.1±0.03xl06 compared to 0.6±0.04xl06 respectively).
5.4.5.2 MICE
The percentage of leukocyte subtypes found in the BAL of naive, vehicle treated and FP 
treated mice is shown in figure 5.17. A significant reduction in percentage of eosinophils was 
observed in FP treated mice compared to vehicle (3.3±1.2% compared to 14.8±1.8% 
respectively). A significant reduction in eosinophil percentage was also observed in chronic 
OVA -  FP treated mice compared to chronic OVA -  vehicle treated (2.0±0.4% compared to 
13.0±0.7% respectively). However, a significantly greater percentage of macrophages were 
observed in the acute OVA -  FP treated mice compared to the acute OVA -  vehicle treated 
group (83.3±2.7% compared to 71.3±2.9% respectively).
5.4.6 LUNG HISTOLOGY OF CHRONIC CHALLENGED GUINEA PIGS
AND MICE
Figure 5.18 (A-C) show a bronchiole from naive, chronic OVA -  vehicle treated and chronic 
OVA -  FP treated guinea pigs. General morphology is shown after haematoxylin and eosin 
staining. The vehicle treated guinea pigs have increased levels of smooth muscle, increased 
thickness of the lamina propria and a thicker epithelium compared to the naive guinea pig 
bronchiole. Compared to vehicle the FP guinea pig shows less features of airway remodelling 
as there is less smooth muscle present and the epithelium and lamina propria is not as thick. 
When the bronchiole pictures are zoomed in leukocytes are visible in the lung tissue. Figure 
5.19 shows the mean pathology scores for leukocyte infiltration of the same three groups. 
Scoring ranged from 0-5 with the higher the score the more inflammatory cells present in the 
peri-bronchiole. There were clearly more cells present in the both the OVA challenged 
groups compared to naive guinea pigs. FP treatment significantly reduced the mean 
pathology score compared to vehicle (1.8±0.3 compared to 4.5±0.5). Figure 5.20 (A-C) 
shows haematoxylin and eosin stained bronchioles from naive, chronic OVA -  vehicle 
treated and chronic OVA -  FP treated mice. The differences between the FP and vehicle
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treated mice were more difficult to see than in the guinea pigs. However, there still appeared 
to be slight loss of smooth muscle and lamina propria thickness after FP treatment. The 
bronchioles for both treatment groups showed more airway remodelling than the naive mice. 
The mean pathological score for these groups is found in figure 5.21 FP treatment caused 
significant reduction in peri-bronchiolar cell number compared to vehicle (1.8±0.3 compared 
to 4.5±0.5).
Figure 5.22 (A-C) shows the three guinea pig groups whose bronchioles have been stained 
with picrosirius red to assess percentage bronchiolar collagen. The vehicle treated OVA 
challenged group showed substantial red stained collagen in the lamina propria. The 
bronchiole of the FP treated guinea pig had less collagen than the vehicle treated guinea pig. 
The quantitative results are shown in figure 5.23 it is clear to see that FP causes a reduction in 
the percentage of bronchiolar collagen compared to vehicle treated guinea pigs (26.8±4.8% 
compared to 53.5±5.3% respectively). Figure 5.24 (A-C) shows naive, chronic OVA with 
vehicle treatment and chronic OVA with FP treatment mouse bronchioles stained with 
picrosirius red. The area of red-stained collagen-containing lamina propria was greatest in the 
chronic OVA vehicle treated group. A more clear difference was observed between the two 
treatment groups, with FP treatment showed less collagen than vehicle treatment. Figure 5.25 
represents the percentage of bronchiolar collagen found in the mouse groups. It shows that FP 
treatment significantly reduced the percentage of collagen compared to vehicle (27.9±6.4% 
compared to 55.3±8.1% respectively).
Figures 5.26 (A-C) show an AB/PAS stained bronchiole from each of the three guinea pig 
groups. Vehicle treated chronic OVA challenged guinea pigs showed strong bright pink 
staining of the epithelium, representing mucin associated goblet cells. FP treatment had less 
of the bright pink stained mucin associated goblet cells than vehicle treatment. The number of 
mucin associated goblet cells per 10,000 epithelial pixels is shown in figure 5.27. FP reduces 
the number compared to vehicle (3.3±0.3 compared to 8.2±0.8). AB/PAS stained bronchioles 
from the three mouse groups are shown in figure 5.28 (A-C). FP treatment reduced levels of 
mucin associated goblet cells compared to vehicle. This is confirmed quantifiably as FP 
significantly reduced the number compared to vehicle (4.2±0.7 compared to 9.6±1.6) (figure 
5.29).
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Figure 5.4 -  Mean time-course values of sGaw in OVA sensitised guinea pigs that were challenged with 0.01 % OVA 
and treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours 
pre-OVA challenge and 6 hours post-OVA challenge. The histogram represents maximum bronchoconstriction values 
during baseline, EAR, LAR and 24 hours. Mean changes in sGaw are expressed as mean±S.E.M. percentage change 
from baseline where a negative value represents a bronchoconstriction. * significantly different from FP treated guinea 
pigs; A significant difference between vehicle and FP treatment. Two-tailed T-test (P<0.05; n=6). Raw FP treatment 
sGaw values (cm/H20) -  Base (0.68±0.03), 0-6 hours (0.23±0.01), 7-12 hours (0.65±0.03) and 24 hours (0.71±0.06). 
Raw vehicle treatment sGaw values (cm/H20) -  Base (0.67±0.08), 0-6 hours (0.29±0.07), 7-12 hours (0.48±0.04) and 24 
hours (0.69±0.06).
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Figure 5.5 -  Area under the curve analysis comparing OVA sensitised guinea pigs challenged with 0.01% OVA and 
treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre- 
OVA challenge and 6 hours post-OVA challenge. Only negative peaks are considered, any peaks that have a positive 
value o f sGaw are excluded. Total includes all negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR 
includes from 6-24 hours. Area under the curve is measured in %.hour. * significantly different from vehicle treatment. 
Two-tailed T-test (P<0.05; n=6).
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Figure 5.6 -  Mean time-course values o f Penh in OVA sensitised mice that were challenged twice with 0.5% OVA 4 hours
apart and treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours
pre-OVA challenge and 6 hours post-OVA challenge. The histogram represents maximum bronchoconstriction values
during baseline, EAR, LAR and 19 hours (24 hours after first exposure). Mean changes in Penh are expressed as
mean±S.E.M. percentage change from baseline where a positive value represents a bronchoconstriction. * significantly
different from FP treated mice; A significant difference between vehicle and FP treatment. Two-tailed T-test (P<0.05; n=6).
Raw FP treatment P ^  values (AU) -  Base (0.36±0.02), 0-6 hours (0.55±0.03), 7-12 hours (0.52±0.03) and 24 hours
(0.35±0.03). Raw vehicle treatment P ^  values (AU) -  Base (0.37±0.03), 0-6 hours (0.56±0.04), 7-12 hours (0.41±0.03)
and 24 hours (0.38±0.03).
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Figure 5.7 -  Area under the curve analysis comparing OVA sensitised mice challenged with a two doses o f 0.5% OVA 
and treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre- 
OVA challenge and 6 hours post-OVA challenge. Only positive peaks are considered, any peaks that have a negative 
value o f Penh are excluded. Total includes all negative peaks from 0-19 hours, EAR includes from 0-6 hours and LAR 
includes from 6-19 hours. Area under the curve is measured in %.hour. *significantly different from vehicle treatment. 
Two-tailed T-test (P<0.05; n=6).
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Figure 5.8 -  Response of the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs challenged with OVA (0.01%) and treated with a 15 minute inhalation o f saline/DMSO/Ethanol 
(40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Values were 
recorded 24 hours before OVA challenge and again 24 hours post-OVA challenge. Mean changes in sGaw are expressed as 
mean±S.E.M. percentage change from baseline where a negative value represents a bronchoconstriction. *significantly 
different from pre-challenge values of sGaw. Two-tailed T-test (P<0.05; n=6).
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Figure 5.9 -  Response of the airways to a 60 second intermittent dose o f methacholine (30 mg/ml) in OVA sensitised 
mice challenged OVA (0.5%) and treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 
mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 hours before 
OVA challenge and again 24 hours post- OVA challenge. Mean changes in Penh are expressed as mean±S.E.M. percentage 
change from baseline where a positive value represents a bronchoconstriction. * significantly different from pre-challenge 
values of Penh;Asignificantly different from vehicle treated post-OVA. One-way Analysis o f Variance followed by a 
Bonferroni post-test (P<0.05; n=6).
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Figure 5.10 -  Mean time-course values o f sGaw in OVA sensitised guinea pigs that had multiple challenges o f  OVA
and treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours
pre-OVA challenge and 6 hours post-OVA challenge. The histogram represents maximum bronchoconstriction values
during baseline, EAR, LAR and 24 hours. Mean changes in sGaw are expressed as mean±S.E.M. percentage change
from baseline where a negative value represents a bronchoconstriction. *significantly different from FP treated guinea
pigs; A significant difference between vehicle and FP treatment. Two-tailed T-test (P<0.05; n=6). Raw FP treatment
sGaw values (cm/H20) -  Base (0.66±0.03), 0-6 hours (0.35±0.06), 7-12 hours (0.64±0.02) and 24 hours (0.68±0.02).
Raw vehicle treatment sGaw values (cm/H20) -  Base (0.75±0.06), 0-6 hours (0.33±0.08), 7-12 hours (0.56±0.05) and 24
hours (0.75±0.05).
3000-
.C
£
O
>
2500-
2000
D
O 1500
0)■OcD
(0
<D
1000 -
<  500-
□  = Chronic OVA challenged -  vehicle treated 
■  = Chronic OVA challenged -  FP treated
T
Total
A
i
*  n
EAR LAR
Figure 5.11 -  Area under the curve analysis comparing OVA sensitised guinea pigs challenged with a chronic dosing o f  
OVA and treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 
hours pre-OVA challenge and 6 hours post-OVA challenge. Only negative peaks are considered, any peaks that have a 
positive value o f  sGaw are excluded. Total includes all negative peaks from 0-24 hours, EAR includes from 0-6 hours and 
LAR includes from 6-24 hours. Area under the curve is measured in %.hour. * significantly different from vehicle treated 
guinea pigs. Two-tailed T-test (P<0.05; n=6).
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Figure 5.12 -  Mean time-course values o f Penh in OVA sensitised mice that were challenged repeatedly with 2% 
OVA three times a week for six weeks and treated with a 15 minute inhalation o f saline/DMSO/Ethanol 
(40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. The 
histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 24 hours. Mean changes 
in Penh are expressed as mean±S.E.M. percentage change from baseline where a positive value represents a 
bronchoconstriction. * significantly different FP treatment; A significant difference between vehicle and FP 
treatment. Two-tailed T-test (P<0.05; n=6). Raw FP treatment P^h values (AU) -  Base (0.63±0.25), 0-6 hours 
(1.08±0.47), 7-12 hours (0.71±0.28) and 24 hours (0.64±0.25). Raw vehicle treatment Penh values (AU) -  Base 
(0.34±0.03), 0-6 hours (0.54±0.03), 7-12 hours (0.53±0.02) and 24 hours (0.34±0.02).
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Figure 5.13 -  Area under the curve analysis comparing OVA sensitised mice challenged with repeated doses of 2% OVA 
and treated with a 15 minute inhalation of saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre- 
OVA challenge and 6 hours post-OVA challenge. Only positive peaks are considered, any peaks that have a negative 
value o f Pgnh are excluded. Total includes all negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR 
includes from 6-24 hours. Area under the curve is measured in %.hour. * significantly different from vehicle treatment. 
Two-tailed T-test (P<0.05; n=6).
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Figure 5.14 Response o f  the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs chronically challenged with OVA and treated with a 15 minute inhalation o f saline/DMSO/Ethanol 
(40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Values were 
recorded 24 hours before OVA challenge and again 24 hours post-final OVA challenge. Mean changes in sGaw are 
expressed as mean±S.E.M. percentage change from baseline where a negative value represents a bronchoconstriction. 
'significantly different from pre-challenge values o f sGaw. Two-tailed T-test (P<0.05; n=6).
500
400-
g 300
CL
C
§> 2 oo-
nsi
O 100-
- 100 <
□  = Chronic OVA challenged -  vehicle treated 
■  = Chronic OVA challenged -  FP treated
Pre-Exposures
T
Post-Exposures
Figure 5.15. -  Response o f the airways to a 60 second intermittent dose o f methacholine (10 mg/ml) in OVA sensitised 
mice challenged repeatedly over 7 weeks with OVA (2%) and treated with a 15 minute inhalation of  
saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA 
challenge. Values were recorded 24 hours before the first OVA challenge and again 24 hours post-final OVA challenge. 
Mean changes in P^h are expressed as mean±S.E.M. percentage change from baseline where a positive value represents a 
bronchoconstriction. ’•‘significantly different from pre-challenge values o f  Penh;Asignificantly different from vehicle treated 
post-OVA. One-way Analysis o f Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 5.16 The number o f total cells, macrophages, eosinophils, lymphocytes and neutrophils found in the 
bronchoalveolar fluid o f  naive (non-sensitised) and OVA challenged (acute and chronic) guinea pigs treated with a 15 
minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 
hours post-OVA challenge. Results are expressed as mean±S.E.M. *significantly different from acute OVA -  vehicle 
treated; #significantly different from chronic OVA -  vehicle treated; Asignificant different from acute OVA -  FP 
treatment. One-way Analysis o f  Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 5.17 -  The percentage o f  macrophages, eosinophils, lymphocytes and neutrophils found in the bronchoalveolar 
fluid of naive (non-sensitised) and OVA challenged (acute and chronic) mice treated with a 15 minute inhalation of  
saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA 
challenge and OVA challenged (acute and chronic) mice. Results are expressed as mean±S.E.M. *significantly different 
from acute OVA -  vehicle treated; #significantly different from chronic OVA -  vehicle treated. One-way Analysis o f  
Variance followed by a Bonferroni post-test (P<0.05; n=6).
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figure 5.18 (A-C) -  Bronchioles o f chronic saline challenge, non-treated, guinea pigs and chronic OVA challenged 
guinea pigs treated with a 15 minute inhalation o f  saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 
iiours pre-OVA challenge and 6 hours post-OVA challenge stained with haematoxylin and eosin to display general 
morphology (lOOOx magnification).
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Figure 5.19 -  The mean pathology score o f  cells found in the peri-bronchiolar space o f naive (non-sensitised) and OVA 
challenged (acute and chronic) guinea pigs treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or 
FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Results are expressed as 
mean±S.E.M. *significantly different from chronic OVA -  vehicle treated. Two-tailed t-test (P<0.05; n=4).
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Figure 5.20 (A-C) -  Bronchioles o f  chronic saline, non-treated, mice and chronic OVA challenged mice treated with a 15
minute inhalation of saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6
hours post-OVA challenge stained with haematoxylin and eosin to display general morphology (lOOOx magnification).
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sure 5.21 - The mean pathology score o f  cells found in the peri-bronchiolar space o f naive (non-sensitised) and OVA 
ilenged (acute and chronic) mice treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP 
Oil mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Results are expressed as 
mtS.E.M. *significantly different from chronic OVA -  vehicle treated. Two-tailed t-test (P<0.05; n=4).
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Figure 5.22 (A-C) -  Bronchioles o f  chronic saline, non-treated, guinea pigs and chronic OVA challenged guinea pigs
seated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-
OVA challenge and 6 hours post-OVA challenge stained with picrosirius red to display collagen (lOOOx magnification).
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Figure 5.23 -  Effect o f  a chronic OVA challenge and treatment with a 15 minute inhalation o f saline/DMSO/Ethanol 
(40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on percentage 
bronchiolar collagen in guinea pigs. Results are expressed as mean±S.E.M. *significantly different from vehicle treatment. 
Two-tailed t-test (P<0.05; n=4).
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Figure 5.24 (A-C) -  Bronchioles o f chronic saline, non-treated, mice and chronic OVA challenged mice treated with a 15
minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6
hours post-OVA challenge stained with picrosirius red to display collagen (lOOOx magnification).
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Figure 5.25 -  Effect of a chronic OVA challenge and treatment with a 15 minute inhalation o f saline/DMSO/Ethanol 
(40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on percentage 
bronchiolar collagen in mice. Results are expressed as mean±S.E.M. * significantly different from vehicle treatment. Two- 
tailed t-test (P<0.05; n=4).
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Figure 5.26 (A-C) -  Bronchioles o f chronic saline, non-treated, guinea pigs and chronic OVA challenged guinea pigs 
treated with a 15 minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre- 
OVA challenge and 6 hours post-OVA challenge stained with alcian blue/periodic acid Schiff to display goblet cells
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Figure 5.27 -  Effect o f  a chronic OVA challenge and treatment with a 15 minute inhalation o f saline/DMSO/Ethanol 
(40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on number o f  
mucin associate goblet cells per 10,000 epithelial pixels. Results are expressed as mean±S.E.M. * significantly different 
from vehicle treatment. Two-tailed t-test (P<0.05; n=4).
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Figure 5.28 (A-C) -  Bronchioles o f  chronic saline, non-treated, mice and chronic OVA challenged mice treated with a 15 
minute inhalation o f saline/DMSO/Ethanol (40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 
hours post-OVA challenge stained with alcian blue/periodic acid Schiff to display goblet cells (lOOOx magnification).
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Figure 5.29 -  Effect o f  a chronic OVA challenge and treatment with a 15 minute inhalation o f saline/DMSO/Ethanol 
(40%/30%/30) or FP (0.51 mg/ml) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on number o f  
mucin associate goblet cells per 10,000 epithelial pixels. Results are expressed as mean±S.E.M. * significantly different 
from vehicle treatment. Two-tailed t-test (P<0.05; n=4).
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5.5 DISCUSSION
5.5.1 EARLY AND LATE ASTHMATIC RESPONSES IN ACUTE AND
CHRONIC OVALBUMIN CHALLENGED GUINEA PIG AND MICE
As expected the corticosteroid FP had no inhibitory effect on the EAR in acute and chronic 
OVA challenged and sensitised guinea pigs and mice. Evidence is shown for this in both the 
time-course graphs and area under the curve analysis. This suggests that corticosteroids have 
little, if any, effect on preventing mast cell degranulation and reducing neutrophil number as 
these are heavily involved in the EAR. These findings also support the fact that administering 
a p2 agonist in combination with corticosteroids would prove to be more effective than 
corticosteroids alone at treating asthma.
In the same groups FP significantly inhibited the LAR when compared to vehicle treatment. 
This follows what is seen in the literature in both animal models (Lawrence et al., 1998) and 
humans (Palmqvist et al., 2005). This finding is expected when considering the mechanism of 
action of corticosteroids. The fact that they are able to inhibit one of the main causes of the 
LAR, eosinophilia, and also inhibit gene transcription of inflammatory mediators such as 
leukotrienes and certain interleukins explains why they are so effective at preventing the 
second bronchoconstriction commonly observed in asthmatics. The acute and chronic guinea 
pig and mouse models showed the same response to FP treatment as humans suggesting they 
are possibly representative of asthma. However, the EAR and LAR are two of many features 
of asthma so the other parameters must be assessed before more conclusions can be drawn.
5.5.2 AIRWAY HYPERRESPONSIVENESS IN ACUTE AND CHRONIC
OVALBUMIN CHALLENGED GUINEA PIG AND MICE
In acute and chronic OVA challenged guinea pigs that were given a histamine challenge after 
the final OVA challenge AHR was observed when vehicle was administered. However, in the 
groups administered with FP AHR was inhibited.
The finding that FP can inhibit AHR is no new phenomenon, studies by Toward and 
Broadley (2004) in guinea pigs have previously shown inhibition by dexamethasone. How
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corticosteroids inhibit AHR is not so well known. The reason for the lack of knowledge of 
how AHR is inhibited is a result of the lack of understanding in the how AHR occurs in the 
first place. A strong correlation between exhaled nitric oxide, which is increased in 
asthmatics compared to non-asthmatics, and AHR has been found (Salome et al., 1999). 
Eosinophils have also been implicated in AHR (Bradley et al., 1991). An increase in 
eosinophil number would result in the increased release of major basic protein which would 
lead to epithelial damage, the removal of a diffusion barrier and ultimately AHR (Wardlaw et 
al., 2002). The fact that corticosteroids have such a broad spectrum of anti-inflammatory 
effects means that they are effective drugs in treating several aspects of asthma, although 
sometimes the mechanism of how this is achieved is unclear.
5.5.3 CELLULAR INFLUX IN ACUTE AND CHRONIC OVALBUMIN
CHALLENGED GUINEA PIG AND MICE
The total number of leukocytes found in the BAL fluid of acute and chronic OVA challenged 
guinea pigs that were treated with FP were reduced in number when compared to vehicle. 
This total decrease was mainly a result of the significant decrease in BAL eosinophil number 
that FP caused. To observe a decrease in eosinophil number is expected as corticosteroids 
cause increased eosinophil apoptosis and inhibit the recruitment of eosinophils to the airways 
by suppressing the production of chemotactic mediators and adhesion molecules (Barnes and 
Adcock 2003).
FP treatment in mice led to a decreased percentage of BAL eosinophils compared to vehicle. 
In acute OVA challenged mice treated with FP an increased percentage of macrophages was 
observed. However, this does not necessarily mean that the absolute number of macrophages 
has increased compared to vehicle. It is more likely to be a relative increase in proportion to 
eosinophils which were reduced. It is no surprise to find FP having such a prominent effect 
on eosinophils in both the guinea pig and mouse models as the LAR and AHR was inhibited 
in these models and eosinophils are believed to have an important role in both of these 
features.
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5.5.4 LUNG HISTOLOGY IN CHRONIC OVALBUMIN CHALLENGED 
GUINEA PIG AND MICE
In chronic OVA challenged guinea pigs that were administered vehicle a clear build up of 
extracellular matrix proteins and smooth muscle can be observed compared to naive guinea 
pigs. Qualitatively, it appears FP treatment reduces the level of extracellular matrix proteins 
and smooth muscle compared to vehicle treatment. This was also true in the mouse model. FP 
treatment was also able to significantly reduce the mean pathology score in both guinea pigs 
and mice. This is consistent with what was observed in the total BAL cell count for the 
guinea pigs and also suggests that although a greater percentage of macrophages were 
counted in mice there may be a lesser number present after FP treatment.
FP inhibited the levels of collagen found in the bronchiole of chronic OVA challenged guinea 
pigs and mice shown both quantifiably and quantitatively. A study in human asthmatics has 
previously shown that FP treatment significantly reduces sputum levels of procollagen type I 
C-terminal peptide (PICP), a marker of ongoing collagen type I deposition (Kai et al., 2007). 
However, this study showed that levels were not reduced to control levels which is also true 
of the findings in the guinea pig and mouse models. There is some evidence that collagen is 
able to contribute to glucocorticoid resistance (Bonacci et a l , 2006) suggesting that 
corticosteroids may not always be effective at reducing collagen. As previously mentioned, 
corticosteroids sire able to reduce mucous levels, therefore it is not surprising that a decrease 
in mucin associated goblet cells was observed after FP treatment in guinea pigs and mice 
compared to vehicle. OVA sensitised rats treated with FP have been shown to have reduced 
levels of goblet cells compared vehicle treated rats (Leung et a l , 2005).
5.5.5 GENERAL CONCLUSIONS
Inhaled corticosteroids are the most effective treatment for chronic asthma (Barnes, 2002). 
Corticosteroids are effective at inhibiting many inflammatory targets which is important for 
the control of asthma (Barnes and Adcock 2003). Attempts to find alternative treatments that 
are more specific have been unsuccessful (Barnes, 1999). The main drawback of using 
corticosteroids is that they are ineffective at preventing the EAR; this is overcome by 
administering P2 agonists.
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FP was effective at preventing the LAR and AHR in acute and chronic OVA challenged 
guinea pigs and mice. It was also able to reduce the number of eosinophils in the BAL fluid 
and partially reverse the airway remodelling observed in the chronic challenged models. All 
of these changes were observed after only three doses of FP. This suggests that it could be 
possible that long-term FP treatment could completely reverse airway remodelling. The fact 
that the results seen in the chronic OVA guinea pig and mouse model after FP are similar to 
those seen in humans strengthen the claim that they are effective models and would prove 
useful in a pre-clinical setting for the evaluation of new anti-asthma drugs.
157
CHAPTER 6
Chapter 6 
Effect of 
phosphodiesterase 
IV inhibitor 
treatment on acute 
and chronic models
of asthma
158
CHAPTER 6
6.1 INTRODUCTION
6.1.1 PHOSPHODIESTERASE IV INHIBITORS
Although corticosteroids are the most effective anti-inflammatory drugs used to treat asthma 
there are still cases of steroid insensitivity and systemic side-effects after long-term use. As a 
result there is a need for alternative therapies. Phosphodiesterase (PDE) 4 inhibitors have 
been in development as novel anti-inflammatory agents to treat asthma and chronic 
obstructive pulmonary disease (COPD) since the 1980s, however, to date none have been 
marketed (Spina, 2008). Despite the promising results in the treatment of asthma with PDE4 
inhibitors in clinical trials and pre-clinical testing (Spina, 2008) they have major drawbacks 
when it comes to their side effects. Vomiting and nausea are a common symptom following 
PDE4 inhibitor treatment. If the dose is lowered to eradicate the side effects then it is less 
effective as an anti-inflammatory drug. Research in overcoming this problem is ongoing. As 
there are four known genes which code for PDE4 then a more selective approach could be the 
answer. Currently it seems that PDE4D plays an important role in inflammatory cell 
activation (Seybold et al., 1998). Despite all of the problems with PDE4 inhibitors there is 
still plenty of optimism in the literature that using them to suppress inflammation is viable 
(Giembycz, 2008; Spina, 2008).
6.1.2 MECHANISM OF ACTION
PDE4 is an enzyme that acts specifically on cyclic adenosine monophosphate (cAMP) by 
hydrolysing cAMP into 5’ adenosine monophosphate (5’AMP) (figure 6.1). cAMP is an 
intermediate, or second messenger, in the physiological responses to many hormones, 
neurotransmitters or drugs. It has been shown to play a key role in all types o f cells involved 
in the pathophysiology of asthma (Nejman-Gryz et al., 2006). cAMP is formed when a ligand 
binds to a transmembrane receptor causing the receptor to activate adenylyl cyclase usually 
via a G-protein mechanism. Adenylyl cyclase is an enzyme that breaks a bond in adenosine 
trisphosphate (ATP) leading to the formation of the cyclic phosphate cAMP. As cAMP is 
usually closely controlled by PDE4 the amount of cellular response is limited. However, if 
PDE4 is inhibited the intracellular level of cAMP increases causing a prolonged cellular 
response.
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The mechanism of upregulation of PDE4 gene expression is unknown (Tang et al., 2005), 
however it has been established that cAMP induces the expression of various PDE4 subtype 
genes (Conti & Jin, 1999). PDE4 can be activated by phosphorylation (Houslay, 2001), IL-2 
(Crocker et al. , 2000), IL-3 (Ahmad et al., 1999), IL-4 or interferon (IFN) y (Li et al., 1992).
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Figure 6.1 - Schematic diagram to demonstrate the effect that PDE4 inhibitors have. A ligand binds to a 
transmembrane receptor causing activation o f adenylyl cyclase. This converts ATP into cAMP leading to a kinase 
cascade and ultimately the cellular response. PDE4 regulates this response and converts cAMP into 5 ’AMP (A.). 
PDE4 inhibitors are able to prevent the conversion o f cAMP to 5 ’AMP. This leads to a greater cellular 
concentration o f  cAMP which in turn causes increased cellular response (B.). ATP = adenosine trisphosphate; 
cAMP = cyclic adenosine monophosphate; 5 ’AMP = 5 ’adenosine monophosphate; PDE4 = phosphodiesterase 
type IV.
The increased level of cAMP leads to several anti-inflammatory effects such as inhibition of 
the creation of reactive oxygen species in neutrophils and eosinophils amongst other roles 
(Nielson & Vestal, 1989). Smooth muscle relaxation in the respiratory system is also 
promoted by cAMP (Schramm & Grunstein, 1992). Clearly these effects would be beneficial 
in asthma making PDE4 an excellent target for therapeutics.
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6.1.3 USE IN ASTHMA MODELS
PDE4 inhibitors have shown very promising effects in asthma. However, the effect of 
assessing PDE4 inhibitors in asthma has been confined to animals and clinical trial data as a 
result there is limited knowledge on long-term and large population effects. Studies in rats 
(Tang et al., 2005) and mice (Deng et al., 2006) have shown increased cAMP-PDE enzyme 
activity in the lung following OVA sensitisation and challenge. PDE4 inhibitors were shown 
to reduce this in the same studies.
As cAMP is able to cause respiratory smooth muscle relaxation it would be expected that 
treatment with PDE4 inhibitors should reduce the EAR. This has been shown with rolipram 
in guinea pigs (Nejman-Gryz et al., 2006) and with roflumilast in mice (Hoymann et a l , 
2009). A slight attenuation in the EAR was also observed in the study by van Schalkwyk et 
al., (2005) in humans treated with roflumilast. It is possible with a higher dose the EAR could 
have been completely inhibited but because of the side-effects that PDE4 inhibitors cause this 
was not feasible to examine. In the same study roflumilast had very positive results in 
decreasing the LAR. This proves that PDE4 inhibitors also have anti-inflammatory effects as 
the LAR is driven by inflammatory mediators. There is very limited data on the effects of 
PDE4 inhibitors on the LAR in animal models. A study by Toward and Broadley (2004) 
showed that rolipram was unable to attenuate the LAR in OVA sensitised and challenged 
guinea pigs, many other studies just consider the EAR and AHR.
AHR is a common feature of asthma and as a result is one of the primary targets for asthma 
therapeutics. Several studies have shown PDE4 inhibitors are able to inhibit AHR in mice 
(Hoymann et al., 2009), rats (Raeburn et al., 1994), guinea pigs (Danahay & Broadley, 1998; 
Holbrook et al., 1996; Howell et al., 1993; Raeburn et al., 1994; Santing et al., 1995) and 
monkeys (Turner et al., 1994). Roflumilast was shown to be effective at reducing AHR in 
humans following a histamine challenge (Louw et al., 2007) further supporting the potential 
PDE4 inhibitors have as anti-inflammatory drugs to treat asthma. As eosinophils are believed 
to have a role in causing AHR (Wardlaw et al., 2002) it is no surprise to find evidence that 
PDE4 inhibitors can reduce eosinophil BAL fluid number (Deng et al., 2006). Kita et al., 
(2008) have shown that in OVA sensitised and exposed mice a PDE4 and PDE1 inhibitor, 
KF19514, is able to reduce the number of eosinophils found in the lamina propria. Guinea 
pigs treated with rolipram also show a reduced influx of eosinophils (Nejman-Gryz et al.,
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2006). This is also the case in mice treated with roflumilast (Hoymann et a l,  2009). 
Reductions in neutrophil numbers have also been associated with PDE4 inhibitors (Deng et 
al, 2006).
Although the ability to reduce the inflammation associated with an asthmatic episode is 
extremely important when analysing a potential therapeutic, the ability of the drug to prevent 
or reverse airway remodelling caused by long-term inflammation is equally as important. 
Roflumilast can inhibit matrix protein deposition in human smooth muscle cells (Burgess et 
al, 2006) and it can inhibit the increase of epidermal growth factor induced MUC5AC 
expression in human epithelial cells suggesting that PDE4 inhibitors may be able to combat 
airway remodelling. On top of this cyclic AMP may have an additional role in modulating 
airway smooth muscle hypertrophy and hyperplasia, which are common morphologic features 
of chronic asthma (Munakata, 2006).
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6.2 AIMS AND OBJECTIVES
6.2.1 AIMS
The aim of this chapter was to assess the effect of the PDE4 inhibitor, roflumilast, compared
to vehicle treatment on acute and chronic OVA challenged guinea pigs and mice. The
parameters investigated were early and late phase bronchoconstriction, airway 
hyperresponsiveness, cellular influx and lung histology. This chapter will give an indication 
of how effective this relatively novel compound is against both acute and chronic guinea pig 
and mouse models that represent human asthma.
6.2.2 OBJECTIVES
• To investigate the effect of roflumilast treatment on acute OVA exposed guinea pigs 
and mice by measuring lung function, response to histamine and cellular influx 
compared to vehicle treatment.
• To investigate the effect that roflumilast treatment has on chronic OVA exposed 
guinea pigs and mice by measuring lung function, response to histamine and cellular 
influx compared to vehicle treatment.
• To assess bronchiole structure, collagen deposition and levels of goblet cell 
hyperplasia in roflumilast-treated chronic OVA challenged guinea pigs and mice 
compared to vehicle.
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6.3 METHODS
Chapter 2 details the complete methods used for this chapter; the following is a brief 
overview. For each guinea pig study group in this chapter six male Dunkin-Hartley guinea
pigs weighing 200-250 g were used. For the mouse studies, male BALB/c mice weighing 20-
25g were used.
6.3.1 SENSITISATION
Guinea pigs and mice were sensitised by an intra-peritoneal, bilateral injection of a 
suspension containing OVA (100 pg) and Al(OH) 3 (100 mg) in PBS on days 1 and 5. The 
guinea pigs were administered 1 ml and the mice 0.25 ml.
6.3.2 OVALBUMIN CHALLENGES
Guinea pig OVA challenges for both acute and chronic groups were carried out in a stainless 
steel exposure chamber (40 cm diameter, 15 cm height) with a Wright nebuliser attached. The 
nebuliser delivered the OVA or saline at an air pressure of 20 lb p.s.i. and at a rate of 0.3 
ml/min. The same nebuliser was used for mice OVA exposures but the chamber used was a 
Perspex box (38 cm length; 20 cm width; 20 cm height). If the animals appeared to be 
distressed at any stage during the exposure they were immediately removed and exposure 
was considered complete
6.3.2.1 ACUTE PROTOCOL -  GUINEA PIGS
An hour exposure to OVA (0.01%) was used as the acute challenge in guinea pigs, this 
occurred on day 15(14 days subsequent to the first sensitisation injection).
6.3.2.2 CHRONIC PROTOCOL -  GUINEA PIGS
On day 15 the guinea pigs following the chronic protocol were challenged with OVA 
(0.01%) for an hour. Following this on days 17-29, every 48 hours, they were challenged
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with OVA (0.1%). This challenge was preceded with an injection of mepyramine (30 mg/kg). 
Finally on day 31 an hour long exposure to OVA (0.1%), minus mepyramine, occurred.
6.3.2.3 ACUTE PROTOCOL -  MICE
In order to provoke an acute response to OVA the mice were challenged with two OVA 
(0.5%) exposures lasting an hour each separated by a 4 hour gap on day 15.
6.3.2.4 CHRONIC PROTOCOL -  MICE
For the chronic group the mice were challenged with OVA (2%) three times a week for six 
weeks for 30 minutes (18 challenges). On the first day of the seventh week (day 57), an hour 
long challenge occurred.
6.3.3 LUNG FUNCTION MEASUREMENTS
Lung function in guinea pigs was measured using whole-body plethysmography to obtain a 
value of sGaw- Values were recorded at baseline, then 0, 15, 30, 45 and 60 minutes following 
the final exposure, then hourly until 12 hours with a final recording at 24 hours. All values 
were compared to baseline. Lung function in mice was recorded using an unrestrained 
chamber (Buxco) in order to obtain values of Penh- Again a baseline value was recorded and 
all other readings were compared to this. Following the final exposure Penh was recorded at 0 , 
20, 40, 60, 90 and 120 minutes and then hourly until 10 hours with a final reading at 19 hours 
for the acute protocol or 24 hours for the chronic protocol.
6.3.4 AIRWAY HYPERRESPONSIVENESS MEASUREMENTS
6.3.4.1 GUINEA PIGS
In order to determine whether AHR is present values of sGaw were again used. Prior to OVA 
or saline exposures (day 14), the guinea pigs were challenged with histamine (1 mMol, 20 
seconds) and recordings were taken 0, 5 and 10 minutes following the challenge. These 
values were compared to baseline values taken before histamine was administered. The same 
process was repeated immediately following the 24 hour reading taken after the final OVA or 
saline exposure.
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6.3.4.2 M ICE
To investigate airway responsiveness in mice 10 mg/ml methacholine was used in the acute 
challenged group and 30 mg/ml in the chronic challenged group. As with the guinea pigs this 
process of challenging occurred pre- and post-OVA or saline challenges. To obtain values in 
mice Penh was used, firstly 2  minutes of baseline values were recorded and averaged. 
Following this a 1 minute intermittent methacholine challenge occurred and then Penh values 
were recorded for 5 minutes and averaged. Percentage change from baseline was then 
recorded.
6.3.5 TOTAL AND DIFFERENTIAL CELL COUNTS
6.3.5.1 GUINEA PIGS
Guinea pigs were administered a lethal dose of sodium pentobarbitone following the final 
AHR test. The trachea was then cannulated and the lungs removed. Saline was instilled into 
the lungs then removed three minutes later. The fluid removed was used to carry out a total 
cell count and then was subsequently centrifuged and stained so a differential count could be 
carried out.
6.3.5.2 MICE
The methods for removing the BAL fluid and differential cell count were the same as in the 
guinea pigs. However, a total cell count was not carried out on mice as the BAL fluid was 
heavily tainted with blood as a result of damage to the trachea when removing the fluid.
63.6 DRUG ADMINISTRATION
Guinea pigs and mice were administered with 1 mg/kg roflumilast dissolved in methyl 
cellulose and delivered orally via a gavage needle. Administration occurred 24 hours and 0.5 
hours before the final OVA or saline challenge and 6  hours post challenge.
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6.3.7 H ISTO LO G ICAL ANALYSIS OF G UINEA PIG  AND M O USE LUNGS
3-5 mm thick portions of the left superior lobe sliced 1 mm below the bronchus were 
processed into wax blocks. Sections (6 pm) were then sliced using a microtome and fixed 
onto a glass slide. The slices were stained using either the haematoxylin and eosin, picrosirius 
red or AB/PAS protocols to show general morphology, collagen deposition and mucin 
associated goblet cells respectively. The peribronchiole (surrounding the small airways) 
region of sections stained with haematoxylin and eosin were scored for numbers of 
inflammatory cells. The parameters for scoring were on a semi-quantitative scale as absent 
(0), minimal (1), slight (2), moderate (3), marked (4), or severe (5) (Barends et al., 2004). 
The area of bronchiolar collagen and number of mucin associated goblet cells were calculated 
as a percentage using ImageJ software.
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6.4 RESULTS
6 .4 .1  L U N G  F U N C T I O N  O F  A C U T E  C H A L L E N G E D  G U I N E A  P I G S  A N D
M I C E
6 .4 .1 .1  G U I N E A  P I G S
Figure 6.2 represents sensitised guinea pigs challenged with a single OVA exposure that were 
treated with roflumilast or vehicle. The vehicle treated group had an immediate 
bronchoconstriction (-66.1±3.0%) which resolved around 4 hours. The roflumilast treated 
group also had an immediate bronchoconstriction (-36.3±3.4%) however, this was 
significantly smaller for the first 30 minutes of recording. At 7 hours the vehicle treated 
group had a second bronchoconstriction (-35.9±6.5%) which was not the case in the 
roflumilast treated group. When comparing the maximum bronchoconstriction values 
roflumilast significantly inhibits at the EAR time point compared to the vehicle group (- 
36.6±3.4% compared to -66.7±2.6% respectively) and at the LAR time point (-4.2±1.0% 
compared to -35.9±6.5% respectively).
Figure 6.3 shows that when comparing area under the curve analysis the roflumilast treated 
group have a significantly smaller area than the vehicle treated group throughout the entire 
test period (186.1±37.0%.hr compared to 792.6±193.2%.hr respectively), at the early phase 
(172.0±33.3%.hr compared to 403.9±88.3%.hr respectively) and at the late phase 
(22.4±7.3%.hr compared to 325.2±124.2%.hr respectively).
6 .4 .1 .2  M I C E
In figure 6.4 the effect of vehicle and roflumilast treatment on the lung function of acute 
OVA challenged mice is shown. After vehicle treatment, OVA showed an early phase peak 
increase in Penh at 2 hours (63.9±2.5%). Roflumilast significantly reduced the OVA response 
at this time point (32.4±2.7%) and also at 90 minutes and 3 hours. At the late phase time 
points, vehicle treatment was unable to prevent a bronchoconstriction at 7 hours (59.9±3.1%). 
However, roflumilast significantly reduced this response (5.7±4.5%) and the significant 
reduction was still present after 8  hours. WTien comparing the effect that roflumilast and 
vehicle had on maximum bronchoconstriction values in acute OVA challenged mice a 
significant reduction at the EAR time point was seen in roflumilast treated mice compared to
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vehicle treated mice (36.3±1.8% compared to 63.9±2.5% respectively). This was also true at 
the LAR time point (14.9±2.2% compared to 60.7±2.8% respectively).
Area under the curve analysis is shown in figure 6.5. Although no significant difference is 
seen throughout the total curve between the drug and vehicle treatments, roflumilast caused a 
significantly reduced area under the curve compared to vehicle at both the EAR time point 
(652.0±61.9%.hr compared to 972.0±77.1%.hr respectively) and LAR time point 
(224.3±44.0%.hr compared to 659.2±115.9%.hr respectively).
6 .4 .2  A I R W A Y  H Y P E R R E S P O N S I V E N E S S  O F  A C U T E  C H A L L E N G E D
G U I N E A  P I G S  A N D  M I C E
6 .4 .2 .1  G U I N E A  P I G S
Figure 6 . 6  represents the effect of challenging an acute OVA guinea pig with histamine. In 
the vehicle treated group a significant bronchoconstriction was observed immediately 
following the histamine in the post-challenge compared to pre-challenge (-21.1±3.6% 
compared to 0.9±1.9% respectively). This bronchoconstriction persisted for 5 minutes after 
the histamine (-15.2±3.1% compared to -0.1±0.9% respectively). Roflumilast treated guinea 
pigs showed no post-challenge response to histamine.
6 .4 .2 .2  M I C E
The effect of roflumilast and vehicle treatment on AHR in mice is shown in figure 6.7. 
Vehicle treated mice had a massive increase to 30 mg/ml methacholine post-OVA challenges 
compared to pre-OVA challenges (1335.6±97.6% compared to -6.9±2.6% respectively). 
Roflumilast treatment significantly inhibited the AHR observed in the vehicle treated group 
(13.8±3.1% compared to 1335.6±97.6% respectively).
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6 .4 .3  L U N G  F U N C T I O N  O F  C H R O N I C  C H A L L E N G E D  G U I N E A  P I G S
A N D  M I C E
6 .4 .3 .1  G U I N E A  P I G S
The effect of roflumilast and vehicle treatment on the lung function response to the final 
OVA challenge of chronic challenged OVA guinea pigs is shown in figure 6 .8 . In the vehicle 
treated group an immediate bronchoconstriction was observed (-70.0±2.0%) which recovered 
at around 6  hours. Roflumilast treatment was unable to prevent an immediate 
bronchoconstriction (-44.8±10.2%) however, it was significantly less than in the vehicle 
group up to 3 hours. Roflumilast treatment was also able to reduce the bronchoconstriction 
usually seen after 7 hours, however, the vehicle group still had this reduction in sGaw (- 
31.2±4.9%). When comparing the effect of roflumilast treatment to vehicle treatment on 
maximum bronchoconstriction values, a significant reduction was observed at the early phase 
time point (-44.8±10.2% compared to -70.4±1.1% respectively) and late phase time point (- 
4.3±0.7% compared to -31.2±4.9%).
6 .4 .3 .2  M I C E
If the lung function curve is analysed using area under the curve, as shown in figure 6.9, then 
roflumilast treatment significantly reduced the total area compared to vehicle treatment 
(305.5±41.4%.hr compared to 1094.6±136.5%.hr respectively). This was also true during the 
EAR (268.8±55.1%.hr compared to 831.0±28.1%.hr respectively) and LAR (53.0±17.2%.hr 
compared to 305.5±101.6%.hr respectively).
Figure 6.10 shows that chronic OVA challenged mice treated with vehicle had an early phase 
bronchoconstriction at 2 hours (65.7±3.3%). Roflumilast treatment was able to significantly 
reduce this though a response was still observed (32.5±3.5%). A late phase 
bronchoconstriction was seen in the vehicle treated group at 7 hours (61.6±2.0%). 
Roflumilast was also able to reduce this response (12.0±1.8%) and still had a significantly 
smaller response after 8  hours. When assessing maximum bronchoconstriction values, 
roflumilast treatment significantly reduced values of Penh compared with vehicle treatment 
(37.0±2.5% compared to 65.7±3.3% respectively) and this is also the case for the LAR 
(13.1±1.9% compared to 61.6±2.0% respectively).
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Area under the curve analysis, as shown in figure 6.11, highlights the area reduction that 
roflumilast treatment has compared to vehicle treatment throughout the curve 
(1048.9±76.7%.hr compared to 1546.8±135.8%.hr respectively), during the EAR 
(672.4±36.9%.hr compared to 942.9±79.3%.hr respectively) and the LAR (277.1±49.9%.hr 
compared to 703.9±62.9%.hr respectively).
6 .4 .4  A I R W A Y  H Y P E R R E S P O N S I V E N E S S  O F  C H R O N I C  C H A L L E N G E D
G U I N E A  P I G S  A N D  M I C E
6 .4 .4 .1  G U I N E A  P I G S
Figure 6 .12 represents the effect of a histamine challenge on roflumilast or vehicle treated, 
chronic OVA exposed guinea pigs. Roflumilast inhibited AHR as no significant difference in 
sGaw was observed between pre- and post-0 VA exposure after histamine. However, in the 
vehicle treated group a significant bronchoconstriction was observed post-OVA exposure 
compared to pre-OVA exposure immediately following a histamine challenge (-33.8±5.9% 
compared to -1.3±2.0% respectively) and this bronchoconstriction was still present 5 minutes 
after the histamine challenge (-22.1±1.9% compared to 0.5±1.2% respectively).
6 .4 .4 .2  M I C E
The response of chronic OVA challenged, roflumilast or vehicle treated mice to 10 mg/ml 
methacholine is shown in figure 6.13. Vehicle treated mice clearly demonstrated AHR post- 
OVA challenge as a significant bronchoconstriction was observed compared to pre-OVA 
challenge (387.5±12.6% compared to -2.2±5.5% respectively). Treatment with roflumilast 
inhibited the AHR observed post-OVA challenge in the vehicle treated mice (28.4±5.0% 
compared to 387.5±12.6% respectively).
6 .4 .5  C E L L  C O U N T S  I N  A C U T E  A N D  C H R O N I C  C H A L L E N G E D  G U I N E A
P I G S  A N D  M I C E
6 .4 .5 .1  G U I N E A  P I G S
Figure 6.14 highlights the effects of roflumilast and vehicle treatment on cellular BAL fluid 
levels in acute and chronic challenged guinea pigs. In the acute OVA challenged group
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roflumilast significantly decreases the total number of cells compared to vehicle treatment 
(3.4±0.3xl06 compared to 6.7±0.5xl06 respectively). This is also true for levels of 
eosinophils (1.3±0.3xl06 compared to 4.9±0.2xl06  respectively). In the chronic OVA 
challenged group roflumilast also decreases the total number of cells compared to vehicle 
(3.8±0.1xl06 compared to 10.9±0.3xl06 respectively) and eosinophil number (1.4±0.1xl06  
compared to 5.7±0.3xl06  respectively). However, in the chronic group roflumilast also 
decreases the number of macrophages ( 1 .6 ± 0 .1 x l 0 6 compared to 4 .7 ±0 .3 x l 0 6 respectively) 
and neutrophils (0.1±0.03xl06 compared to 0.3±0.4xl06 respectively) compared to vehicle. 
The levels were restored to the same levels as observed in acute OVA roflumilast treated 
guinea pigs.
6 .4 .5 .2  M I C E
Figure 6.15 represents the BAL fluid differential cell counts for acute and chronic OVA 
challenged mice treated with roflumilast or vehicle. In the acute challenged mice roflumilast 
significantly reduced the percentage of eosinophils compared to vehicle ( 1 .2 ±0 .2 % compared 
to 16.7±1.0% respectively). As a consequence there was a corresponding significant increase 
in the percentage of macrophages compared to vehicle (87.0±1.0% compared to 69.8±2.0% 
respectively). This was also the case in the chronic challenged group. Roflumilast again 
showed a significant reduction in the percentage of eosinophils compared to vehicle 
(2.5±0.4% compared to 13.9±1.1% respectively). Therefore, a greater percentage of 
macrophages observed following roflumilast treatment compared to vehicle (8 6 .0 ±2 .6 % 
compared to 72.3±1.1% respectively). No differences were observed in lymphocyte or 
neutrophil percentage for both groups.
6 .4 .6  L U N G  H I S T O L O G Y  O F  C H R O N I C  C H A L L E N G E D  G U I N E A  P I G S
A N D  M I C E
Figure 6.16 (A-C) shows a haematoxylin and eosin stained guinea pig bronchiole that was 
naive, chronic OVA challenged -  vehicle treated or chronic OVA challenged -  roflumilast 
treated. Roflumilast treatment reduced the amount of smooth muscle present around the 
bronchiole compared to vehicle treatment. The epithelium of the roflumilast treated guinea 
pig also appeared thinner compared to the vehicle treated guinea pig, however, there did not 
appear to be much difference in the thickness of the lamina propria between both groups. The
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number of inflammatory cells found in the peribronchiolar space of each of these groups have 
been scored and analysed and the outcome is shown in figure 6.17. Roflumilast treatment 
significantly reduces the number of lung inflammatory cells compared to vehicle (2 .3 ±0 . 3  
compared to 4.8±0.3). However, roflumilast is unable to reduce the cells to naive levels.
Figure 6.18 (A-C) represents the bronchioles of mice that are either naive or chronic OVA 
challenged treated with vehicle or roflumilast stained with haematoxylin and eosin to show 
general morphology. Roflumilast treatment appeared to reduce the levels of smooth muscle 
and decrease the thickness of the epithelium and lamina propria compared to vehicle 
treatment. The scoring of inflammatory cells found in the peribronchiolar space in these 
groups is shown in figure 6.19. The number of cells found in the vehicle treated group is 
significantly reduced with roflumilast treatment (4.8±0.3 compared to 1.8±0.3) though not to 
naive levels.
Picrosirius red stained guinea pig bronchioles that are naive, chronic OVA -  vehicle treated 
or chronic OVA -  roflumilast treated are shown in figure 6.20 (A-C). Decreased levels of 
collagen were observed compared to vehicle following roflumilast treatment. The percentage 
of bronchiolar collagen in these guinea pigs is represented in figure 6.21. Treatment with 
roflumilast significantly reduces bronchiolar collagen compared to vehicle treatment 
(23.2±6.0% compared to 46.7±2.9% respectively) in chronic challenged guinea pigs.
Picrosirius red stained bronchioles for the same three treatment groups in mice are shown in 
figure 6.22 (A-C). These show that roflumilast treatment reduces the level of collagen 
compared to vehicle. The percentage of bronchiolar collagen for each of these three groups is 
represented in figure 6.23. It shows that roflumilast treatment significantly reduced the 
amount of bronchiolar collagen compared to vehicle treatment (25.9±4.7% compared to 
59.4±2.8% respectively).
Naive, chronic OVA -  vehicle treated and chronic OVA -  roflumilast treated guinea pig 
bronchioles that were stained with alcian blue/periodic acid Schiff are shown in figure 6.24 
(A-C). Less goblet cells were observed in the bronchioles of roflumilast treated guinea pigs 
compared to vehicle. The number of mucin associated goblet cells per 10,000 epithelial 
pixels in naive, chronic OVA — vehicle treated or chronic OVA — roflumilast treated guinea 
pigs is shown in figure 6.25. Roflumilast treatment significantly reduces the number of goblet 
cells compared to vehicle treatment (3.6±0.3 compared to 9.1±1.7).
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The mouse stained bronchioles are shown in figure 6.26 (A-C). Mice treated with roflumilast 
appear to have less goblet cells (stained bright pink) than vehicle treated mice. In figure 6.27 
the effect that roflumilast and vehicle treatment has on the mucin associated goblet cells of 
chronic OVA challenged mice is shown. The graph shows that roflumilast significantly 
reduced the number of mucin associated goblet cells per 1 0 , 0 0 0  epithelial pixels compared to 
vehicle (3.4±0.8 compared to 10.3±2.3).
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Figure 6.2 -  Mean time-course values o f sGaw in OVA sensitised guinea pigs that were challenged with 0.01 % OVA  
and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post- 
OVA challenge. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 24 
hours. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from baseline where a negative value 
represents a bronchoconstriction. * significantly different from roflumilast treated guinea pigs; A significant difference 
between vehicle and roflumilast treatment. Two-tailed T-test (P<0.05; n=6). Raw roflumilast treatment sGaw values 
(cm/HzO) -  Base (0.67±0.04), 0-6 hours (0.42±0.02), 7-12 hours (0.64±0.03) and 24 hours (0.66±0.05). Raw vehicle 
treatment sGaw values (cm/H20) -  Base (0.62±0.03), 0-6 hours (0.21±0.02), 7-12 hours (0.40±0.05) and 24 hours 
(0.57±0.06).
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Figure 6.3 -  Area under the curve analysis comparing OVA sensitised guinea pigs challenged 0.01% OVA and treated 
orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA 
challenge. Only negative peaks are considered, any peaks that have a positive value o f sGaw are excluded. Total includes 
flll negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR includes from 6-24 hours. Area under the 
curve is measured in %.hour. * significantly different from vehicle treatment. Two-tailed T-test (P<0.05; n=6).
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Figure 6.4 Mean time-course values o f  Penh in OVA sensitised mice that were challenged twice with 0.5% OVA 4 hours 
apart and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours 
post-OVA challenge. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 19 
hours (24 hours after first exposure). Mean changes in Penh are expressed as mean±S.E.M. percentage change from baseline 
where a positive value represents a bronchoconstriction. ^significantly different from roflumilast treated mice; A significant 
difference between vehicle and roflumilast treatment. Two-tailed T-test (P<0.05; n=6). Raw roflumilast treatment Penh 
values (AU) -  Base (0.32±0.03), 0-6 hours (0.44±0.04), 7-12 hours (0.37±0.03) and 24 hours (0.34±0.03). Raw vehicle 
eatment Pet, values (AU) -  Base (0.30±0.01), 0-6 hours (0.49±0.02), 7-12 hours (0.48±0.02) and 24 hours (0.31±0.01).
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Figure 6.5 Area under the curve analysis comparing OVA sensitised mice challenged with a two doses o f  0.5% OVA 
and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post- 
OVA challenge. Only positive peaks are considered, any peaks that have a negative value o f Penh are excluded. Total 
includes all negative peaks from 0-19 hours, EAR includes from 0-6 hours and LAR includes from 6-19 hours. Area under 
die curve is measured in %.hour. *significantly different from vehicle treatment. Two-tailed T-test (P<0.05; n=6).
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Figure 6.6 -  Response o f  the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs challenged with OVA (0.01%) and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 
hours pre-OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 hours before OVA challenge and 
again 24 hours post-OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from 
baseline where a negative value represents a bronchoconstriction. Significantly different from pre-challenge values o f  
sGaw. Two-tailed T-test (P<0.05; n=6).
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Figure 6.7 -  Response o f the airways to a 60 second intermittent dose o f methacholine (30 mg/ml) in OVA sensitised 
mice challenged OVA (0.5%) and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA 
challenge and 6 hours post-OVA challenge. Values were recorded 24 hours before OVA challenge and again 24 hours 
post- OVA challenge. Mean changes in P^h are expressed as mean±S.E.M. percentage change from baseline where a 
positive value represents a bronchoconstriction. * significantly different from pre-challenge values o f Penh; Significantly 
different from vehicle treatment post-OVA challenge. One-way Analysis o f Variance followed by a Bonferroni post-test 
(P<0.05; n=6).
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Figure 6.8 Mean time-course values o f sGaw in OVA sensitised guinea pigs that had multiple challenges o f OVA and 
treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post- 
OVA challenge. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 24 
hours. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from baseline where a negative value 
represents a bronchoconstriction. * significantly different from roflumilast treated guinea pigs; A significant difference 
between vehicle and roflumilast treatment. Two-tailed T-test (P<0.05; n=6). Raw roflumilast treatment sGaw values 
(cm/H20) -  Base (0.69±0.02), 0-6 hours (0.38±0.07), 7-12 hours (0.66±0.02) and 24 hours (0.71±0.02). Raw vehicle 
treatment sGaw values (cm/H20) -  Base (0.42±0.03), 0-6 hours (0.12±0.01), 7-12 hours (0.30±0.01) and 24 hours 
(0.39±0.01). 3 0 0 0  t
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Figure 6.9 - Area under the curve analysis comparing OVA sensitised guinea pigs OVA sensitised guinea pigs challenged 
with a chronic dosing o f OVA and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA 
challenge and 6 hours post-OVA challenge. Only negative peaks are considered, any peaks that have a positive value of 
sGaw are excluded. Total includes all negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR includes 
from 6-24 hours. Area under the curve is measured in %.hour. * significantly different from vehicle treatment. Two-tailed 
T-test (P<0.05; n=6).
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Figure 6.10 -  Mean time-course values o f Penh in OVA sensitised mice that were challenged repeatedly with 2% OVA three 
times a week for six weeks and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA 
challenge and 6 hours post-OVA challenge. The histogram represents maximum bronchoconstriction values during baseline, 
EAR, LAR and 19 hours (24 hours after first exposure). Mean changes in Penh are expressed as mean±S.E.M. percentage 
change from baseline where a positive value represents a bronchoconstriction. * significantly different from roflumilast 
treated mice; A significant difference between vehicle and roflumilast treatment. Two-tailed T-test (P<0.05; n=6). Raw 
roflumilast treatment POTh values (AU) -  Base (0.30±0.01), 0-6 hours (0.42±0.01), 7-12 hours (0.34±0.01) and 24 hours 
(0.34±0.02). Raw vehicle treatment P ^  values (AU) -  Base (0.35±0.02), 0-6 hours (0.58±0.03), 7-12 hours (0.56±0.03) and 
24 hours (0.36±0.02).
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Figure 6.11 -  Area under the curve analysis comparing OVA sensitised mice challenged with repeated doses o f 2% OVA 
and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post- 
OVA challenge. Only positive peaks are considered, any peaks that have a negative value o f  Penh are excluded. Total 
includes all negative peaks from 0-19 hours, EAR includes from 0-6 hours and LAR includes from 6-19 hours. Area under 
the curve is measured in %.hour. *significantly different from vehicle treatment. Two-tailed T-test (P<0.05; n=6).
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Figure 6.12 -  Response o f the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs chronically challenged with OVA and treated orally with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 
hours pre-OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 hours before OVA challenge and 
again 24 hours post-OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from 
baseline where a negative value represents a bronchoconstriction. * significantly different from pre-challenge values o f  
sGaw. Two-tailed T-test (P<0.05; n=6).
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Figure 6.13 -  Response o f the airways to a 60 second intermittent dose o f methacholine (10 mg/ml) in OVA sensitised mice 
challenged repeatedly with 2%  OVA three times a week for six weeks and treated orally with methyl cellulose or 
roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 
hours before OVA challenge and again 24 hours post- OVA challenge. Mean changes in P^h are expressed as mean±S.E.M. 
percentage change from baseline where a positive value represents a bronchoconstriction. * significantly different from pre­
challenge values o f Penhi Asignificantly different from vehicle treatment post-OVA challenge. One-way Analysis o f  
Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 6.14 -  The number o f  total cells, macrophages, eosinophils, lymphocytes and neutrophils found in the 
bronchoalveolar fluid o f naive (non-sensitised) and OVA challenged (acute and chronic) guinea pigs orally treated with 
methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Results 
are expressed as mean±S.E.M. * significantly different from acute OVA -  vehicle treated; #significantly different from 
chronic OVA -  vehicle treated. One-way Analysis o f Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 6.15 -  The percentage o f macrophages, eosinophils, lymphocytes and neutrophils found in the bronchoalveolar 
fluid o f naive (non-sensitised) and OVA challenged (acute and chronic) mice orally treated with methyl cellulose or 
roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Results are expressed as 
mean±S.E.M. *significantly different from acute OVA -  vehicle treated; #significantly different from chronic OVA -  
vehicle treated. One-way Analysis o f Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 6.16 (A-C) -  Bronchioles o f chronic saline challenge, non-treated, guinea pigs and chronic OVA challenged
guinea pigs orally treated with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours
post-OVA challenge stained with haematoxylin and eosin to display general morphology (lOOOx magnification).
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Figure 6.17 -  The mean pathology score o f cells found in the peri-bronchiolar space of naive (non-sensitised) and OVA 
challenged (acute and chronic) guinea pigs treated orally treated with methyl cellulose or roflumilast (1 mg/kg). Results 
are expressed as mean±S.E.M. *significantly different from chronic OVA -  vehicle treated. Two-tailed t-test (P<0.05; 
n=4).
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Figure 6.18 (A-C) -  Bronchioles o f chronic saline, non-treated, mice and chronic OVA challenged mice orally treated
with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge
stained with haematoxylin and eosin to display general morphology (lOOOx magnification).
Epithelium Lamina propria
184
CHAPTER 6
S
£1
2
§
ChrSal
Figure 6.19 The mean pathology score o f cells found in the peri-bronchiolar space o f naive (non-sensitised) and OVA 
challenged (acute and chronic) mice treated orally treated with methyl cellulose or roflumilast (1 mg/kg). Results are 
expressed as mean±S.E.M. ^significantly different from chronic OVA -  vehicle treated. Two-tailed t-test (P<0.05; n=4).
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Figure 6.20 (A-C) -  Bronchioles o f  chronic saline, non-treated, guinea pigs and chronic OVA challenged guinea pigs
orally treated with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA
challenge stained with picrosirius red to display collagen (lOOOx magnification).
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Figure 6.21 -  Effect o f  a chronic OVA challenge and treatment o f  methyl cellulose or roflumilast (1 mg/kg) administered 
orally 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on percentage bronchiolar collagen in guinea 
pigs. Results are expressed as mean±S.E.M. *significantly different from vehicle treatment. Two-tailed t-test (P<0.05; 
n=4).
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Figure 6.22 (A-C) -  Bronchioles o f  chronic saline, non-treated, mice and chronic OVA challenged mice orally treated
with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge
stained with picrosirius red to display collagen (lOOOx magnification).
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Figure 6.23 -  Effect o f  a chronic OVA challenge and treatment o f methyl cellulose or roflumilast (1 mg/kg) administered 
orally 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on percentage bronchiolar collagen in mice. 
Results are expressed as mean±S.E.M. *significantly different from vehicle treatment. Two-tailed t-test (P<0.05; n=4).
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figure 6.24 (A-C) -  Bronchioles o f chronic saline, non-treated, guinea pigs and chronic OVA challenged guinea pigs
'rally treated with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA
lallenge stained with alcian blue/periodic acid Schiff to display goblet cells (lOOOx magnification).
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Figure 6.25 -  Effect o f  a chronic OVA challenge and treatment and treatment o f methyl cellulose or roflumilast (1 mg/kg) 
administered orally 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on number o f mucin associate 
goblet cells per 10,000 epithelial pixels in guinea pigs. Results are expressed as mean±S.E.M. ♦significantly different from 
vehicle treatment. Two-tailed t-test (P<0.05; n=4).
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Figure 6.26 (A-C) -  Bronchioles o f chronic saline, non-treated, mice and chronic OVA challenged mice orally treated
with methyl cellulose or roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge
stained with alcian blue/periodic acid Schiff to display goblet cells (lOOOx magnification).
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Figure 6.27 -  Effect of a chronic OVA challenge and treatment and treatment of methyl cellulose or roflumilast (1 mg/kg) 
administered orally 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on number of mucin associate 
goblet cells per 10,000 epithelial pixels in mice. Results are expressed as mean±S.E.M. * significantly different from 
vehicle treatment. Two-tailed t-test (P<0.05; n=4).
193
CHAPTER 6
6.5 DISCUSSION
6.5.1 EARLY AND LATE ASTHMATIC RESPONSES IN ACUTE AND
CHRONIC OVALBUMIN CHALLENGED GUINEA PIGS AND MICE
Sensitised guinea pigs and mice challenged with nebulised OVA using either an acute or 
chronic protocol led to an EAR and LAR which was not affected by oral methyl cellulose 
treatment. The PDE4 inhibitor, roflumilast, attenuated the EAR and virtually abolished the 
LAR. Roflumilast prevents the breakdown of cAMP into 5’AMP causing increased 
intracellular cAMP concentration. It has been suggested that cAMP can cause respiratory 
smooth muscle to relax (Schramm & Grunstein, 1992), therefore increased levels of cAMP 
could be causing a bronchodilation effect and attenuating the EAR. Underwood et al., (1998) 
showed that a PDE4 inhibitor, SB 207499, inhibited OVA induced contractions on guinea pig 
isolated tracheal strips but had no effect on exogenous agonist-induced contractions. This 
suggests SB 207499 inhibits the release of mediators from mast cells but does not exert a 
direct bronchodilation. The inhibition of mast cell mediator release would contribute to a 
reduction in the EAR. Therefore there may be two separate mechanisms in how roflumilast 
attenuated the EAR.
In asthmatic patients treated with the PDE4 inhibitor CDP840 twice daily for 9.5 days the 
LAR was reduced by 30% (Harbinson et al., 1997). It is possible that the decrease in BAL 
fluid eosinophil levels that PDE4 inhibitors cause (Deng et al., 2006) results in no LAR. 
Eosinophils are one of the main causes of the LAR as their degranulation or activation causes 
the release o f several inflammatory mediators (Chapoval et al., 1999) and creation of reactive 
oxygen species (Nielson & Vestal, 1989). The guinea pigs and mice in this chapter that were 
treated with roflumilast showed inhibition of the LAR compared to vehicle treatment despite 
the fact that they were only administered drug three times. This suggests that either the 
chronic changes in the animal models are not as severe as in humans or roflumilast is a more 
potent PDE4 inhibitor than CDP840.
The findings in this chapter are similar to those found in human asthmatics treated with 
roflumilast (van Schalkwyk et al., 2005). However, the findings are contradictory to those 
found by Toward and Broadley (2004) who showed that rolipram was unable to attenuate the 
LAR in acute OVA challenged guinea pigs. The fact that roflumilast reduced the LAR in
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these models suggests it has anti-inflammatory properties, this is corroborated by the fact that 
ciclamilast has been shown to inhibit tumour necrosis factor (TNF)-a (Deng et al., 2006). 
TNF-a can activate NF-kB which was shown in chapter 5 to be able to cause inflammatory 
gene transcription.
6.5.2 AIRWAY HYPERRESPONSIVENESS IN ACUTE AND CHRONIC
OVALBUMIN CHALLENGED GUINEA PIGS AND MICE
AHR was observed in both acute and chronic OVA challenged guinea pigs and mice treated 
with vehicle. Roflumilast treatment was able to inhibit the AHR provoked by a histamine 
(guinea pigs) or methacholine (mice) challenge. Previous studies have shown that PDE4 
inhibitors can prevent AHR in animal models of asthma (Danahay & Broadley, 1998; 
Holbrook et al., 1996; Howell et al., 1993; Raeburn et al., 1994; Santing et al., 1995) and 
human asthmatics (Louw et al., 2007). As previously mentioned the exact mechanisms of 
how hyperresponsiveness occurs is unknown, however, the epithelial shedding that occurs 
during asthma would lead to the airways being more sensitive to allergens and could possibly 
be a factor in AHR. Epithelial shedding can be caused by major basic protein (Barnes, 2002) 
and reactive oxygen species (Hirata et al., 1996) released from eosinophils. As increased 
levels o f cAMP leads to the inhibition of the creation of reactive oxygen species in 
neutrophils and eosinophils (Nielson & Vestal, 1989) it is possible that PDE4 inhibitors 
prevent AHR via this route at least in the acute OVA challenged models. It is possible that 
roflumilast prevents AHR by blocking histamine and methacholine, however, this scenario is 
unlikely as one would expect to see little, if  any, EAR if this was the case.
6.5.3 CELLULAR INFLUX IN ACUTE AND CHRONIC OVALBUMIN
CHALLENGED GUINEA PIGS AND MICE
Total leukocyte BAL fluid number was significantly reduced in roflumilast treated guinea 
pigs and mice compared to vehicle. Previous data has shown that PDE4 inhibitors can reduce 
eosinophil (Hoymann et al., 2009; Nejman-Gryz et al., 2006) and neutrophil (Deng et al., 
2006) number so this is no surprise. A significant reduction of eosinophil number and 
percentage was observed in guinea pigs and mice respectively. Eosinophils can be recruited 
to the airways by the cytokine eotaxin (Nejman-Gryz et a l ,  2006) which has been shown to
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be inhibited by PDE4 inhibitors (Deng et al., 2006). This inhibition could explain why no 
LAR or AHR was observed in roflumilast treated animals.
Although an increase in macrophage BAL percentage was observed in mice this is likely to 
be misleading and a result of eosinophil percentage decrease. Chronic OVA challenged 
guinea pigs treated with roflumilast showed a reduction in macrophage number whereas the 
acute OVA challenged group did not. This suggests that chronic inflammation causes an 
increase in macrophages which is attenuated by PDE4 inhibitors. There is little evidence to 
link PDE4 inhibitors and macrophage reduction, however, Mehats et al., (2008) showed that 
rolipram was able to reduce the increase in monocyte chemotactic protein (MCP)-l. As 
MCP-1 chemoattracts macrophages this could explain the reduction observed in the chronic 
OVA guinea pigs.
There is a large amount of evidence that PDE4 inhibitors can reduce neutrophil numbers in 
the airways (Deng et al., 2006), this is likely a result o f the PDE4 inhibiting TNF-a, which 
can cause influx of neutrophils (Nejman-Gryz et al., 2006). However, no reduction in 
neutrophils was observed in any of the groups in this chapter. This lack of impact on 
neutrophil number is probably a result of the low number of neutrophils counted in the first 
place. Neutrophils are predominately involved in the EAR so it is likely by the time a lavage 
was carried out most of the neutrophils have been removed or undergone apoptosis.
6.5.4 LUNG HISTOLOGY IN CHRONIC OVALBUMIN CHALLENGED
GUINEA PIGS AND MICE
Chronic OVA challenges cause massive structural changes to the bronchioles of OVA 
sensitised guinea pigs and mice such as an increase in epithelial and lamina propria thickness 
and increased levels o f smooth muscle. It is clear to see in the haematoxylin and eosin stained 
bronchioles that although roflumilast treatment attenuates these changes they are still 
considerably different from naive bronchioles. When the number of inflammatory cells in the 
peribronchiolar space were scored chronic OVA vehicle treated guinea pigs and mice show 
the greatest amount of cells. Roflumilast is able to significantly decrease the number of 
inflammatory cells found in the lung tissue. Previous data by Kita et al., (2008) showed that a 
PDE4 inhibitor, KF19514, was able to reduce the number of inflammatory cells in the lamina 
propria of OVA exposed mice and data above shows that roflumilast can reduce the
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inflammatory cells found in the BAL fluid so the fact it can have a role in decreasing 
inflammatory cells in the peribronchiolar space was expected.
Roflumilast alleviated the airway remodelling caused by repeated asthmatic episodes in 
several ways. As shown in this chapter roflumilast can significantly inhibit the production of 
collagen caused by chronic OVA challenges. Although an increased amount of collagen was 
observed in the picrosirius red stained bronchioles that were treated with roflumilast 
compared to naive, the fact that roflumilast is able to somewhat decrease collagen production 
will lead to a decreased thickening of the bronchiole wall and thus make breathing easier for 
asthmatics. It is likely that these findings also apply for human asthmatics as Burgess et al., 
(2006) showed that roflumilast inhibits collagen I.
Increased mucus in the airways is a serious consequence of asthma as it can cause airway 
occlusion. Mucus is released from goblet cells that increase in number during chronic asthma. 
Mucin associated goblet cells appear bright pink when stained with alcian blue/periodic acid 
Schiff. It is clear to see that chronic OVA exposures causes increased numbers mucin 
associated goblet cells in vehicle treated guinea pigs and mice. Roflumilast treatment 
significantly reduces the number of goblet cells therefore decreasing the amount of airway 
mucus. Goblet cells can increase in number by undergoing metaplasia from epithelial cells. It 
has been shown that the interleukins 4, 9 and 13, which increase in number during an 
asthmatic episode, can upregulate MUC5AC genes in epithelial cells (Temann et al., 1997). 
MUC5AC upregulation can cause the metaplasia of epithelial cells to goblet cells (Rogers, 
1994). However, roflumilast has been shown to inhibit this upregulation in human epithelial 
cells (Mata et al., 2005).
6.5.5 GENERAL CONCLUSIONS
The fact that roflumilast can inhibit all of the features of asthma assessed in these models 
suggest they could have both bronchodilator or mast cell inhibiting effects, as they reduce the 
EAR, and anti-inflammatory effects, as they reduce the LAR, AHR, cellular influx and 
remodelling. Although roflumilast was unable to completely reverse airway remodelling the 
administration points must be considered. Roflumilast was only administered before the final 
OVA exposure in the chronic groups, therefore airway remodelling had probably developed 
by then suggesting that roflumilast is reversing and not preventing. It is possible that if
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roflumilast was given before, or immediately after, every OVA exposure then a greater 
reduction in airway remodelling and even EAR may be observed. Considering roflumilast 
was only administered three times throughout the whole study, therefore the effect that it has 
was very impressive. This explains why there is so much interest in PDE4 inhibitors as a 
potential alternative to corticosteroids in asthma therapy.
Currently no PDE4 inhibitor has passed phase III clinical trials and therefore there are none 
commercially available. The reason for this is the side-effects that PDE4 inhibitors cause 
such as vomiting and nausea. Several approaches have been tried to overcome these side- 
effects. Administrating lower doses of PDE4 inhibitors have been tried but lack of efficacy 
was observed (Giembycz, 2008). Another alternative is a different route of administration. 
Giving a drug orally means that it only reaches the required destination after passing through 
the stomach, it is possible that it is this fact that causes the side-effects. As a result 
administration as an inhalation has been trialled though thus far the results have been 
disappointing (Spina, 2008). Further research has focused on the subtypes of PDE4 
suggesting that it is possible that the inhibition of a PDE4 subtype may cause the side-effect 
to dimish (Spina, 2008).
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7.1 INTRODUCTION
7.1.1 NITRIC OXIDE
Nitric oxide (NO) is a free radical gas that acts as a multifunctional cell messenger. It is 
involved in many physiological and pathological processes in the body and has roles ranging 
from neurotransmission to vasodilation of blood vessels. NO is formed from L-arginine, 
oxygen and nicotinamide adenine dinucleotide phosphate (reduced) (NADPH) in the 
presence of NO synthase (NOS) (figure 7.1).
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Figure 7.1 -  A diagram to show the formation o f  nitric oxide from L-arginine, NADPH and oxygen catalysed 
by the enzym e NO synthase and some o f  the roles nitric oxide can have. NO = Nitric oxide; GTP = 
Guanosine trisphosphate; cGMP = Cyclic guanosine monophosphate; 0 2‘ = Superoxide oxygen molecule; 
OONO' = Peroxynitrite. Diagram adapted from Hancock (2005).
There are three forms of NOS, endothelial NOS (eNOS), neuronal NOS (nNOS) and 
inducible NOS (iNOS). The enzymes eNOS and nNOS are calcium-dependent and are 
produced constitutively (Jagnandan et al., 2005), whereas iNOS is calmodulin-independent. 
The production of new iNOS can be stimulated by the presence of interferon (IFN) -  y, 
interleukin (IL) -  1 and lipopolysaccharide (LPS) amongst other things (Hancock, 2005).
NO gets released by nerve stimulation of the parasympathetic nervous system (Belvisi et al., 
1991). The enzyme guanylyl cyclase is one of the main cellular targets of NO. NO binds to 
the enzyme to activate it which leads to the production, and subsequent intracellular increase 
in concentration, o f cyclic guanosine monophosphate (cGMP). Normally, cGMP is converted
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into guanosine monophosphate GMP by phosphodiesterase V to regulate the intracellular 
concentration of cGMP (Hancock, 2005). There are a number of cellular effects that an 
increased concentration of cGMP can cause, such as muscle relaxation.
7.1.2 THE ROLE OF NITRIC OXIDE IN ASTHMA
Increased levels of NO in exhaled air ( F E n o )  are found in asthmatics compared to healthy 
individuals (Alving et al., 1993), with the source of NO appearing to be epithelial cells and 
macrophages (Arock et al., 1994; Warner et al., 1995). However, whether NO has a 
beneficial or detrimental effect is hotly debated (Mathrani et al., 2007). There is evidence that 
NO is somewhat of a double-edged sword depending on concentration (Toward & Broadley, 
2004). The pro-inflammatory and anti-inflammatory effects that NO can have are shown in 
table 7.1.
Pro-inflammatory • f eosinophil infiltration
• f vascular permeability
• |  airway narrowing
• I eosinophil apoptosis
Anti-inflammatory • I leukocyte chemotaxis and function
• f smooth muscle relaxation
• I mast cell activation
• f eosinophil apoptosis
Airway Hyperreactivity • depending on degree of iNOS activation
Mucus Secretion • f !  secretion
Table 7.1 - The roles that nitric oxide play in asthma can be both beneficial and detrimental. Table adapted 
from (Nevin & Broadley, 2002)
Another pro-inflammatory issue that is caused by NO is the formation of peroxynitrite. The 
reactive oxygen species that are produced from the increased number of leukocytes in the 
airways react with excess NO to form the tissue damaging agent, peroxynitrite (Saleh et al.,
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1998). Peroxynitrite has been shown to induce airway hyperresponsiveness in guinea pigs 
(Sadeghi-Hashjin et al., 1996) and damage pulmonary epithelial cells (Zhu et al., 2000). 
Peroxynitrite is highly reactive and as a result readily adds a nitro group to tyrosine to form 
the more stable product 3-nitrotyrosine (3-NT) (Saleh et al., 1998). Lungs from mild 
asthmatics (Saleh et al., 1998) and those who died of status asthmaticus (Kaminsky et al.,
1999) showed increased levels of 3-NT compared to non-asthmatics. Peroxynitrite or tyrosine 
nitration causes several pro-inflammatory factors in asthma such as increased number of 
prostaglandins, increased levels of NF-kB and steroid resistance (Barnes, 2002). However, 
the conversion also appears to have anti-inflammatory effects, causes collagen degradation 
and makes the glucocorticoid receptor steroid sensitive (Barnes, 2002), supplying more 
evidence for the fact that NO has both beneficial and detrimental roles.
Nitric oxide could play a role in airway remodelling as some of the relevant cellular and 
molecular events needed for remodelling are induced by NO. Gabazza et al., (2000) 
described a correlation between nitrite/nitrate concentration and airway wall thickness. As a 
result o f the detrimental effects and the fact that levels of NO have been shown to increase 
within thirty minutes of an allergen challenge (Mehta et al., 1997) there has been increased 
research into NO inhibitors as asthma therapeutics.
7.1.3 INDUCIBLE NITRIC OXIDE INHIBITORS AND THEIR ROLE AS '
POTENTIAL ASTHMA THERAPEUTICS
In order to reduce levels of NO, targeting the production of the molecule is a sound approach. 
Several drugs have been created that either selectively target each subtype of NOS or target 
all subtypes in a non-selective manner. As levels of NO increase during asthma iNOS appears 
to be the main cause of this increase (Mathrani et al., 2007), therefore a great deal of focus 
has gone into finding more out about the role of iNOS and developing iNOS inhibitors. In 
order to evaluate the role of iNOS in asthma, knock-out (KO) mice deficient of iNOS have 
been developed. However, the findings in these mice are just as contradictory as NO itself. A 
study by Duguet et al., (2001) in KO C57BL/6 mice showed iNOS was pro-inflammatory and 
pro-eosinophillic. The following year Koarai et al., (2002) showed iNOS had no effect on 
inflammation or AHR and the year after that Kenyon et al., (2003) showed that iNOS was 
anti-inflammatory and it in fact reduced AHR. Both studies were also in KO C57BL/6 mice.
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The use of iNOS inhibitors has done little to establish whether NO should be a realistic target 
for anti-asthma drugs. Several studies on mice have been carried out using 1400W, a slow, 
tight binding, highly selective inhibitor of iNOS (Garvey et a l ,  1997). Iijima et a l ,  (2001) 
tested 1400W on male A/J mice and demonstrated iNOS to be pro-eosinophillic but anti- 
neutrophillic. Koarai et a l ,  (2000) also showed iNOS to be pro-eosinophillic and to increase 
AHR in BALB/c mice since 1400W inhibited these endpoints. The finding that iNOS 
increased during airways inflammation induced by allergen was corroborated by Muijsers et 
al, (2001) using 1400W in male BALB/c mice. However, a study by Richard et al, 
referenced by Mathrani et a l ,  (2007) showed that iNOS decreased AHR, since 1400W 
treatment exacerbated the AHR.
GW274150F is a highly selective iNOS inhibitor (Alderton et a l ,  2005). Recently it was 
assessed as a potential asthma therapeutic providing further conflicting data on the 
effectiveness of iNOS inhibitors in asthma. Knowles et al, (2007) showed GW274150F was 
able to inhibit AHR and total cell infiltration in mice and the LAR in guinea pigs but had no 
effect on the LAR and eosinophillia in rats. Despite these findings GW274150F went into 
clinical trials in mild asthmatics and although iNOS was effectively inhibited by 
GW274150F, there was no effect on AHR or inflammatory cell number (Singh et a l,  2007). 
As GW274150F was able to inhibit AHR and total cell influx in acute asthma models of mice 
but had no effect on AHR in humans this suggests that either airway remodelling or the vast 
differences between the pulmonary structure of mice and humans accounts for these findings. 
If chronic allergen exposure and airway structural changes cause iNOS inhibitors to be 
ineffective this suggests that the use of acute animal models of asthma for drug research has 
severe limitations and should be reviewed.
i
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7.2 AIMS AND OBJECTIVES
7.2.1 AIMS
The aim of this chapter was to assess the effect of treatment with an iNOS inhibitor 
(GW274150F) compared to vehicle treatment on acute and chronic OVA challenged guinea 
pigs and mice. The parameters investigated were early and late phase bronchoconstriction, 
airway hyperresponsiveness, cellular influx and lung histology. This chapter will give an 
indication of how effective this novel compound is against both acute and chronic guinea pig 
and mouse models.
7.2.2 OBJECTIVES
• To investigate the effect that GW274150F treatment has on acute OVA exposed 
guinea pigs and mice by measuring lung function, response to histamine and cellular 
influx compared to vehicle treatment.
• To investigate the effect that GW274150F treatment has on chronic OVA exposed 
guinea pigs and mice by measuring lung function, response to histamine and cellular 
influx compared to vehicle treatment.
• To assess bronchiole structure, collagen deposition and levels of goblet cell 
hyperplasia in GW274150F treated chronic OVA challenged guinea pigs and mice 
compared to vehicle.
A
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7.3 METHODS
The methods used in the chapter can be found in greater detail in chapter 2. In this chapter six 
male Dunkin-Hartley guinea pigs weighing 200-250 g and six male BALB/c mice weighing 
20-25 g were used. The animals were purchased from Harlan (UK) and housed at Cardiff 
University.
7.3.1 SENSITISATION
Guinea pigs and mice were sensitised by an intra-peritoneal, bilateral injection of a 
suspension containing OVA (100 pg) and Al(OH) 3  (100 mg) in 1 ml in guinea pigs and 0.25 
ml in mice of PBS on days 1 and 5.
7.3.2 OVALBUMIN CHALLENGES
A stainless steel exposure chamber (40 cm diameter, 15 cm height) was used for OVA 
challenges in both acute and chronic guinea pigs. A Perspex box measuring (38 cm length; 20 
cm width; 20 cm height) was used for mice. A Wright nebuliser delivered the OVA or saline 
at an air pressure of 20 lb p.s.i. and at a rate of 0.3 ml/min. The animals were removed from 
the chamber if they appeared to be distressed during exposure and the challenge was 
considered complete.
7.3.2.1 ACUTE PROTOCOL -  GUINEA PIGS
On day 15 (14 days subsequent to the first sensitisation injection) the guinea pigs were 
challenged with OVA (0.01%) for 1 hour.
73.2.2 CHRONIC PROTOCOL -  GUINEA PIGS 
The process begins the same way for the chronic protocol as the acute protocol with a OVA 
(0.01%) hour long challenge on day 15. Following this on days 17-29 the guinea pigs were 
challenged with OVA (0.1%) preceded with mepyramine (30 mg/kg) protection. On day 31 
an hour long challenge of OVA (0.1%) without mepyramine occurred, this was the day lung 
function was measured.
7.3.2.3 ACUTE PROTOCOL -  MICE 
Two OVA (0.5%) exposures lasting an hour each separated by 4 hours were used to 
challenge the mice in an acute manner. These occurred on day 15.
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73.2  A  CHRONIC PROTOCOL -  MICE
OVA (2%) was again used to challenge the mice. However, to mimic the chronic features of 
asthma exposures occurred for 30 minutes three times a week for six weeks (18 challenges). 
On the first day of the seventh week (day 57) the mice were challenged for an hour and lung 
function measurements were taken immediately following this.
7.3.3 LUNG FUNCTION MEASUREMENTS
Values of sGaw were used as guinea pig lung function measurements. They were obtained by 
using whole-body plethysmography. Before the final OVA challenge a baseline value of sGaw 
was recorded, all subsequent values were taken as a percentage of this. After the exposure 
values were recorded at 0, 15, 30, 45 and 60 minutes, then every hour until 12 hours with a 
final reading at 24 hours.
To measure lung function in mice values of Penh were used, obtained by using an unrestrained 
chamber (Buxco). Like with the guinea pigs a baseline value was recorded and all subsequent 
results were taken as a percentage of this. Values were recorded 0, 20, 40, 60, 90 and 120 
minutes post-challenge, then hourly until 10 hours with a final reading at 19 hours for the 
acute protocol or 24 hours for the chronic protocol.
73.4 AIRWAY RESPONSIVENESS MEASUREMENTS
7.3.4.1 GUINEA PIGS
1 mMol of histamine (20 seconds) was used to detect responsiveness in guinea pig airways. 
Histamine challenges occurred before the first OVA exposure and after the final OVA 
exposure. Baseline readings of sGaw were recorded, the histamine then was administered via a 
nose-only inhalation. Readings of sGaw were then recorded 0, 5 and 10 minutes after the 
histamine challenge.
7.3.4.2 MICE
The effect o f methacholine (10 mg/ml for acute challenged, 30 mg/ml for chronic challenged) 
in mice assessed airway responsiveness. Measurements were taken 24 hours before the first 
OVA exposure and 24 hours after the final OVA exposure. To detect the presence of AHR 2 
minutes o f baseline values were recorded, followed by 1 minute of methacholine and then 5 
minutes of readings. The post-methacholine values were averaged and taken as a percentage 
of mean baseline values.
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7.3.5 TOTAL AND DIFFERENTIAL CELL COUNTS
7.3.5.1 GUINEA PIGS
Once the final histamine challenge has finished the guinea pigs were euthanised, the trachea 
cannulated and the lungs removed. Saline was then pumped into the lungs and withdrawn 
obtaining BAL fluid. A total and differential cell count was then carried out using the BAL 
fluid.
7.3.5.2 MICE
As the BAL fluid gets contaminated with blood when cannulating the trachea no total cell 
count can be earned out. The BAL fluid is still used to carry out a differential cell count by 
centrifuging it onto slides and staining.
7.3.6 DRUG ADMINISTRATION
5 mg/kg of GW274150F was dissolved in methyl cellulose and administered orally via a 
gavage needle 24 and 0.5 hours before the final OVA exposure and 6  hours post exposure.
7.3.7 HISTOLOGICAL ANALYSIS OF GUINEA PIG AND MOUSE LUNGS 
Slices measuring between 3 to 5 mm were cut 1 mm below the bronchus of the left superior 
lobe and then processed into wax blocks. A microtome was used to cut 6 pm sections of the 
processed lung samples and they were then fixed onto a glass slide. The slides were stained 
with using either the haematoxylin and eosin, picrosirius red or AB/PAS protocols to stain for 
general morphology, collagen and mucin associated goblet cells respectively. Using imageJ 
software the percentage of bronchiolar collagen and number of mucin associated goblet cells 
were calculated. The peribronchiole, periphery of the small airways, of sections that were 
stained with haematoxylin and eosin was scored for number of cells present to evaluate 
whether the number of inflammatory cells differed in the lung tissue of various treatment 
groups. The parameters for scoring were on a semi-quantitative scale as absent (0), minimal 
(1), slight (2), moderate (3), marked (4), or severe (5) (Barends et al., 2004).
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7.4 RESULTS
7.4.1 THE LUNG FUNCTION OF ACUTE CHALLENGED GUINEA PIGS
AND MICE
7.4.1.1 GUINEA PIGS
Figure 7.2 represents the lung function of acute OVA challenged guinea pigs treated with 
vehicle or GW274150F. The vehicle treated group showed an immediate bronchoconstriction 
(-66.1 ±3.0%) which recovered around 4 hours. A bronchoconstriction was also observed 
immediately after the OVA challenge in the GW274150F treated group (-69.8±2.6%), this 
resolved around 5 hours. A second bronchoconstriction was observed at 7 hours in the 
vehicle treated group, however, GW274150F significantly inhibited this (-35.9±6.5% 
compared to -1.8±3.7% respectively). When comparing maximum bronchoconstriction no 
significant difference between drug treatment and vehicle occurred during the EAR. 
GW274150F significantly reduced the LAR compared to vehicle (-5.6±2.8% compared to - 
35.9±6.5% respectively). Area under the curve analysis is shown in figure 7.3. No significant 
difference was seen between the drug treatment and vehicle for all time points.
7.4.1.2 MICE
In vehicle and GW274150F treated mice a peak bronchoconstriction was observed 2 hours 
following a single OVA challenge as shown in figure 7.4 (63.9±2.5% and 65.7±1.9% 
respectively). Although the values of Penh for both groups do not decline to baseline value 
they steadily decrease until 7 hours when they both had a second bronchoconstriction. 
However, this time the GW274150F treatment led to significant inhibition of the 
bronchoconstriction compared to vehicle treatment (28.1±3.3% compared to 59.9±3.1% 
respectively). The maximum EAR bronchoconstriction values showed no significant 
difference between both treatment groups. For the LAR GW274150F significantly reduced 
the maximum bronchoconstriction values compared to vehicle (34.3±3.6% compared to 
60.7±2.8% respectively). Figure 7.5 shows area under the curve analysis for acute OVA 
challenged, GW274150F or vehicle treated mice. No significant difference was observed 
between GW274150F and vehicle treatment throughout each point.
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7.4.2 AIRWAY HYPERRESPONSIVENESS OF ACUTE CHALLENGED
GUINEA PIGS AND MICE
7.4.2.1 GUINEA PIGS
Figure 7.6 shows the response of acute OVA challenged, vehicle and GW274150F treated 
guinea pigs to histamine (1 mMol, 20 seconds). Vehicle treatment did not prevent a 
significant bronchoconstriction that was observed immediately following the histamine in the 
post-challenge compared to pre-challenge (-21.1±3.6% compared to 0.9±1.9% respectively). 
This bronchoconstriction persisted for 5 minutes after the histamine (-15.2±3.1% compared 
to -0.1 ±0.9% respectively). In the GW274150F treated guinea pigs, there was no 
bronchoconstriction post-OVA challenge.
7.4.2.2 MICE
Die effect o f 30 mg/ml methacholine on vehicle or GW274150F treated mice pre- and post- 
OVA challenge is displayed in figure 7.7. AHR was observed in the vehicle treated mice 
represented by a significant increase in Penh post-OVA challenge compared to pre-OVA 
challenge (1335.6±97.6% compared to -6.9±2.6% respectively). GW274150F treatment 
significantly attenuated AHR compared to vehicle treatment (279.6±78.6% compared to 
1335.6±97.6%). However, the response to mechacholine in GW274150F treated mice was 
still significantly greater than the pre-OVA level (279.6±78.6% compared to 2.2±4.2% 
respectively).
7.43 LUNG FUNCTION OF CHRONIC CHALLENGED GUINEA PIGS
AND MICE
7.4.3.1 GUINEA PIGS
Figure 7.8 represents the lung function of chronic OVA challenged guinea pigs treated with 
vehicle or GW274150F. Following the final OVA challenge an immediate 
bronchoconstriction occurred in both the vehicle (-70.0±2.0%) and GW274150F (- 
60.6±3.2%) treated groups. These resolved at 6  hours and 5 hours respectively. On the 7 hour 
mark a second bronchoconstriction was again observed in both the vehicle (-31.2±4.9%) and 
GW274150F (-32.2±7.5%) treated groups. When comparing maximum bronchoconstriction 
values no significant difference was seen between vehicle treatment and GW274150F 
treatment. Area under the curve analysis, represented in figure 7.9, again showed no 
significant difference between both vehicle and GW274150F treated groups throughout all 
time points.
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7.4.3.2 MICE
In chronic OVA challenged mice an early phase bronchoconstriction was observed after 2 
hours following either vehicle treatment (65.7±3.3%) or GW274150F treatment (56.0±4.7%) 
as shown in figure 7.10. Although this increase in Penh steadily resolved it never reached 
baseline levels and a second bronchoconstriction was observed after 7 hours in both vehicle 
treated (61.6±2.0%) and GW274150F treated mice (51.1±5.8%). If the maximum 
bronchoconstriction values for the EAR and LAR are both analysed then GW274150F 
treatment caused no significant difference from vehicle treatment. This was also the case 
when area under the analysis was considered (figure 7.11).
7.4.4 AIRWAY HYPERRESPONSIVENESS OF CHRONIC CHALLENGED
GUINEA PIGS AND MICE
7.4.4.1 GUINEA PIGS
Figure 7.12 shows AHR was observed in the vehicle treated group as a significant decrease in 
sGaw was observed when comparing post-OVA challenge results with pre-OVA challenge 
results at both 0 (-33.8±5.9% compared to -1.3±2.0% respectively) and 5 (-22.1±1.9% 
compared to 0.5±1.2% respectively) minutes. GW274150F treatment was unable to prevent 
this bronchoconstrictor response following histamine (1 mMol, 20 sec) in post-OVA 
challenged guinea pigs compared to pre-OVA challenged (-27.5±5.6% compared to 
0.6±0.5% respectively). This significant bronchoconstriction was still present 5 minutes after 
the histamine challenge (-10.8±3.6% compared to 0.2±0.8% respectively).
7.4.4.2 MICE
Figure 7.13 represents the effect of challenging vehicle and GW274150F treated mice with 
10 mg/ml methacholine before and after repeated OVA challenges. AHR was observed in the 
vehicle treated group as the mice show a significantly greater level of percentage change 
from baseline post-OVA challenge compared to pre-OVA challenge (387.5±12.6% compared 
to -2.2±5.5% respectively).GW274150F was unable to reduces the level of AHR and a 
significant Penh increase was observed post-OVA challenge compared to pre-OVA challenge 
(397.7±40.0% compared to -10.5±2.8% respectively).
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7.4.5 CELL COUNTS IN ACUTE AND CHRONIC CHALLENGED GUINEA 
PIGS AND MICE
7.4.5.1 GUINEA PIGS
The effect of GW274150F or vehicle treatment on the BAL cellular level in acute and 
chronic OVA challenged guinea pigs is shown in figure 7.14. GW274150F treatment 
significantly reduced the total number of cells compared to vehicle treatment in both acute 
(4.4±0.5xl06 compared to 6.7±0.5xl06 respectively) and chronic (8.9±0.5xl06 compared to 
10.9±0.3xl06 respectively) OVA challenged guinea pigs. In GW274150F treated guinea pigs 
the total number of cells counted was also significantly greater after multiple OVA 
challenges compared to a single OVA challenge (8.9±0.5xl06 compared to 4.4±0.5xl06 
respectively). In acute OVA challenged guinea pigs significantly more macrophages were 
counted after GW274150F treatment compared to vehicle treatment (2.8±0.3xl06 compared 
to 1.7±0.2xl06 respectively), however, the opposite was true for eosinophil number 
(1.3±0.3xl06 compared to 4.9±0.2xl06 respectively). In the chronic groups GW274150F had 
no significant effect on eosinophil number compared to vehicle but the level was significantly 
greater than acute OVA guinea pigs treated with GW274150F (4.9±0.3xl06 compared to 
1.3±0.3xl06  respectively). In terms of neutrophil number, GW274150F treatment 
significantly reduced the number of cells compared to vehicle treatment in both acute 
(0.09±0.02xl06 compared to 0.3±0.04xl06 respectively) and chronic (0.1±0.03xl06 compared 
to 0.3±0.04xl06 respectively) OVA challenged guinea pigs.
7.4.5.2 MICE
Figure 7.15 represents the percentage of macrophages, eosinophils, lymphocytes and 
neutrophils found in the BAL fluid of acute and chronic OVA challenged mice that have been 
treated with vehicle or GW274150F. No significant difference was observed between either 
challenge protocol or either treatment throughout all the cellular subtypes.
7.4.6 LUNG HISTOLOGY OF CHRONIC CHALLENGED GUINEA PIGS 
AND MICE
Figures 7.16 (A-C) show naive, chronic OVA -  vehicle treated and chronic OVA -  
GW274150F treated guinea pig bronchioles stained with haematoxylin and eosin. This 
staining shows the general morphology of the bronchioles. The guinea pigs treated with either 
GW274150F or vehicle both had a thicker lamina propria and epithelium and more smooth 
muscle than the naive guinea pigs. GW274150F treatment did not seem to make a great deal
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of difference to the bronchiole structure compared to vehicle treatment. Figure 7.17 
demonstrates the scored value of inflammatory cells found in the peribronchiolar space, the 
greater the number the more cells. Treatment with GW274150F has no significant effect on 
the number of cells compared to vehicle treatment (4.0±0.4 compared to 4.6±0.3). Figure 
7.18 (A-C) shows bronchioles from mice which are either naive or chronic OVA challenged 
treated with vehicle or GW274150F. The figures show the general morphology of the 
bronchiole as it has been stained with haematoxylin and eosin. As with the guinea pigs, the 
mice that were treated with drug or vehicle showed the characteristics of airway remodelling. 
The stained bronchioles also enabled the number of inflammatory cells in the peribronchiolar 
space to be scored (figure 7.19). Treatment with GW274150F had no significant effect on cell 
scored compared to vehicle treatment in chronic OVA challenged mice (4.8±0.3 compared to 
4.8±0.3).
Figures 7.20 (A-C) show guinea pig bronchioles stained with picrosirius red to assess 
collagen deposition. Figure 7.21 represents the percentage of bronchiolar collagen in the 
same three groups. GW274150F is unable to significantly alter the amount of collagen 
compared to vehicle (53.3±2.6% compared to 46.7±2.9%). The bronchioles of mice that have 
undergone the same treatments and staining protocol are shown in figure 7.22 (A-C). The 
level o f bronchiolar collagen in these mice are shown quantitatively in figure 7.23 
GW274150F treatment had no effect compared to vehicle treatment on reducing bronchiolar 
collagen percentage (49.7±7.9% compared to 59.4±2.8%).
The bronchioles of naive, chronic OVA -  vehicle treated and chronic OVA -  GW274150F 
treated guinea pigs are shown in figure 7.24 (A-C). The bronchioles have been stained with 
alcian blue/periodic acid Schiff to show the amount of mucin associated goblet cells per 
10,000 epithelial pixels. The data in quantitative form is shown in figure 7.25. GW274150F 
treatment had no significant effect compared to vehicle treatment (8 .8 ± 1 . 0  compared to
9.1 ±1.7). The stained bronchioles of mice that underwent the same protocols are shown in 
figure 7.26 (A-C). When the mucin associated goblet cells are counted and analysed (figure 
7.27) the data show that GW274150F treatment was not significantly different from vehicle 
treatment (9.7±2.9 compared to 10.3±2.3).
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Figure 7.2 -  Mean time-course values o f sGaw in OVA sensitised guinea pigs that were challenged with 0.01 % OVA 
and treated orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours 
post-OVA challenge. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 
24 hours. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from baseline where a negative 
value represents a bronchoconstriction. *signiflcantly different from GW274150F treated guinea pigs; A significant 
difference between vehicle and GW274150F treatment. Two-tailed T-test (P<0.05; n=6). Raw GW274150F treatment 
sGm values (cm/H20) -  Base (0.80±0.06), 0-6 hours (0.24±0.03), 7-12 hours (0.75±0.04) and 24 hours (0.81±0.04). 
Raw vehicle treatment sGaw values (cm/H20) -  Base (0.62±0.03), 0-6 hours (0.21±0.02), 7-12 hours (0.40±0.05) and 24 
hours (0.57±0.06).
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Figure 7.3 -  Area under the curve analysis comparing OVA sensitised guinea pigs challenged 0.01% OVA and treated 
orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA 
challenge. Only negative peaks are considered, any peaks that have a positive value o f  sGaw are excluded. Total includes 
ill negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR includes from 6-24 hours. Area under the 
curve is measured in %.hour. * significantly different from vehicle treatment. Two-tailed T-test (P<0.05; n=6).
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Figure 7.4 -  Mean time-course values o f Penh in OVA sensitised mice that were challenged twice with 0.5% OVA 4 hours 
.->art and treated orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours 
:ost-OVA challenge. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 19 
are (24 hours after first exposure). Mean changes in Penh are expressed as mean±S.E.M. percentage change from baseline 
here a positive value represents a bronchoconstriction. * significantly different from GW274150F treated mice; A 
gnificant difference between vehicle and GW274150F treatment. Two-tailed T-test (P<0.05; n=6). Raw GW274150F 
reatment Pcnh values (AU) -  Base (0.36±0.02), 0-6 hours (0.59±0.02), 7-12 hours (0.48±0.03) and 24 hours (0.37±0.02). 
\w vehicle treatment Penh values (AU) -  Base (0.30±0.01), 0-6 hours (0.49±0.02), 7-12 hours (0.48±0.02) and 24 hours 
0.31±0.01).
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igure 7.5 -  Area under the curve analysis comparing OVA sensitised mice challenged with two doses o f  0.5% OVA and 
;ated orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post- 
'V'A challenge. Only positive peaks are considered, any peaks that have a negative value o f  Penh arc excluded. Total 
acludes all negative peaks from 0-19 hours, EAR includes from 0-6 hours and LAR includes from 6-19 hours. Area under 
tfcurve is measured in %.hour. * significantly different from vehicle treatment. Two-tailed T-test (P<0.05; n=6).
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Figure 7.6 -  Response o f  the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs challenged with OVA (0.01%) and treated orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 
hours pre-OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 hours before OVA challenge and 
again 24 hours post-OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from 
baseline where a negative value represents a bronchoconstriction. *significantly different from pre-challenge values o f  
sGaw. Two-tailed T-test (P<0.05; n=6).
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Figure 7.7 -  Response o f  the airways to a 60 second intermittent dose o f methacholine (30 mg/ml) in OVA sensitised 
mice challenged OVA (0.5%) and treated orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre- 
OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 hours before OVA challenge and again 24 
hours post- OVA challenge. Mean changes in Penh are expressed as mean±S.E.M. percentage change from baseline where 
a positive value represents a bronchoconstriction. *significantly different from pre-challenge -  vehicle treated; # 
significantly different from pre-challenge -  GW274150F treated Asignificantly different from vehicle treatment (post­
challenge). One-way Analysis o f  Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 7.8 -  Mean time-course values o f sGaw in OVA sensitised guinea pigs that had multiple challenges o f OVA and 
treated orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post- 
OVA challenge. The histogram represents maximum bronchoconstriction values during baseline, EAR, LAR and 24 
hours. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from baseline where a negative value 
represents a bronchoconstriction. (n=6). Raw GW274150F treatment sGaw values (cm/H20) -  Base (0.71±0.03), 0-6 
hours (0.28±0.01), 7-12 hours (0.48±0.04) and 24 hours (0.71±0.03). Raw vehicle treatment sGaw values (cm/H20) -  
Base (0.42±0.03), 0-6 hours (0.12±0.01), 7-12 hours (0.30±0.01) and 24 hours (0.39±0.01).
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Figure 7.9 -  Area under the curve analysis comparing OVA sensitised guinea pigs OVA sensitised guinea pigs challenged 
with a chronic dosing o f  OVA and treated orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre- 
OVA challenge and 6 hours post-OVA challenge. Only negative peaks are considered, any peaks that have a positive 
value o f sGaw are excluded. Total includes all negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR 
includes from 6-24 hours. Area under the curve is measured in %.hour. (n=6).
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figure 7.10 -  Mean time-course values o f  Penh in OVA sensitised mice that were challenged repeatedly with 2% OVA three 
limes a week for six w eeks and treated orally with methyl cellulose or GW 274150F (5 mg/kg) 24 and 0.5 hours pre-OVA  
challenge and 6 hours post-O V A  challenge. The histogram represents maximum bronchoconstriction values during baseline, 
EAR, LAR and 19 hours (24 hours after first exposure). Mean changes in Penh are expressed as mean±S.E.M. percentage 
change from baseline where a positive value represents a bronchoconstriction. ( n=6). Raw GW 274150F treatment P^h 
values (AU) -  Base (0 .34±0.01), 0-6 hours (0.53±0.02), 7-12 hours (0.49±0.03) and 24 hours (0.38±0.01). Raw vehicle 
treatment Penh values (A U ) -  Base (0.35±0.02), 0-6 hours (0.58±0.03), 7-12 hours (0.56±0.03) and 24 hours (0.36±0.02).
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figure 7.11 -  Area under the curve analysis comparing OVA sensitised mice challenged with repeated doses o f  2% OVA  
md treated orally with methyl cellulose or G W 274150 (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post- 
OVA challenge. Only positive peaks are considered, any peaks that have a negative value o f  Penh are excluded. Total 
includes all negative peaks from 0-19 hours, EAR includes from 0-6 hours and LAR includes from 6-19 hours. Area under 
Ic curve is measured in %.hour.(n=6).
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Figure 7.12 -  Response o f the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs chronically challenged with OVA and treated orally with methyl cellulose or GW274150F (5 mg/kg) 24 and 
0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 hours before OVA challenge and 
again 24 hours post-OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from 
baseline where a negative value represents a bronchoconstriction. * significantly different from vehicle pre-challenge 
values o f sGaw.; A significantly different from GW274150F pre-challenge values o f sGaw. Two-tailed T-test (P<0.05; n=6).
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Figure 7.13 -  Response o f  the airways to a 60 second intermittent dose o f methacholine (10 mg/ml) in OVA sensitised mice 
challenged repeatedly with 2% OVA three times a week for six weeks and treated orally with methyl cellulose or 
roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 
hours before OVA challenge and again 24 hours post- OVA challenge. Mean changes in P^h are expressed as mean±S.E.M. 
percentage change from baseline where a positive value represents a bronchoconstriction. * significantly different from 
vehicle pre-challenge; #significantly different from GW274150F pre-challenge Penh value. One-way Analysis o f Variance 
followed by a Bonferroni post-test (P<0.05; n=6).
A  = Chronic OVA challenged -  vehicle treated (pre-challenge)
□  = Chronic OVA challenged -  vehicle treated (post-challenge)
A  = Chronic OVA challenged -  GW274150F treated (pre-challenge) 
O = Chronic OVA challenged -  GW274150F treated (post-challenge)
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Figure 7.14 -  The number o f total cells, macrophages, eosinophils, lymphocytes and neutrophils found in the 
bronchoalveolar fluid o f naive (non-sensitised) and OVA challenged (acute and chronic) guinea pigs orally treated with 
methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. 
Results are expressed as mean±S.E.M. *significantly different from acute OVA -  vehicle treated; ^significantly different 
from chronic OVA -  vehicle treated; A significantly different from acute OVA -  GW274150F treated. One-way Analysis 
of Variance followed by a Bonferroni post-test (P<0.05; n=6).
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Figure 7.15 -  The percentage o f  macrophages, eosinophils, lymphocytes and neutrophils found in the bronchoalveolar 
fluid of naive (non-sensitised) and OVA challenged (acute and chronic) mice orally treated with methyl cellulose or 
roflumilast (1 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge and OVA challenged (acute 
and chronic) mice. Results are expressed as mean±S.E.M. (n=6).
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Figure 7.16 (A-C) -  Bronchioles o f chronic saline challenge, non-treated, guinea pigs and chronic OVA challenged
guinea pigs orally treated with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6
hours post-OVA challenge stained with haematoxylin and eosin to display general morphology (lOOOx magnification).
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Figure 7.17 -  The mean pathology score o f cells found in the peri-bronchiolar space o f naive (non-sensitised) and OVA 
challenged (acute and chronic) guinea pigs treated orally treated with methyl cellulose or GW274150F (5 mg/kg). Results 
are expressed as mean±S.E.M. (n=4).
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Figure 7.18 (A-C) -  Bronchioles o f  chronic saline, non-treated, mice and chronic OVA challenged mice orally treated
with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge
stained with haematoxylin and eosin to display general morphology (lOOOx magnification).
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Figure 7.19 -  The mean pathology score o f cells found in the peri-bronchiolar space of naive (non-sensitised) and OVA 
challenged (acute and chronic) mice treated orally treated with methyl cellulose or GW274150F (5 mg/kg). Results are 
expressed as mean±S.E.M. (n=4).
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'igure 7.20 (A-C) -  Bronchioles o f  chronic saline, non-treated, guinea pigs and chronic OVA challenged guinea pigs
tally treated with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-
A'A challenge stained with picrosirius red to display collagen (lOOOx magnification).
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Figure 7.21 -  Effect o f  a chronic OVA challenge and treatment o f methyl cellulose or GW274150F (5 mg/kg) 
administered orally 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on percentage bronchiolar 
collagen in guinea pigs. Results are expressed as mean±S.E.M. (n=4).
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Figure 7.22 (A-C) -  Bronchioles o f chronic saline, non-treated, mice and chronic OVA challenged mice orally treated
with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge
stained with picrosirius red to display collagen (lOOOx magnification).
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Figure 7.23 -  Effect o f  a chronic OVA challenge and treatment o f  methyl cellulose or GW274150F (1 mg/kg) 
administered orally 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on percentage bronchiolar 
collagen in mice. Results are expressed as mean±S.E.M. (n=4).
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Figure 7 .2 4  (A-C) -  Bronchioles o f  chronic saline, non-treated, guinea pigs and chronic OVA challenged guinea pigs
wily treated with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-
OVA challenge stained with alcian blue/periodic acid Schiff to display goblet cells (lOOOx magnification).
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Figure 7.25 -  Effect o f a chronic OVA challenge and treatment and treatment o f methyl cellulose or GW274150F (5 
mg/kg) administered orally 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on number o f mucin 
associate goblet cells per 10,000 epithelial pixels in guinea pigs. Results are expressed as mean±S.E.M. (n=4).
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Figure 7.24 (A-C) -  Bronchioles o f  chronic saline, non-treated, mice and chronic OVA challenged mice orally treated
with methyl cellulose or GW274150F (5 mg/kg) 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge
stained with alcian blue/periodic acid Schiff to display goblet cells (lOOOx magnification).
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Figure 7.27 -  Effect o f a chronic OVA challenge and treatment and treatment of methyl cellulose or GW274150F (5 
mg/kg) administered orally 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge on number o f mucin 
associate goblet cells per 10,000 epithelial pixels in mice. Results are expressed as mean±S.E.M. (n=4).
231
CHAPTER 7
7.5 DISCUSSION
7.5.1 EARLY AND LATE ASTHMATIC RESPONSES IN ACUTE AND
CHRONIC OVALBUMIN CHALLENGED GUINEA PIG AND MICE
Guinea pigs and mice that were sensitised and challenged with OVA still had an EAR despite 
treatment with the iNOS inhibitor GW274150F. NO can activate guanylyl cyclase which in 
turn forms cGMP and ultimately results in cellular effects including smooth muscle 
relaxation. Therefore, the fact that GW274150F had no effect on the EAR was not surprising. 
Treatment with iNOS inhibitors could in fact be detrimental in terms of the EAR as it could 
be inhibiting the bronchodilation effect that NO has. However, no evidence for iNOS 
inhibitors potentiating the EAR was observed in these models suggesting that NO may not be 
having a bronchodilator effect.
In acute OVA challenged guinea pig and mice GW274150F had some effect on the LAR. 
When comparing values of sGaw against time for vehicle versus GW274150F it is evident, 
and statistically shown, that the LAR is attenuated. This was also the case when maximum 
values of sGaw for the LAR and area under the curve was assessed.. A similar result was 
observed in acute OVA mice, although it is clear to see that GW274150F is having an effect 
on the LAR it is not reducing it to basal levels and the area under the curve is not 
significantly different from vehicle. Previous work with the same iNOS inhibitor showed it 
could inhibit the LAR in guinea pigs but not rats (Knowles et al., 2007). However, in order 
for the LAR to be reduced in guinea pigs a dose of 30 mg/kg was used which is a great deal 
more than the dose used in clinical trials.
GW274150F had no effect on the LAR in the chronic OVA challenged guinea pigs and mice. 
This suggests that if GW274150F was having an anti-inflammatory effect in the acute model 
it is lost after airway remodelling has occurred. It appears that although increased levels of 
nitric oxide are observed in asthmatics it is not nitric oxide that is causing the LAR. Whilst it 
is possible that nitric oxide is just one of a number of mechanisms involved in the LAR the 
evidence shown here suggest this role may only be in mild asthma where chronic airway 
inflammation and remodelling has not occurred. Evidence for this theory is corroborated by 
the fact that treatment with GW274150F had no effect on the LAR in humans with mild 
asthma (Singh et al., 2007).
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7.5.2 AIRWAY HYPERRESPONSIVENESS IN ACUTE AND CHRONIC
OVALBUMIN CHALLENGED GUINEA PIG AND MICE
The inhibition of iNOS by GW274150F causes a significant reduction in the AHR observed 
when acute OVA challenged guinea pigs and mice are treated with vehicle, although in mice 
the level of Pcnh is still significantly greater than pre-challenge. These findings suggest that 
GW274150F may be having an anti-inflammatory effect, possibly by having a protective role 
on the pulmonary epithelial cells. Studies have shown the iNOS generated NO increases 
AHR (Komlosi et al., 2006; Muijsers et al., 2001) and treatment with an iNOS inhibitor can 
inhibit AHR (Knowles et al., 2007). These findings support the findings in the acute OVA 
challenge groups in this chapter. However, some studies have shown iNOS derived NO 
decreases AHR (Kenyon et al., 2003) which is in direct contrast to the findings here.
If GW274150F is having a protective effect in acute asthma, that effect is abolished in 
chronic asthma as in both the guinea pig and mouse chronic OVA model AHR was observed 
after GW274150F treatment. It appears that the epithelial shedding and influx of 
inflammatory mediators associated with chronic asthma cannot be reversed or inhibited by 
GW274150F treatment. AHR was still present in human asthmatics treated with 
GW274150F, however, the drug was able to reduce levels of NO (Singh et al., 2007). This 
suggests that either NO is involved in causing AHR in mild asthma but not chronic asthma or 
GW274150F has an effect on something unrelated to NO in mild asthma which attenuates 
AHR. Although there is a strong correlation between exhaled nitric oxide and AHR (Downie 
et a l,  2007; Salome et al., 1999) it would appear that NO itself is not a direct cause of AHR.
7.5.3 CELLULAR INFLUX IN ACUTE AND CHRONIC OVALBUMIN 
CHALLENGED GUINEA PIG AND MICE
Treatment with GW274150F significantly reduced total cell number and eosinophil number 
in the BAL fluid of acute OVA challenged guinea pigs. However, these reductions were still 
greater than naive levels. The reduction in eosinophils by GW274150F is likely to explain 
why a reduction in LAR and AHR was observed in this model. GW274150F treatment 
appeared to cause an increase in macrophages this could be a result of the fact that NO can 
reduce leukocyte chemoattraction and function (Nevin & Broadley, 2002). In the chronic 
OVA challenged guinea pigs there was a slight reduction in total cell count after GW274150F
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treatment. It is likely that this was caused by the significant reduction in neutrophils that was 
also observed. A reduction in neutrophils after iNOS inhibitor treatment was also observed in 
the acute guinea pig model and has been shown previously in the literature in Candida- 
induced acute lung injury (Ohsugi et al., 2007).
No significant difference was observed in eosinophil numbers between the vehicle and 
GW274150F treated chronic OVA challenged guinea pigs. This could explain why the iNOS 
inhibitor was unable to have an effect on the LAR or AHR in the chronic guinea pig model. 
The fact that GW274150F was unable to inhibit eosinophillia in the chronic model but was in 
the acute model resulted in significantly greater levels of total inflammatory cells and 
eosinophils in the BAL fluid of the chronic group.
In both acute and chronic OVA mice GW274150F was unable to significantly alter the 
percentage of inflammatory cells in the BAL fluid compared to vehicle treatment. This could 
be misleading as total cell counts were not carried out. Judging by the fact that GW274150F 
inhibited the LAR and AHR in the acute guinea pigs and significantly reduced eosinophil 
numbers in guinea pigs suggests that it may in fact be reducing eosinophil influx in acute 
OVA challenged guinea pigs. Other studies in mice have shown that iNOS is pro- 
eosinophillic (Iijima et al., 2001; Koarai et al., 2002) further corroborating this theory. As 
GW274150F was unable to attenuate the LAR and AHR in chronic OVA challenged mice 
suggests that it is having no effect on eosinophil influx. If GW274150F had a pronounced 
effect on total cell count in chronic challenged models it would show in the lung histology 
(discussed in the next section). In human studies GW274150F had no significant effect on 
inflammatory cell number and differential cells numbers (Singh et al., 2007). There was no 
significant reduction in neutrophil number as observed in the guinea pig model. This could 
either be a result of the difference between humans and guinea pigs or it could be a dosing 
effect as in the human studies dosing lasted 14 days.
7.5.4 LUNG HISTOLOGY IN CHRONIC OVALBUMIN CHALLENGED
GUINEA PIG AND MICE
Quantifiably it is quite clear to see that GW274150F has little if no effect on the structural 
changes in the airways that are caused by chronic OVA challenge. Therefore it is no surprise 
to see that GW274150F has proved a poor asthma therapeutic in the chronic OVA guinea pig
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and mouse models and also in human asthmatics. Several components of airway remodelling 
such as increased airway vascularity (Orsida et al., 1999) and airway wall thickness 
(Kasahara et al., 2002) have been suggested to contribute AHR. This could explain why 
GW274150F was able to inhibit AHR in the acute models but not in the chronic models.
When the number of inflammatory numbers in the peribronchiolar space were scored 
GW274150F had no significant effect on score compared to vehicle in both the guinea pigs 
and mice. In guinea pigs this does not correlate with what was observed in the BAL fluid as a 
slight decrease in total cell number was seen, however, it may account for why the LAR and 
AHR was not inhibited by GW274150F. No significant differences were observed in cell 
number in the chronic challenged mice compared to vehicle in both the BAL fluid and 
peribronchiolar space. This suggests that either iNOS is not a pro-eosinophillic as some 
studies suggest (Iijima et al., 2001; Koarai et al., 2002) or that GW274150F is unable to 
inhibit the cellular effects of iNOS.
No significant change was observed in collagen deposition or number of mucin associated 
goblet cells in the GW274150F stained bronchioles compared to vehicle. If the iNOS 
inhibitor is having no effects on the key components of airway remodelling then it is 
understandable why the drug did not work in clinical trials. There is evidence that the iNOS 
inhibitor 1400W is able to attenuate airway remodelling (Starling et al., 2009) suggesting this 
drug may have some potential as a future asthma therapeutic. However, this study was carried 
out in lung strips from guinea pigs and may not be reproducible in vivo. Despite that it is also 
possible that iNOS may be a feasible target and GW274150F is unable to prevent the effects 
of iNOS activation. This theory regarding GW274150F is supported by the findings that there 
was no reduction in 3-NT in GW274150F treated asthmatics compared to placebo (Singh et 
al., 2007).
7.5.5 GENERAL CONCLUSIONS
The role of NO in the airways is somewhat of an enigma, there is evidence that it can be both 
pro-inflammatory and anti-inflammatory (Nevin and Broadley 2002). It is possible that the 
effect of NO is dependent on whether it is coming from iNOS or eNOS. Another explanation 
is that the effect of NO could be dependent on the dose present, i.e. the higher the dose the 
more damage it causes to the airways. Despite the confusing nature of NO it is known that
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asthmatics exhale more NO than non-asthmatics and therefore there has been suggestions that 
reducing levels of NO could help alleviate some of the symptoms of asthma (Singh et al, 
2007; Mathrani et al., 2007). Inhibitors of NO synthase, the enzyme that catalyses the 
formation NO, have been evaluated in animal models of asthma with mixed results (Mathrani 
et al., 2007). GW274150F, an inhibitor of iNOS that had relatively promising results in 
animal asthma models was entered into clinical trials but was not effective in human 
asthmatics.
GW274150F was able to inhibit the LAR, AHR and some cellular influx in acute OVA 
models of asthma, however, it had little effect in the chronic OVA models. It is likely the 
main causes of the failure of GW274150F in the chronic model was that it was unable to 
inhibit eosinophil influx and airway remodelling. In the chronic model airway remodelling is 
allowed to develop before any drugs are administered. Therefore it is possible that although 
GW274150F is unable to reverse airway remodelling it could prevent it if administration 
occurred before each OVA challenge. However, fluticasone propionate and roflumilast were 
both administered at the same point in the protocol as GW274150F and these drugs were able 
to reverse airway remodelling and other features associated with asthma. Some subject will 
already have some degree of airway remodelling before treatment is administered, as a result 
a drug which can reverse airway remodelling would be favoured over a drug that may be able 
to prevent exacerbation.
This study proves that the chronic OVA model of asthma is a much closer representation of 
human asthma than the acute OVA model. GW274150F treatment had the same outcome in 
the parameters that were assessed in the chronic model and humans with mild asthma with 
the exception of total cell influx in the guinea pigs. GW274150F appeared to be quite an 
effective anti-inflammatory in the acute OVA model and as such a potential asthma therapy. 
These results were therefore misleading. Using the chronic OVA model, although time 
consuming and originally more expensive, could prove cost effective in the long-term as it 
would be unlikely that a drug that fails in chronic OVA animal models would work in 
humans or be put into clinical trials.
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8.1 INTRODUCTION 
8.1.1 m a g n e t i c  r e s o n a n c e  i m a g i n g
Magnetic resonance imaging (MRI) is a non-invasive technique which is used extensively for 
imaging areas of the human body such as the brain. MRI uses magnetic fields and 
electromagnetic radio frequency waves to produce anatomical images with excellent contrast 
between tissues, water and fat. MR imaging has also been used in research involving animal 
models because it is a non-invasive technique (Kraft et al., 2004; Tigani et al., 2007) and is a 
useful tool to investigate inflammation.
8.1.1.1 THEORY OF MRI
Conventional MRI detects protons between tissue, water and fat. Protons are positively 
charged particles found in the nucleus of an atom. When a subject is placed in a MRI scanner 
the magnetic force causes the protons to align themselves with a static magnetic field (Bo), 
with the magnet either in a parallel or anti-parallel nature. As parallel alignment requires less 
energy than anti-parallel there are more parallel aligned protons than anti-parallel. Protons are 
always oscillating, when an external magnetic force is applied the protons move in a cone 
shape, a process called precessing (figure 8.1). The faster a proton precesses the higher the 
precession frequency. A stronger magnetic current causes a higher precession frequency and 
therefore the protons precess quicker. The precession frequency can be calculated using the 
Larmor equation:
coo = yB0
The precession frequency (too) is equal to the gyromagnetic ratio (y) which in protons is 42.5 
MHzT multiplied by the strength of the external magnetic field (B0).
As protons precess very quickly there are magnetic forces in opposing directions that cancel 
each other out. However, as there are more parallel aligned protons these are left over. 
Protons have components along x, y and z axis and as a result parallel aligned protons that are 
precessing the left of the cone can cancel out protons precessing to the right of the cone. The 
only direction which protons cannot be cancelled out is in the direction of the external 
magnetic force (x-axis). Here all the magnetic forces add up to make a magnetic vector in the 
external magnetic field direction. This is known as longitudinal magnetisation (figure 8.1).
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However, in cases where the nuclei have even number of protons it would be possible for all 
protons to cancel each other out and longitudinal magnetisation would not occur. Therefore in 
MRI the best nuclei to use are those with an odd amount of protons. As hydrogen only has 
one proton and is abundant throughout the body it is commonly used for MRI.
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Figure 8 .1: Protons are spinning in a cone along the z-axis, a process called processing. More protons process in a 
parallel direction as this requires less energy. The protons that process in an anti-parallel direction get cancelled out by 
lose in a parallel direction. The parallel protons still have forces along the y and x axis, these become cancelled out by 
conesponding parallel protons leaving magnetic force in the z-axis direction. This is known as longitudinal 
■gnetisation. Diagram adapted from Schering (1990).
The longitudinal magnetic forces cannot be measured as it is parallel to the external magnetic 
field, therefore a radio wave is sent into the MRI machine. The radio wave is a short burst of 
an electromagnetic wave known as the RF (radio frequency) pulse. The purpose of the RF 
pulse is to disturb the precessing protons. In order for the RF pulse to do this it needs to have 
the same frequency as the protons so it can exchange energy with them. As the precession 
frequency can be calculated by using the Larmor equation this also calculates the required 
frequency of the RF pulse. Once the RF pulse and protons have the same frequency they can 
exchange energy, a process called resonance. As some protons gain extra energy from the RF 
pulse they switch from parallel alignment to anti-parallel and therefore cancel out their 
corresponding proton. This results in decreased longitudinal magnetisation. The RF pulse 
also causes the protons to align in the same directions so they are ‘in phase’. This causes the
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magnetic vectors to add up in this direction, a process known as transversal magnetisation 
(figure 8.2).
z  RF Pulse 7
X l
■►Y
Figure 8.2: When an RF pulse is introduced protons pick up energy from it, a process called resonance. This 
causes some protons to become anti-parallel and results in them cancelling the z-axis magnetic field o f the parallel 
protons, reducing longitudinal magnetisation. The RF pulse also causes the protons to precess together or ‘in 
phase’. This establishes a new magnetic force along the x-y plane called transversal magnetisation. Diagram 
adapted from Schering (1990).
The newly established magnetic vector moves with the precessing protons at the precession 
frequency. This constant moving and changing causes an electric current. There is also a 
moving magnetic vector within the MRI machine which induces an electric current in an 
antenna, this is the MRI high intensity oedemic signal. As the transversal magnetic vector 
processes it comes towards then away from the antenna at the precession frequency. 
Therefore the MRI signal has the precession frequency. However, before an image can be 
established from the signal it is necessary to know where in the body the signal comes from.
In order to discover where the signal comes from the magnetic field which the subject is 
placed in has different strengths at each point of the cross section of the subject. As 
precession frequency depends on magnetic field if the magnet strength varies then the MR 
signal will also have different frequencies.
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When capturing an image the RF pulse is switched off. As a result the transverse 
magnetisation starts to decrease, a process called transversal relaxation, and the longitudinal 
magnetisation starts to increase, known as longitudinal relaxation. This is caused by the 
protons returning to a lower energy state and resorting back to parallel alignment. However, 
not all protons do this at the same time. As the protons steadily become parallel they no 
longer cancel out the magnetic vectors of the other parallel protons. This eventually results in 
transversal magnetisation disappearing and longitudinal magnetisation resorting to the 
original strength. The time this process takes to occur is known as longitudinal relaxation 
time or Ti and can be plotted as a T| curve (figure 8.3).
Longitudinal
Magnetisation
Time
Figure 8.3: A graph which shows the level o f longitudinal magnetisation versus time after an RF pulse is 
turned off. This is known as a T|-curve. Diagram adapted from Schering (1990).
A T| curve only shows increase in longitudinal magnetisation. However, transversal 
magnetisation is also decreasing. This can be plotted as a T2 curve (figure 8.4). The time that 
Ti and T: takes establishes the characteristics of tissue. Liquids have a long Ti and T2 process 
whereas fat has a shorter Tj and T2. The Ti process is longer in water as it takes protons 
longer to get rid of the RF pulse-supplied energy to the surrounding lattice as the molecules 
move more rapidly than larger fat molecules. The T2 process is quicker in fat as larger 
molecules do not move around so much so not so many magnetic fields are cancelled out and 
protons can get out of phase easier than in water.
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■Time
Figure 8.4: A graph which shows the level o f transversal magnetisation versus time after an RF pulse is turned 
off. This is known as a T2-curve. Diagram adapted from Schering (1990).
The MRI signal intensity is directly determined by magnetic vectors inducing electrical 
currents in the antenna. The vector has a spiralling motion when changing from transversal to 
longitudinal magnetisation therefore the signal intensity fluctuates but disappears with time. 
As some tissues take longer to become longitudinal than others by using more than one RF 
pulse, a pulse-sequence, the signal before the second RF pulse allows the differentiation 
between the signals (figure 8.5).
A
B
Figure 8.5: If more than one RF pulses are used a differentiation between magnetic vectors can be observed when the second 
RF pulse is added. This allows for differentiation between tissues. Here tissue B has a longer Tr curve and as a result 
longitudinal magnetisation has not recovered to the point o f  tissue A. Diagram adapted from Schering (1990).
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This time between RF pulses is known as time to repeat or TR. If a shorter TR is used the 
differences in signal intensity between the tissues is determined by their difference in Ti and 
thus gives a Ti weighed image. To obtain a T2 weighed image a different process is used. If 
the RF pulse usually applied is 90° then a certain time after this is turned off (TE/2) a 180° 
pulse is sent. This makes the protons turn around, at this stage the slower protons are in front 
of the faster protons, however, the faster protons catch up and a strong signal is observed 
from the protons being in phase again. The 180° pulse is also called an echo, therefore TE 
stands for time to echo. If a short TE is used then the signal will be stronger but 
differentiation between the tissue will be less pronounced. If a long TE is used the difference 
will be more pronounced but the signal will pick up more background noise. Multiple slices 
will result in a better signal to noise ratio. Manipulation of gradients and RF pulses will 
allows any slide or orthogonal direction within the subject to be imaged. After these 
processes have occurred a mathematical process called Fourier transformation allows the 
analysis of the signals. The signals can be assigned to a certain location in the slice allowing 
the image to be reconstructed. MRI theory adapted from Schering (1990).
8.1.2 OEDEMA
The purpose of using MRI analysis in this chapter is to assess the levels of pulmonary 
oedema in the acute and chronic guinea pig models o f asthma. Pulmonary oedema is defined 
as an abnormal accumulation of fluid in the extravascular compartments of the lung 
(Gluecker et al., 1999). Pulmonary oedema can be caused by an increase in either the 
permeability or hydrostatic pressure within the lung blood vessels resulting in fluid escaping 
the microvasculature and entering the surrounding tissue (Beckmann et al., 2001). Plasma 
leakage, oedema formation and mucus hypersecretion all contribute to luminal airway 
narrowing and therefore impair lung function (Ble et al., 2008). Therefore using MR imaging 
could prove a useful tool in evaluating oedema formation in asthmatics and also to determine 
the efYect that potential therapeutics have on oedema.
Several studies have used MR imaging on animal models of asthma. Ovalbumin (OVA) 
sensitised and challenged Brown-Norway rats showed increased oedema 6 hours after 
challenge. This oedema increased to a maximum at 48 hours and then decreased at 96 hours 
(Tigani et al., 2007). This study also showed that oedema peaked 6 hours after repeated 
challenges and then steadily decreased. However, the peak level of oedema decreased after
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each challenge suggesting that tolerance could have occurred. Further studies in Brown- 
Norway rats showed a correlation between MRI high intensity oedemic signals and BAL 
eosinophil number following OVA sensitisation and challenge (Tigani et al., 2002). In OVA 
sensitised mice an increase in oedema was observed 24 hours after the second OVA 
challenge (Ble et al., 2008). However, like in the rats the MRI high intensity oedemic signal 
became less intense after each challenge.
8.1.3 DEXAMETHASONE
Dexamethasone is a corticosteroid which is recommended for moderate to severe asthma 
(Shefrin & Goldman, 2009). However, although it is an extremely potent corticosteroid, the 
side-effects associated with dexamethasone limit its use (Ducharme et al., 2003). Despite this 
dexamethasone has been commonly used in animal models of asthma and has been effective 
at reducing the LAR, AHR and cellular influx associated with asthma (Kumar et al., 2003; 
Toward & Broadley, 2004). The mechanism of action of corticosteroids is described in 
greater detail in chapter 5; however, there is evidence that corticosteroids can prevent 
pulmonary oedema in animal models of asthma (Beckmann et al., 2001; Tigani et al., 2002). 
By using a potent corticosteroid it is possible to assess whether levels of oedema can be 
reduced and also whether the reduction of the late asthmatic response correlates with oedema 
reduction.
i
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8.2 AIMS AND OBJECTIVES
8.2.1 AIMS
The aim of this chapter was to assess the level of lung oedema in acute and chronic OVA 
challenged guinea pigs at various time points to determine whether repeated challenges 
causes greater oedema and whether time after challenge makes a difference. The effect of 
dexamethasone treatment compared to vehicle treatment on acute OVA challenged guinea 
pigs on lung oedema was determined using MRI. The effect that dexamethasone has on the 
early and late phase bronchoconstriction, airway hyperresponsiveness, cellular influx was 
also assessed.
8.2.2 OBJECTIVES
• To investigate what effect, if any, that acute and chronic OVA exposures in sensitised 
guinea pigs has on levels of lung oedema using MRI
• To investigate the effect that dexamethasone treatment has on acute OVA exposed 
guinea pigs by measuring lung function, response to histamine and cellular influx 
compared to vehicle treatment.
• To investigate what effect, if any, that dexamethasone treatment has on the levels lung 
oedema in acute OVA exposed guinea pigs MRI.
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3.3 METHODS
In this study the sensitisation, exposures and subsequent MR imaging was carried out at 
GlaxoSmithKline in Harlow. For each study group six male Dunkin-Hartley guinea pigs 
(Harlan, UK) weighing 150-175 g were used. The guinea pigs were ordered in at a lower 
weight to ensure the chronic group could fit comfortably into the MRI machine. The 
conditions in which the guinea pigs were kept were the same as in the animal service 
laboratories in Cardiff (detailed in chapter 2). All animal work carried out in 
GlaxoSmithKline was carried out by technicians. During this period I was controlling the 
imaging and running the MRI machine.
The studies involving lung function measurements and cellular influx after dexamethasone 
treatment were carried out in Cardiff. Six male Dunkin-Hartley guinea pigs (Harlan, UK) 
weighing 200-250 g were used for each group.
83.1 SENSITISATION
Guinea pigs were sensitised by an intra-peritoneal, bilateral injection of a suspension 
containing OVA (100 pg) and Al(OH)3 (100 mg) in 1 ml o f PBS on days 1 and 5.
83.2 OVALBUMIN CHALLENGES
OVA challenges for both acute and chronic groups were carried out in a stainless steel 
exposure chamber (40 cm diameter, 15 cm height) with a Wright nebuliser attached. The 
nebuliser delivered the OVA or saline at an air pressure of 20 lb p.s.i. and at a rate of 0.3 
ml/min. The guinea pigs remained in the chamber for 1 hour, however, if they appeared to be 
distressed they were immediately removed from the chamber and exposure was considered 
complete. These methods were the same at both Harlow and Cardiff.
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8.3.2.1 ACUTE PROTOCOL -  GUINEA PIGS
On day 15 the guinea pigs were challenged with a 1 hour exposure to OVA (0.01%).
8.3.2.2 CHRONIC PROTOCOL -  GUINEA PIGS
The guinea pigs were exposed to a 1 hour exposure to OVA (0.01%) on day 15. On days 17- 
29 (every 48 hours) the guinea pigs were exposed to OVA (0.1%) for 1 hour, this was 
preceded with an injection of mepyramine (30 mg/kg). On the final day (day 31) a 1 hour 
exposure of OVA (0.1%) was carried out.
8.3.3 MR IMAGING OF GUINEA PIG LUNGS
In order to capture MR images of lungs a Bruker 4.7 Tesla magnet was used. The magnet had 
a 11.6 cm gradient insert and a 72 mm coil and cradle. Images with a 7.2 cm field of view, 
slice thickness of 1.8 mm and interslice distance of 2.4 mm were taken.
Before the guinea pigs were placed in the MRI machine they were anaesthetised with 
isofluorane (1-4%) and oxygen/air as the carrier for the isoflourane, this was maintained 
throughout the whole time they were in the machine via an actively scavenged open face 
mask unit. Respiration was monitored using a transducer. The guinea pigs were placed in the 
supine position for imaging. As reproducing the position of the guinea pig for each scan was 
important for comparison of the images two scout images were recorded to check the 
positioning of the axial, coronal and sagittal views. Baseline images were captured before any 
challenges took place, subsequent to the final exposure images were taken 15 minutes, 4, 7 
and 25 hours. The following images show the slices captured in one scan.
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8.3.4 M RI ANALYSIS OF GUINEA PIG LUNGS
In order to analyse the level of oedema seen in the lungs for each of the images the lung 
cavity was drawn around for every slice taken using the computer program Analyze. Figure 
8.6a shows an example of an image with the lung cavity drawn around. After drawing around 
the lungs a threshold is applied to the image by eye, this then allows all areas of the image 
that is not a certain intensity to be excluded (shown in figure 8.6b). The volume of bright 
intensity in the lung image can then be recorded in mm3. A naive group of guinea pigs was 
introduced to establish the baseline volume of bright intensity as drawing around the lung 
cavity also includes the heart which appears bright. Therefore, theoretically volume of bright 
intensity observed which is greater than the naive volume (greater than the red dashed line in 
the graphs) is a result of oedema.
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Excluded area
E.6: To analyse the level o f lung oedema the lung cavity was firstly drawn around (A.). Following this a was applied by eye, this allows all areas o f dark intensity to be excluded (B.), this is air space in the lungs. Tie o f  bright intensity, which is solid tissue or fluid, is then measured in mm3.
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8 3 . 5  L U N G  F U N C T I O N  M E A S U R E M E N T S
Lung function methods are described in detail in section 2.2.3. Briefly, whole-body 
plethysmography was used to determine values of sGaw from which changes in lung function 
can be observed. Baseline values were recorded before the guinea pig was exposed to OVA, 
following the exposure values were recorded at 0, 15 minutes, 30 minutes, 45 minutes and 60 
minutes post-exposure, then hourly until 12 hours with a final reading at 24 hours. In order to 
capture both the early and late asthmatic responses maximum bronchoconstriction values 
between 0-6 hours and 7-12 hours were recorded and displayed as a histogram next to the 
time course plot.
8 3 . 6  A I R W A Y  R E S P O N S I V E N E S S  M E A S U R E M E N T S
Airway responsiveness was measured by investigating the response of guinea pigs to 1 mMol 
histamine (20 seconds). Exposures to histamine occurred 24 hours pre-OVA exposure and 24 
hours post-OVA exposure. Readings of sGaw were taken at baseline and 0, 5 and 10 minutes 
following the histamine exposure.
8 3 . 7  T O T A L  A N D  D I F F E R E N T I A L  C E L L  C O U N T S
After the final histamine exposure the guinea pigs were administered a lethal dose of sodium 
pentobarbitone and their lungs were lavaged. The recovered BAL fluid was used to carry out 
a total and differential cell count. These methods are fully described in section 2.2.7.
8 3 . 8  D R U G  A D M I N I S T R A T I O N
Dexamethasone was administered by an intraperitoneal bilateral injection at a dose of 20 
mg/kg. The vehicle used was saline and DMSO in a 50:50 mix. Administration occurred at 
three separate times, 24 hours and 30 minutes before the OVA exposure and 6 hours after the 
exposure.
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8.4 RESULTS
8 .4 .1  M R I  A N A L Y S I S  O F  A C U T E  A N D  C H R O N I C  C H A L L E N G E D
G U I N E A  P I G S
Figures 8.7 (A-E) show a single slice taken from naive, saline challenged and OVA 
challenged guinea pigs 7 hours post-exposure. Figure 8.8 represents the effect that sensitising 
a guinea pig with OVA and challenging it with a single exposure of saline or OVA had on the 
volume of bright intensity in its lungs. A significant difference was observed between the 
OVA challenged and saline challenged guinea pigs at 4 hours (6.4±0.2xl03 mm3 compared to 
4.8±0.2xl03 mm3 respectively), 7 hours (7.6±0.2xl03 mm3 compared to 5.1±0.2xl03 mm3 
respectively) and 25 hours (6.5±0.2xl03 mm3 compared to 4.5±0.2xl03 mm3 respectively) 
following exposure.
In figure 8.9 the effect of chronic exposures of saline or OVA on the volume of bright 
intensity in the lungs of sensitised guinea pigs is shown. Multiple challenges of OVA caused 
a significantly greater intensity than multiple challenges of saline at baseline (7.3±0.4xl03 
mm3 compared to 5.5±0. lxlO3 mm3 respectively), 15 minutes (7.7±0.6xl03 mm3 compared to 
5.4±0.2xl03 mm3 respectively), 4 hours (8.9±0.6xl03 mm3 compared to 5.9±0.2xl03 mm3 
respectively), 7 hours (9.0±0.7xl03 mm3 compared to 6.0±0.2xl03 mm3 respectively) and 25 
hours (7.4±0.5xl03 mm3 compared to 5.7±0.2xl03 mm3 respectively) following the final 
exposure.
Figure 8.10 shows the comparison between acute and chronic challenged guinea pigs. At the 
baseline time point multiple exposures of OVA caused a significantly greater volume of 
bright intensity than a single OVA challenge (7.3±0.4xl03 mm3 compared to 4.0±0.08xl03 
mm3 respectively). This was also true 15 minutes (7.7±0.6xl03 mm3 compared to 
5.1±0.2xl03 mm3 respectively) and 4 hours (8.9±0.6xl03 mm3 compared to 6.4±0.2xl03 mm3 
respectively) after the final challenge. However, no significant difference was seen at the 7 
hour and 25 hour time points.
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A. Naive (non-sensitised)
B. OVA sensitised -  Acute saline challenged
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C. OVA sensitised -  Chronic saline challenged
D. OVA sensitised -  Acute OVA challenged
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E. OVA sensitised -  Chronic OVA challenged
Figures 8.7 (A-E): A single slice showing the MR image o f  the lungs o f  naive and OVA sensitised guinea pigs 
challenged with a single or multiple exposures o f saline or OVA.
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Figure 8.8: The volume o f bright intensity in naive or OVA sensitised acute saline or OVA challenged guinea 
pigs. The red line highlights the basal level o f  bright intensity, this is tissue such as the heart. *significantly 
different from acute saline challenged guinea pigs. Two-tailed T-test (P<0.05; n=6).
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Figure 8.9: The volume o f bright intensity in naive or OVA sensitised chronic saline or OVA challenged guinea 
pigs. The red line highlights the basal level o f bright intensity, this is like caused by tissue such as the heart, 
♦significantly different from chronic saline challenged guinea pigs. Two-tailed T-test (P<0.05; n=6).
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Figure 8.10: The volume o f bright intensity in OVA sensitised guinea pigs challenged with a single or multiple 
saline or OVA exposure. #significant difference between acute and chronic OVA challenge. Two-tailed T-test 
(P<0.05; n=6).
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8.4.2 LUNG FUNCTION OF ACUTE OVALBUMIN CHALLENGED
GUINEA PIGS
Figure 8.11 highlights the effect of treating OVA sensitised, acute OVA challenged guinea 
pigs with dexamethasone or vehicle on lung function. An immediate bronchoconstriction was 
observed in the vehicle treated group (-59.1 ±5.3%), dexamethasone treated guinea pigs also 
showed an immediate bronchoconstriction (-56.8±7.7%). Dexamethasone treated 
significantly reduced levels of bronchoconstriction compared to vehicle treated guinea pigs 7 
hours after the OVA exposure (11.7±3.9% compared to -20.2±5.9% respectively). No 
significant difference was seen between the two treatments at the EAR time point, however, 
dexamethasone significantly reduced the LAR compared to peak sGaw values in the vehicle 
treated group (-5.9±1.2% compared to -26.3±4.8% respectively). Figure 8.12 shows area 
under the curve analysis for the two groups in which no significant difference was observed 
for total area and EAR area. However, dexamethasone treated guinea pigs had a significantly 
smaller area under the curve at the LAR time point than the vehicle treated group 
(37.0±18.4%.hr compared to 249.4±19.3%.hr respectively).
8.4.3 AIRWAY RESPONSIVENESS OF ACUTE OVALBUMIN
CHALLENGED GUINEA PIGS
The effect that dexamethasone and vehicle had on the AHR that a single OVA challenge 
causes is shown in figure 8.13. A significant bronchoconstriction was observed immediately 
following a histamine challenge in guinea pigs that had been exposed to OVA and were 
treated with vehicle compared to the same group pre-OVA (-41.4±7.6% compared to 
0.1 ±1.2% respectively). This bronchoconstriction was still significant 5 minutes after the 
histamine challenge (-24.5±4.6% compared to -1.0±2.1% respectively) but resolved after 10 
minutes. Dexamethasone caused complete inhibition of AHR with no significant difference 
between pre-OVA and post-OVA exposures after a histamine challenge (1 mMol, 20 
seconds).
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8.4.4 TOTAL AND DIFFERENTIAL CELL COUNTS IN ACUTE 
OVALBUMIN CHALLENGED GUINEA PIGS
Figure 8.15 represents the number of cells found in the BAL fluid of acute OVA challenged 
guinea pigs treated with dexamethasone or vehicle. Dexamethasone treatment significantly 
reduced the total number of BAL cells compared to vehicle treatment (2.9±0.2xl06 compared 
to 6.2±0.6xl06 respectively). This was also true for eosinophil number (2.0±0.05xl06 
compared to 1.8±0.08xl06 respectively) and lymphocyte number (0.05±0.01xl06 compared 
to 0.2±0.03xl06 respectively).
8.4.5 MRI ANALYSIS OF ACUTE OVALBUMIN CHALLENGED GUINEA 
PIGS TREATED WITH DEXAMETHASONE
Figures 8.16 (A-B) show a single slice taken from acute OVA challenged guinea pigs treated 
with dexamethasone or vehicle at 7 hours post-exposure. Figure 8.17 represents the volume 
of bright intensity in the lung cavity of OVA sensitised, acute OVA challenged guinea pigs 
treated with either dexamethasone (20 mg/kg) or vehicle (saline-50%:DMSO-50%). 
Dexamethasone significantly reduces the volume of bright intensity compared to vehicle 
treated guinea pigs 7 hours after an OVA exposure (6.4±0.3xl03 mm3 compared to 
9.1±1.0xl03 mm3 respectively).
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Figure 8.11 -  Mean time-course values o f sGaw in OVA sensitised guinea pigs that were challenged with 0.01 % OVA 
and treated with saline/DMSO (50%/50%) or dexamethasone 20 mg/kg) administered i.p. 24 and 0.5 hours pre-OVA 
challenge and 6 hours post-OVA challenge. The histogram represents maximum bronchoconstriction values during 
baseline, EAR, LAR and 24 hours. Mean changes in sGaw are expressed as mean±S.E.M. percentage change from 
baseline where a negative value represents a bronchoconstriction. *significantly different from dexamethasone treated 
guinea pigs; A significant difference between vehicle and dexamethasone treatment. Two-tailed T-test (P<0.05; n=6). 
Raw dexamethasone treatment sGaw values (cm/H20) -  Base (0.55±0.03), 0-6 hours (0.23±0.03), 7-12 hours (0.52±0.03) 
and 24 hours (0.61 ±0.04). Raw vehicle treatment sGaw values (cm/H20) -  Base (0.56±0.02), 0-6 hours (0.22±0.02), 7-12 
hours (0.40±0.03) and 24 hours (0.53±0.04).
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Figure 8.12 -  Area under the curve analysis comparing OVA sensitised guinea pigs challenged with 0.01 % OVA and 
treated with saline/DMSO (50%/50%) or dexamethasone 20 mg/kg) administered i.p. 24 and 0.5 hours pre-OVA 
challenge and 6 hours post-OVA challenge. Only negative peaks are considered, any peaks that have a positive value o f  
sG aw are excluded. Total includes all negative peaks from 0-24 hours, EAR includes from 0-6 hours and LAR includes 
from 6-24 hours. Area under the curve is measured in %.hour. *significantly different from vehicle treatment. Two-tailed 
T-test (P<0.05; n=6). _ ,
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Figure 8.13 -  Response of the airways to a nose-only histamine exposure (1 mMol for 20 seconds) in OVA sensitised 
guinea pigs challenged with 0.01 % OVA and treated with saline/DMSO (50%/50%) or dexamethasone 20 mg/kg) 
administered i.p. 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge. Values were recorded 24 hours 
before OVA challenge and again 24 hours post-OVA challenge. Mean changes in sGaw are expressed as mean±S.E.M. 
percentage change from baseline where a negative value represents a bronchoconstriction. *significantly different from 
pre-challenge values o f sGaw. Two-tailed T-test (P<0.05; n=6).
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Figure 8.14 -  The number o f  total cells, macrophages, eosinophils, lymphocytes and neutrophils found in the 
bronchoalveolar (BAL) fluid o f naive (non-sensitised) and acute OVA challenged guinea pigs treated with saline/DMSO 
(50%/50%) or dexamethasone 20 mg/kg) administered i.p. 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA 
challenge. Results are expressed as mean±S.E.M. *significantly different from acute OVA -  vehicle treated. Two-tailed T-
test (P<0.05; n=6).
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A  = Acute OVA challenged -  vehicle treated (pre-challenge)
□  = Acute OVA challenged -  vehicle treated (post-challenge)
A  = Acute OVA challenged -  dexamethasone treated (pre-challenge)
□  = Acute OVA challenged -  dexamethasone treated (post-challenge)
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A. OVA sensitised -  Acute OVA challenged: V ehicle (saline-50% :DM SO-50% ) treated
B. OVA sensitised -  Acute OVA challenged: Dexamethasone (20 mg/kg) treated
Figures 8.15 (A-B): A single slice showing the MR image o f the lungs o f OVA sensitised guinea pigs challenged 
with a single OVA exposure and treated with saline/DMSO (50%/50%) or dexamethasone 20 mg/kg) 
administered i.p. 24 and 0.5 hours pre-OVA challenge and 6 hours post-OVA challenge.
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Figure 8.16: The volume of bright intensity in naive and OVA sensitised acute OVA challenged guinea pigs 
treated with saline/DMSO (50%/50%) or dexamethasone 20 mg/kg) administered i.p. 24 and 0.5 hours pre-OVA 
challenge and 6 hours post-OVA challenge. The red line highlights the basal level o f bright intensity, this is like 
caused by tissue such as the heart. *significantly different from vehicle treated guinea pigs. Two-tailed T-test 
(P<0.05; n=6).
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8.5 DISCUSSION
8.5.1 THE EFFECT OF ACUTE AND CHRONIC OVALBUMIN
EXPOSURES ON LUNG OEDEMA
Sensitisation with OVA and subsequent OVA challenge caused pulmonary oedema. In the 
acute OVA challenged group a significant difference from the saline challenged was 
observ ed at 4 hours with the maximum levels of oedema observed at 7 hours. At 24 hours the 
levels of oedema were reduced compared to at 7 hours suggesting some recovery, however, 
levels were still significant greater than the saline challenged group suggesting recovery takes 
longer than 24 hours. Although some oedema was observed in the saline challenged group 
this is somewhat expected as the guinea pigs were challenged in a high fluid environment and 
also saline does cause a very slight immune response as observed by maximum 
bronchoconstriction values shown in chapters 3 and 4. The fact that maximum levels of 
oedema were observed at 7 hours suggests oedema may contribute to the LAR.
The chronic OVA challenged group show significantly greater levels of oedema throughout 
all time points compared to saline challenge. The fact that there is an underlying level of 
oedema even at the baseline time-point is likely to be a consequence of repeated challenges 
not allowing the resolution of the oedema and inflammation to control levels. Despite the 
high levels o f basal oedema in the chronic OVA challenged group the levels of oedema still 
increased to a maximum level after 7 hours. However, the increase from baseline levels to 7 
hours is not as pronounced as was observed in the acute OVA group suggesting a maximal 
level of oedema could be reached possibly a result of the remodelling that occurs in the 
chronic airway (see chapter 3).
When levels of oedema were compared between acute and chronic challenges a significantly 
greater baseline level was observed in the chronic OVA challenged group compared to acute 
OVA challenge. However, whether this is exclusively a result of repeated OVA challenges 
causing more oedema or whether the fact that the chronic challenge guinea pigs were larger 
cannot be confirmed for certain. It is likely a result of the repeated challenges because 
although the chronic group have bigger lungs there would be less space for oedema because 
of the chronic remodelling of the airways.
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8.5.2 THE EFFECT OF DEXAMETHASONE TREATMENT ON EARLY
AND LATE ASTHMATIC RESPONSES IN ACUTE OVALBUMIN 
CHALLENGED GUINEA PIGS
Dexamethasone treatment had no effect on the early asthmatic response that was observed 
following an acute OVA challenge in the vehicle treated group. Evidence for this is displayed 
in both a time-course graph with maximum bronchoconstriction values and using area under 
the curve analysis. This was expected as dexamethasone is not a bronchodilator and as a 
result corticosteroids are often administered in combination with P2 agonists to compensate 
for this.
As observed with fluticasone propionate in chapter 5, dexamethasone significantly inhibited 
the late asthmatic response in comparison to vehicle treatment confirming the anti­
inflammatory nature of the drug. Dexamethasone is an oral steroid and is used to treat severe 
asthma (Bonnans et al.y 2003) so the fact that it is so effective against the late asthmatic 
inflammation was expected. Previous data has confirmed the ability of dexamethasone to 
attenuate the late asthmatic response in this acute OVA guinea pig model (Toward & 
Broadley, 2004).
8.5.3 THE EFFECT OF DEXAMETHASONE TREATMENT ON AIRWAY
HYPERRESPONSIVENESS IN ACUTE OVALBUMIN CHALLENGED 
GUINEA PIGS
AHR was observed in vehicle treated guinea pigs that were sensitised and exposed once to 
OVA. However, when levels of airway responsiveness were assessed in dexamethasone 
treated guinea pigs a significant bronchoconstriction was not observed. Therefore, 
dexamethasone, like fluticasone propionate, is able to attenuate the hyperresponsiveness 
observed in the airways of acute OVA exposed guinea pigs following a histamine challenge. 
It is likely that dexamethasone has a protective effect in the same way as fluticasone 
propionate, however, as the exact mechanisms of AHR are unclear how dexamethasone 
prevents AHR is not completely understood. As discussed in chapter 5 nitric oxide has been 
implicated as a cause of AHR (Salome et a l , 1999) as have eosinophils (Bradley et al.y 
1991), therefore it is likely that dexamethasone works by inhibiting one, if not both, of these
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factors. It is unlikely that dexamethasone had an effect by inhibiting the histamine 
administered to assess the responsiveness of the airways as if dexamethasone has anti­
histamine properties it would be more effective against the early asthmatic response. 
Attenuation of AHR by dexamethasone has been previously shown in animal models of 
asthma (Kumar et al., 2003; Toward & Broadley, 2004).
8.5.4 THE EFFECT OF DEXAMETHASONE TREATMENT ON
CELLULAR INFLUX IN ACUTE OVALBUMIN CHALLENGED 
GUINEA PIGS
Eosinophils play a major role in causing the lung inflammation observed in asthma with the 
number of eosinophils correlating with the severity of asthma (Hamid et al., 2003). 
Corticosteroids increase eosinophil apoptosis and also inhibit the recruitment of eosinophils 
to the airways (Barnes & Adcock, 2003). A large influx of eosinophils was observed 
following an OVA challenge in the vehicle treated group compared to naive guinea pigs. This 
influx was significantly reduced by dexamethasone. This would explain why a reduction in 
total number of inflammatory cells in the BAL fluid was observed after dexamethasone 
treatment compared to vehicle. Toward and Broadley (2004) previously showed that 
dexamethasone was able to significantly reduce eosinophil numbers in this model. It is 
possible that this reduction in eosinophils is responsible for the attenuation of the late 
asthmatic response and AHR usually observed.
8.5.5 THE EFFECT OF DEXAMETHASONE TREATMENT ON LEVELS
OF LUNG OEDEMA IN ACUTE OVALBUMIN CHALLENGED 
GUINEA PIGS
Challenging OVA sensitised guinea pigs with a single OVA exposure caused pulmonary 
oedema. A maximum level of oedema was observed after 7 hours, at the same time as the 
LAR. Pre-treating a guinea pig with dexamethasone caused a significant reduction in the 
levels of oedema at 7 hours compared to vehicle treatment. Despite this levels of oedema 
were still higher than naive guinea pigs suggesting that complete eradication of pulmonary 
oedema is not required for late phase attenuation. The volume of bright intensity was greater 
at baseline levels than naive guinea pigs; it is highly unlikely that sensitisation has any effect
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on oedema so the only possible explanation of this is the fact that the drug treated guinea pigs 
were older. Although at basal levels there will be no oedema present the entire lung cavity is 
considered when analysing volume of bright intensity, tissue such as the heart will show up 
with a bright intensity. The drug treated guinea pigs were a few weeks older than the naive 
and as such would have had a larger heart explaining the greater basal level of bright 
intensity. Ideally only considering bright intensity in the lungs would be the ideal scenario, 
however, in an oedema filled lung it is very difficult to distinguish what is lung and what is 
heart and as a result the entire cavity was analysed. In hindsight scanning the naive guinea 
pigs at the same age of the drug treated guinea pigs would have been a better option.
8.5.6 GENERAL CONCLUSIONS
Previous chapters have shown that OVA sensitisation and challenge cause early and late 
asthmatic responses, AHR, cellular influx and airway remodelling (in the chronic challenge 
protocol). This chapter confirms that the OVA sensitisation and challenge also induces 
pulmonary oedema which appears to correlate with the LAR. This LAR oedema can be 
significantly inhibited by corticosteroid treatment. This is not the first time LAR and oedema 
correlation has been observed as antigen-induced LAR was associated with pulmonary 
oedema previously in rats (Miyagawa et al., 2009). However, it appears that this is the first 
study to show pulmonary oedema that can be attenuated with corticosteroid treatment in 
OVA challenged guinea pigs.
Eosinophils, which play a key role in asthma, have been suggested to contribute towards 
oedema (Tigani et al., 2002). As eosinophils play a key role in the LAR this could explain the 
correlation between oedema and the LAR. Oedema has been associated with inducing 
hyperresponsiveness (Hargreave et al., 1986) as have eosinophils (Bradley et al., 1991) 
further corroborating the role of eosinophils in causing pulmonary oedema. Levels of 
eosinophils found in BAL fluid correlate with levels of MRI high intensity oedemic signal 
and in rats pre-treated with budesonide a reduced level of eosinophils and MRI signal was 
observed (Tigani et al., 2002). It is extremely likely that dexamethasone works through the 
same mechanism as budesonide, where by inhibiting eosinophil influx decreased levels of 
oedema, LAR and AHR are observed. However, despite dexamethasone treatment a level of 
oedema which peaked at 7 hours was still observed suggesting that either oedema can also 
occur through an eosinophil-independent mechanism or that a low level of eosinophils are
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needed to cause oedema as dexamethasone treatment did not reduce eosinophil level to that 
of naive guinea pigs.
Although oedema has been shown to develop in the lungs of asthmatics (Beasley et al., 1989; 
Laitinen et al., 1985) in some animal models the levels of oedema appear to reduce after 
multiple challenges (Ble et al., 2008; Tigani et al., 2007). The Tigani study implies that the 
reduced leakage is a result of increased vessel wall thickness following repeated allergen 
challenge. However, the formation of new blood vessels, angiogenesis, is associated with 
chronic asthma (Orsida et al., 1999) suggesting that there should be more plasma leakage 
from an increased number of blood vessels and therefore more oedema. It is likely that the 
decreased levels of oedema in these studies is a result of allergen tolerance. Oral tolerance in 
sensitised animals has been shown to decrease oedema formation (Ruiz Schutz et al., 2009) 
further corroborating that tolerance is the reason less oedema was observed in the Tigani and 
Ble studies.
The fact that oedema was observed in the chronic OVA model, as it is in asthmatics, suggests 
it is an extremely useful pre-clinical model of asthma. The use of MRI for assessing the effect 
of anti-inflammatory drugs could prove to be a useful tool not only in animal models but also 
clinically. It provides a non-invasive way of accurately assessing the levels of oedema in the 
lung, a factor which appears to be highly correlated with levels of pulmonary inflammation. 
One issue of using MRI is that images can be distorted because of the guinea pigs 
spontaneous breathing, however, taking repetitive measurements allows for a better MRI high 
intensity oedemic signal and therefore a clearer image and overcomes this issue. Although the 
increased levels o f oedema correlated with the LAR, nasal congestion cannot be ruled out as 
a potential cause of changes in sGaw values using this method. In order to rule this out 
imaging the nasal passage over the same time periods as the lungs would be a worthwhile 
experiment. However, this was not possible during this thesis because of MRI machine 
availability.
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9.1 MAIN AIMS AND METHODS
Asthma is a chronic disorder that causes massive social and economic cost. However, very 
few models of asthma, used to evaluate the effects of potential asthma therapeutics pre- 
clinically, take into account the chronic nature of asthma. The main aim of this thesis was to 
develop a chronic guinea pig and mouse model that displayed many of the features of asthma 
and to compare this with the acute model that is more commonly used in research (Zosky & 
Sly, 2007). A second aim was to investigate the effects that current and novel asthma 
therapeutics have on these models. The parameters used for comparison were lung function, 
airway response to histamine, inflammatory cell influx, lung histology, response to a variety 
of anti-inflammatory drugs and assessment of lung oedema (guinea pig only). This thesis 
showed clear distinction between acute and chronic challenge protocols most noticeably the 
presence of airway remodelling in the chronic model but not in the acute model. These guinea 
pig and mouse chronic models appear to be the first to display early and late asthmatic 
responses, airway hyperresponsiveness, cellular influx and airway remodelling all in the same 
animal. Several other models have displayed some, but not all, of these features using various 
similar and different protocols (Bazan-Perkins et al., 2009; Femandez-Rodriguez et al., 2008; 
Gosens et al., 2005). There are many different protocols, with differing results, that are used 
on animal models to try and provoke an asthma-like inflammatory response.
9 . 1 . 1 SENSITISATION
All models in this thesis were sensitised with ovalbumin (OVA) and aluminium hydroxide 
dissolved in phosphate buffered saline and administered via an intraperitoneal injection. 
Although this route has been commonly used (Femandez-Rodriguez et al., 2008; Smith & 
Broadley, 2007; Toward et al., 2004) it is argued that this route neglects the fact that humans 
are sensitised by being exposed to allergens via the respiratory mucosa (Cates et al., 2007). 
Cates et al., (2007) suggest this may have a number of significant immunological 
consequences. Studies have tried to overcome this issue by sensitising with an inhalation of 
OVA (Hamelmann et al., 1997). However, this route is rarely successful (Cates et al., 2007). 
It appears that the method of administration can influence the host response (Kumar et al., 
2008). Mice sensitised via the intraperitoneal route have been shown to have higher levels of
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IgE than those sensitised via intranasal administration (Kurup et al., 1992; Zhang et al., 
1997).
Another source of controversy in the method of sensitisation employed throughout this thesis 
is the use of an adjuvant. The adjuvant, aluminium hydroxide, was used to boost the immune 
response to OVA. Adjuvants usually induce a strong Th2-biased response with high levels of 
total and antigen-specific type 1 hypersensitivity reaction antibodies produced (Kumar et al., 
2008). A study by Nakae et al., (2007) showed that AHR and airway inflammation are mast 
cell-independent when an adjuvant is used, however, without an adjuvant these parameters 
are mast cell-dependent. It is likely when an adjuvant is used that the EAR is still mast cell- 
dependent as the bronchoconstriction occurs immediately after allergen challenge. Adjuvant- 
free protocols exist but require many injections to achieve sensitisation (Blyth et al., 1996; 
Hessel et al., 1997).
Despite the argument that the method of sensitisation used in this thesis does not follow the 
same route as human sensitisation the vast majority of studies use this method (Cates et al., 
2007). The fact that an increased level of IgGl was observed in the guinea pig models 
following sensitisation suggests that intraperitoneal administration of OVA does provoke an 
immune response. Further support of this method of sensitisation is that early and late 
bronchoconstrictions, AHR, cellular influx, airway oedema and airway remodelling, all 
features o f human asthma, were all observed in the chronic OVA guinea pig model. Currently 
there are no studies comparing and contrasting the effects that various methods of allergen 
administration and the use, or absence, of adjuvants have on sensitisation and the features of 
asthma observed in the chronic OVA model following further allergen challenge.
9.1.2 CHALLENGE PROTOCOLS
As with the process o f sensitisation there are many different protocols established using 
allergen challenges to provoke asthma-like responses. Although there are differences between 
routes of administration most studies use inhalation of aerosol as the route of choice (Kumar 
et al., 2008). However, the main differences between studies are the number of challenges. It 
is the number of challenges which determine whether a protocol is acute or chronic. Most 
inhalation challenge models are short-term, or acute, and typically consist of one or several 
challenges over a period of time lasting not much more than a week (Kumar et al., 2008). The
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acute guinea pig protocol used in this thesis was optimised by Smith and Broadley (2007) and 
consisted of a single challenge following sensitisation. To provoke a bronchoconstriction in 
the acute OVA mouse model, two inhalations separated by four hours was used. This follows 
a protocol developed by Femandez-Rodriguez et al., (2008) adapted from Ohkawara et al., 
(1997). Although there are other acute protocols which lead to some of the features of asthma 
the model by Femandez-Rodriguez et al., (2008) appeared to be the first to show a biphasic 
bronchoconstriction followed by AHR and correlating cellular influx.
The main reason why acute models of asthma are more commonly used than long-term 
chronic models is that long-term exposure to an allergen can cause tolerance (Schramm et al., 
2003). Although, the exact mechanisms behind tolerance are unclear an element of adaptation 
needs to be implemented before the chronic features of asthma can be observed in animal 
models. In the case of guinea pigs in this thesis, a ten-fold higher dose of OVA was used 
following the original OVA exposure and sensitisation. This protocol was developed in these 
laboratories by John (2007). The higher dose of OVA would cause an anaphylactic response 
as a result o f increased histamine release. To combat this response the histamine Hi receptor 
antagonist mepyramine was used. However, by the day of the final exposure (day 31) 
mepyramine protection was no longer needed highlighting the level of tolerance that the 
guinea pig model underwent. It is possible that if the chronic model was extended longer than 
31 days then the dose of OVA used would have to be increased again to provoke an asthmatic 
response.
Chronic murine models of asthma take around 8 weeks to develop (Kumar et al., 2008). 
However, long-term administration of a high concentration of allergen can lead to the 
development of parenchymal inflammation a condition which is markedly different from 
asthma (Kumar & Foster, 2002). Long-term allergen administration can also lead to down- 
regulation of the inflammation, AHR and structural airway changes as a result of tolerance 
(Jungsuwadee et al., 2004; Palmans et al., 2000; Yiamouyiannis et al., 1999). To overcome 
these issues long-term exposures to a low dose of allergen are now being used (Femandez- 
Rodriguez et al., 2008; Kumar et al., 2008). Although models using this approach have been 
relatively successful at preventing tolerance and displaying some of the features of asthma 
none have shown EAR, LAR, AHR, cellular influx and airway remodelling. The model 
developed by Femandez-Rodriguez et al., (2008) was able to show a biphasic inflammatory 
response, AHR and increased levels of eosinophils. However, airway remodelling was not 
assessed in this model. By using this protocol and assessing airway remodelling, along with
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the other parameters previously measured, it was possible to develop a mouse model of 
asthma that could prove more effective for pre-clinical modelling.
9.1.3 OUTCOMES
9.1.3.1 GUINEA PIGS
Challenging a sensitised guinea pig with OVA on day 15 provoked an inflammatory response 
characterised by an early and late phase bronchoconstriction. Treatment with a corticosteroid, 
fluticasone propionate, PDE4 inhibitor, roflumilast or an iNOS inhibitor, GW274150F, 
attenuated the late phase bronchoconstriction. However, only roflumilast had an inhibitory 
effect on the early bronchoconstriction. The chronic OVA model also had an inflammatory 
response characterised by an early and late asthmatic response. Once again only roflumilast 
was able to reduce the level of bronchoconstriction during the EAR. Fluticasone propionate 
and roflumilast attenuated the LAR but GW274150F was ineffective against the 
bronchoconstriction.
24 hours following the final OVA exposure guinea pigs were challenged with histamine (1 
mMol, 20 secs) to assess airway responsiveness. The acute OVA challenged guinea pigs had 
a bronchoconstriction following histamine challenge representing AHR. The level of 
responsiveness decreased to baseline levels after 72 hours. The AHR was inhibited by each of 
the three drugs. Chronic OVA challenges caused AHR characterised by a bronchoconstriction 
following a histamine challenge. In contrast to the acute model, AHR was inhibited with 
fluticasone propionate and roflumilast treatment but not with GW274150F. AHR was still 
present 72 hours after the final OVA challenge.
Following the final histamine challenge the guinea pigs were killed and lavaged enabling a 
total and differential cell count to be carried out. Acute OVA challenged guinea pigs had 
significantly greater levels of total cells and each of the subtypes assessed (macrophages, 
eosinophils, lymphocytes and neutrophils) than control guinea pigs. 72 hours after challenge 
a significant reduction was observed in total cell number and macrophage, eosinophil and 
neutrophil number. However, the levels of cells still appeared greater than naive guinea pig 
levels. Fluticasone propionate, roflumilast and GW274150F only reduced the total number of 
cells and number of eosinophils. The chronic OVA challenged guinea pigs had significantly 
greater levels o f total cells and all of the subtypes compared to control. The total number of
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inflammatory cells, macrophages, eosinophils and neutrophils all significantly decreased 
when the guinea pigs were given 72 hours to recover following the final OVA exposure. 
When comparing drug treatments against the chronic OVA model roflumilast was the most 
efficient by decreasing levels of total cells, macrophages, eosinophils and neutrophils. 
Fluticasone propionate treatment reduced total cells and eosinophil number and GW274150F 
only affected total cells and neutrophils.
The chronic OVA challenged protocol was the only one to cause airway remodelling in the 
airways of sensitised guinea pigs. Airway remodelling was characterised by an increase in 
pulmonary inflammatory cells, increased smooth muscle, increased levels of collagen found 
in the lamina propria and goblet cell hyperplasia. An increase in pulmonary cells in the 
chronic OVA challenged group compared to control was observed following staining of the 
respective bronchioles with haematoxylin and eosin. Treatment with fluticasone propionate 
and roflumilast significantly decreased the mean pathological score, however, GW274150F 
had no significant effect. The bronchioles of the chronic OVA challenged guinea pig had a 
thicker lamina propria and epithelium and increased levels of smooth muscle than control. 
Treatment with fluticasone propionate appeared to reduce all of these features. Only the 
amount of smooth muscle and thickness of the epithelium was affected by roflumilast 
treatment and GW274150F only appeared to reduce the level of smooth muscle.
MRI analysis in guinea pigs showed the levels of oedema reached a peak that correlated with 
the LAR. Compared to control animals, the acute OVA challenged guinea pigs showed 
significantly greater levels of oedema 4, 7 and 25 hours following challenge. The chronic 
OVA challenged guinea pigs had significantly greater levels of oedema compared to control 
at each of the time points suggesting that there were underlying levels of oedema before the 
final OVA challenge. Despite the high levels of baseline oedema in this model, levels still 
increased following challenge and peaked at 7 hours. At baseline, 0.25 and 4 hours post-final 
OVA challenge the chronic OVA model had significantly greater levels of oedema than the 
acute OVA model. However, at 7 and 25 hours following challenge the differences between 
the two groups were not significant. This suggests that oedema does not disappear as quickly 
as it is formed and therefore this is likely to be why such a high baseline level of oedema was 
observed in the chronic OVA group. Treatment with the corticosteroid, dexamethasone, was 
able to attenuate the LAR, inhibit AHR and reduce the total number of cells and macrophages 
in the acute OVA model. When the effect of dexamethasone on the levels of oedema in the 
acute OVA challenged guinea pigs were compared to vehicle a significant reduction was
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observed at the 7 hour mark. No other significant differences were observed throughout the 
other time points though it is clear to see that despite dexamethasone treatment the levels of 
oedema are still greater than naive guinea pig levels. The effect of dexamethasone treatment 
on the chronic OVA guinea pig model was not assessed.
9.1.3.2 MICE
Mice sensitised with OVA and then challenged twice (4 hours apart) on day 15 have a 
biphasic bronchoconstrictor response. The first response is the EAR. This is slightly delayed 
compared to the guinea pigs possibly because serotonin (the primary mediator in mice mast 
cell degranulation) takes longer than histamine to reach a level that causes 
bronchoconstriction (unpublished observations -  Femandez-Rodriguez et al.). The second 
bronchoconstriction represents the LAR. The effects of fluticasone propionate, roflumilast 
and GW274150F were also assessed on the mouse models. Roflumilast attenuated the EAR 
and LAR in the acute OVA challenged mouse. However, fluticasone propionate and 
GW274150F were only effective against the LAR. The chronic OVA mouse model was 
challenged with three OVA challenges a week for six weeks (18 challenges) followed by a 
final challenge on the first day of the seventh week. This protocol provoked a biphasic 
airways function response characterised by an EAR and LAR. Once again it was only 
roflumilast that was able to have any effect on the EAR. Roflumilast was also able to 
attenuate the LAR as was fluticasone propionate, however, GW274150F was ineffective.
The responsiveness of the airways was assessed in the acute and chronic models using 30 
mg/kg or 10 mg/kg of methacholine respectively. A significant level of AHR was observed 
following OVA challenge in the acute group. This AHR was significantly attenuated by each 
of the drugs administered, however, GW274150F was the least effective and a degree of 
AHR was still present. The chronic OVA group were challenged with a lower dose of 
methacholine so not to cause a fatal level of bronchoconstriction. AHR was observed post- 
final OVA challenge following methacholine challenge though because of the lower dose the 
level of AHR was not as great as in the acute OVA model. Fluticasone propionate and 
roflumilast treatment attenuated the levels of AHR, however, GW274150F was ineffective.
Following the final methacholine challenge the mice were killed and lavaged. However, as 
mice have small trachea, damage and contamination with blood frequently occurs and as a
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result a total cell count could not be accurately carried out. Therefore the only means of 
assessing the bronchoalveolar lavage fluid was by using a differential cell count to determine 
the ratio of inflammatory cell subtypes present in the airways. The acute and chronic OVA 
challenged mice had a significantly greater percentage of eosinophils compared to control. 
However, the percentage of macrophages was apparently significantly decreased in the two 
OVA challenged groups compared to control. It is likely that this is not a real decrease in 
macrophages but a consequence of the increased percentage of eosinophils. Fluticasone 
propionate treatment significantly reduced the percentage of eosinophils in the acute OVA 
challenged mice; with a resulting apparent increase in macrophage percentage also observed. 
This was also the case for roflumilast treatment. GW274150F had no effect on cell 
percentages in the acute OVA challenged mice. In the chronic OVA challenged model a 
significant decrease in eosinophil percentage was observed following fluticasone propionate 
treatment. Roflumilast was also able to significantly decrease eosinophil percentage in the 
chronic OVA challenged model, however, a corresponding increase in macrophage 
percentage was observed. Once again, GW274150F had no effect on cell percentages.
No features of airway remodelling were observed in the acute OVA challenged mouse model, 
although a significant increase in mean pathological score was observed compared to control. 
The chronic OVA challenged mice also had a significantly greater mean pathological score 
compared to control and also had a significantly greater level of pulmonary tissue cells than 
the acute OVA challenged group. Chronic OVA challenges caused structural changes in the 
airways, or airway remodelling, characterised by increased levels of smooth muscle, 
increased thickness of the lamina propria by extracellular matrix proteins such as collagen 
and goblet cell hyperplasia. Compared to vehicle, fluticasone propionate treatment caused a 
reduction in the level of smooth muscle, collagen and goblet cells, though not to the same 
levels as naive mice. Roflumilast treatment was also able to reverse the features of airway 
remodelling observed in the chronic OVA challenged mice compared to vehicle treatment. 
GW274150F had no effect on the structural changes observed in the chronic OVA mouse 
model and therefore was ineffective at reversing airway remodelling.
9.1.4 THE USE OF Pe„b
Whole-body unrestrained plethysmography was used to measure airway responsiveness in 
conscious mice. Enhanced pause (Penh), a non-dimensional parameter based on a
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characteristic change in expiratory waveshape of the unrestrained plethysmograph box signal 
(Lomask, 2006), was used as an indicator of bronchoconstriction. Whole-body 
plethysmography measures two changes in the box pressure: a reduction caused by the 
inspiration of air by the animal and an increase because of the lungs expanding (Buxco 
Research Systems, 2006 referenced by Femandez-Rodriguez et al., 2008). Normally these 
flows cancel each other out. However, in conditions such as asthma the changes in box 
pressure during expiration are more pronounced than during inspiration (Dorsch et al., 1981). 
P cnh has been used repeatedly as an indicator of airway responsiveness to bronchoconstrictors 
(Archer et al., 2004; Femandez-Rodriguez et al., 2008; Lee et al., 2005).
Despite this, the validity of Pcnh as a marker of airway responsiveness has been questioned 
(Adler et al.y 2004; Lundblad et al., 2002). Lundblad et al., (2002) claim that the unrestrained 
plethysmograph waveform, and parameters derived from it (Pcnh), are dominated by 
conditioning and are essentially unrelated to resistance. However, a paper by Lomask (2006) 
discusses the mathematics of unrestrained plethysmography as applied to two types of whole- 
body plethysmographs: a sealed chamber (pressure whole-body plethysmograph, PWBP) and 
a chamber with a pneumotachograph on its wall (flow whole-body plethysmograph, FWBP). 
Lomask (2006) describes how the PWBP waveform is largely dominated by conditioning, 
thus supporting the claim by Lundblad (2006) that unrestrained plethysmography and Pcnh are 
unrelated to resistance. However, Lomask (2006) goes on to describe how the effects of 
resistance are evident in the FWBP waveform and Pcnh is derived from this waveform. 
Lomask (2006) shows that the changes in the FWBP waveform which occur after 
methacholine challenge cannot be down to conditioning and are not just changes in 
respiratory timing but can be quantified by Pcnh- Therefore it would seem that the use of Pcnh 
is acceptable in chambers with a pneumotachograph, which is what was used in this thesis. 
How Pcnh is derived can be found in Appendix 3.
9.2 EXPERIMENTAL LIMITATIONS
As with all models of asthma, guinea pigs and mice have limitations and therefore should not 
be thought of as having asthma. Guinea pigs or mice do not develop asthma, but this thesis 
has entailed provoking an inflammatory response that resembles the features of asthma. 
Therefore a result or response in one of these models may not be the same in human
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asthmatics. Despite this, animal models have still proved very important in understanding the 
mechanisms and potential targets of asthma.
Aside from the obvious differences between humans and guinea pigs, such as the fact that 
humans are bipedal, arguably one of the major downfalls of using guinea pig models of 
asthma is the lack of species-specific reagents. Even though IgGl is the major antibody in 
type 1 hypersensitivity allergies in guinea pigs IgE is still present. In this thesis OVA-specific 
IgGl was assessed however, there is only one ELISA kit commercially available to measure 
OVA-specific IgE in guinea pigs. Establishing reproducible results using this kit proved to be 
difficult and as a result the data obtained was not included in this thesis. If one wanted to 
investigate the role of cytokines in the guinea pig model of asthma this would prove very 
difficult because of the limited amount of kits to do so. These issues are overcome by using 
the mouse model as the immune system in mice is well characterised and several species- 
specific reagents are commercially available.
The mouse model is also not without problems. Mice are inquisitive by nature and therefore 
require a great deal of conditioning and acclimatising to the Buxco chamber before readings 
can be taken. The measurement of Pcnh by whole-body plethysmography also leads to intense 
criticism of the mouse model; this is discussed in the previous section.
Throughout this thesis total bronchoalveolar lavage (BAL) fluid cell counts were included 
for guinea pigs but not mice. This was because the size of the mouse trachea made it very 
difficult to cannulate without damage resulting in the contamination of the BAL fluid with 
red blood cells. As a consequence of this the differential cell count was presented as the 
percentage of inflammatory cell subtypes. This meant if one subtype was to increase in 
percentage then another subtype would show a corresponding decrease in percentage to 
compensate. This led to the situation like in the OVA challenged mice that eosinophil 
percentage was significantly greater than control but macrophage percentage was 
significantly decreased. This made it appear that there were less macrophages in the OVA 
challenge BAL fluid compared to the saline challenge BAL fluid. In reality this probably was 
not the case as OVA challenged guinea pigs have increased numbers of macrophages 
compared to control. However, without the total cell count one cannot say accurately whether 
OVA challenge in mice caused increased numbers of macrophages. The issue was partially 
overcome by the scoring of inflammatory cells in the lung tissue of the mice. This suggested 
that OVA challenged mice had a greater influx of inflammatory cells to the lung tissue
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compared to their respective controls. However, it was not possible to distinguish leukocyte 
subtype using this method.
Another limitation of this thesis is the accuracy of the histological and MRI analysis. These 
methods both involved a degree of analysis by eye; therefore an element of human error is 
possible. Although every effort was made to avoid bias when analysing, such as randomising 
the histological and MRI images assessed, it is possible a degree of subconscious bias may 
still occur. Using an independent worker to carry out blind analysis would overcome this 
issue, unfortunately this was not possible at the time. The fact that all histological analysis 
was 2-dimensional means it is not as accurate as 3-dimensional analysis. However, this 
would have been too time consuming for this thesis and it is likely that most of the changes in 
the airways are represented using 2-dimensional analysis.
9.3 FURTHER WORK
If there were no time or financial constraints there are several studies that this thesis may 
have benefitted from. Firstly, all work was carried out in male animals. It would have been 
interesting to determine whether the same effects occur in female guinea pigs and mice as 
were observed in male guinea pigs and mice in this thesis. Clearly asthma affects both males 
and females, therefore if there is a fundamental difference in how one sex reacts to a drug it 
would be important to discover this, for example whether the steroid oestrogen has some 
effect on the inflammation in asthma.
The dosing schedule of the drugs was 24 and 0.5 hours before the final OVA challenge and 6 
hours after in the chronic model. This measured the ability of the drug to reverse any changes 
observed. Although fluticasone propionate and roflumilast proved to be rather effective 
against airway remodelling it would have been interesting to administer them before each of 
the OVA challenges and therefore determine whether they have preventative properties. It is 
possible that if this method was employed there would be a lack of airway remodelling in the 
chronic model. The dosing schedule that was used during this thesis was not very clinically 
relevant and was only suitable for assessing what changes the drugs can have if they are 
administered before and during an asthmatic episode. In reality it would be almost impossible 
to predict an asthmatic episode was about to happen and therefore administer drugs 24 hours 
and 30 minutes before it occurred. Employing either the preventative method or a randomised
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schedule of drug administration would improve clinical relevance. Usually drugs are 
administered immediately after an asthmatic episode. It would have been interesting to assess 
what effect roflumilast would have using this dosing schedule, as it was shown to have some 
effectiveness against the EAR. However, for the purpose of this thesis the dosing schedule 
used was satisfactory.
When it came to the MRI work at GlaxoSmithKline, assessing the effect of dexamethasone 
on the levels of oedema in the chronic OVA model was not possible. This was partially a 
result o f time and secondly the guinea pigs were becoming too big to fit in the magnet of the 
MRI. Therefore, without financial or time limitations it would be interesting to carry out this 
experiment, this would determine whether levels of oedema can be reduced in the chronic 
OVA model. Currently the chronic OVA guinea pig model only lasts 31 days, extending this 
period may result in either further tolerance to the higher OVA dose or greater levels of 
airway remodelling. With more time it could have been worthwhile to investigate this and 
any potential changes in recovery times.
Another experiment this thesis could benefit from is analysing the pulmonary levels of 3- 
nitrotyrosine (3-NT) protein to determine the levels of nitrosylation of lung proteins as an 
index of nitric oxide production could be a worthwhile experiment. This would determine 
whether GW274150F was inhibiting iNOS. If in vivo elevated 3-NT proteins were still 
present in the lung tissue after GW274150F treatment this would indicate that it was unable 
to completely inhibit iNOS. However, if the proteins were not present this would suggest 
GW274150F is effective at reducing iNOS and that iNOS induced NO does not have a major 
role in causing the asthmatic response. This experiment was attempted though the results 
were inconclusive and therefore left out of this thesis.
9.4 CLINICAL RELEVANCE
Asthma is a chronic inflammatory disorder that affects of 300 million people worldwide 
(WHO). Many of the advances in the understanding of the pathobiology of asthma have come 
from provoked models of airway inflammation in animals (O'Byme et al., 2009). Although a 
few drugs have shown efficacy in animals but not humans, such as GW274150F in the acute 
OVA model, animal models are the only system available for modelling the in vivo processes 
of human asthma (Zosky & Sly, 2007). Currently short-term, or acute, models of asthma are
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commonly used (Zosky & Sly, 2007); however, these models have significant limitations and 
do not take the chronic nature of asthma into account (Kumar & Foster, 2002). The fact that 
the acute OVA model only has one challenge, and the drugs were administered 24 hours and 
half hour before this challenge, is equivalent to trying to treat a sensitised individual before 
their first asthmatic episode.
The chronic OVA models of asthma developed in this thesis demonstrated lung 
inflammation, AHR, inflammatory cell influx and airway remodelling. It seems likely that 
this is the first time that all of these features have been observed in a guinea pig and a mouse 
model. Therefore, these models are extremely relevant for pre-clinical evaluation of potential 
mechanisms of asthma and subsequent therapy.
There are criticisms of the method of sensitisation and use of an adjuvant as detailed in 
section 9.1.1. However, as of yet these methods have not been proven to cause a vastly 
different immune response than the one observed in asthma. Research has been carried out to 
try and find a more clinically relevant allergen than ovalbumin such as house dust mite (Kim 
et al., 2006), olive pollen (Batanero et al., 2002) and Aspergillus fiimigatus extract (Baelder 
et al., 2005). However, ovalbumin is still the allergen of choice to provoke an immune 
response in the majority of studies modelling asthma (Cates et al., 2007) as these other 
models of asthma are not able to produce the same features observed in ovalbumin models.
Perhaps the best evidence that the chronic OVA models are more clinically, or pre-clinically, 
relevant than the acute OVA models was the response to GW274150F treatment. In the acute 
OVA models GW274150F was quite effective at reducing the LAR, AHR and cellular influx. 
However, in the chronic OVA models, GW274150F was not effective though the dosing 
schedule was the same. This was also the case in clinical trials as GW274150F had no effect 
on AHR or inflammatory cells number (Singh et al., 2007). This suggests the chronic OVA 
model is a better representation of human asthma than the acute OVA model, possibly 
because airway remodelling occurs in the chronic OVA model.
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APPENDIX 1
EQUIPMENT
Amplifier (Biopac systems TCI 100) -  Biopac Systems Inc., Santa Barbara, CA, USA. 
Cannula -  Fisher Scientific UK, Loughborough, UK.
Centrifuge (Mistral 3000) -  Mistral, UK.
Cold Plate -  Fisher Scientific UK, Loughborough, UK.
Coverslip -  Surgipath Europe Ltd, Peterborough, UK.
Digital Camera (Camedia C4040ZOOM) -  Olympus, London, UK.
ELISA Plate -  Greiner Bio-One Ltd., Stonehouse, UK.
Exposure Chamber (Guinea Pigs) -  Buxco Research Systems, Winchester, UK. 
Exposure Chamber (Mice) -  Buxco Research Systems, Winchester, UK.
Exposure Tunnel for Airway Responsiveness -  In-house built 
Glass Slides -  Surgipath Europe Ltd, Peterborough, UK.
Histology Cassettes -  Surgipath Europe Ltd, Peterborough, UK.
Microscope (Olympia -  BH-2) -  Olympus, London, UK.
Microtome -  Mistral, UK.
MRI Machine -  Bruker Corporation, Coventry, UK.
Neubauer Haemocytometer -  Supe-rior, Marienfeld, Germany.
Plate Reader (ELISA) -  Sunrise Systems, Cambridge, UK.
Pressure Transducers (UP1 and UP2) -  Pioden Controls Ltd., Canterbury, UK.
Wax Dispenser -  Fisher Scientific UK, Loughborough, UK.
Whole Body Plethysmograph (Gunea Pigs) -  In-house built
Whole Body Plethysmograph (Mice) -  Buxco Research Systems, Winchester, UK.
Wright Nebuliser (Pulmostar) -  Sunrise Medical Ltd., Wollaston, UK.
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MATERIALS
Acid alcohol -  Surgipath Europe Ltd, Peterborough, UK.
Alcian blue -  Surgipath Europe Ltd, Peterborough, UK.
Aluminium hydroxide -  Sigma, Poole, UK.
Aqueous acetic acid -  Sigma, Poole, UK.
Chloroform -  Sigma, Poole, UK.
Citric acid -  Sigma, Poole, UK.
Dexamethasone -  Sigma, Poole, UK.
Dimethyl sulfoxide -  Sigma, Poole, UK.
DPX mountant -  Surgipath Europe Ltd, Peterborough, UK.
Eosin -  Surgipath Europe Ltd, Peterborough, UK.
Ethanol -  Sigma, Poole, UK.
Fluticasone propionate -  GlaxoSmithKline, Stevenage, Herts, UK.
Formaldehyde -  Fisher Scientific UK, Loughborough, UK.
Guinea Pigs -  Harlan, UK.
GW274150F -  GlaxoSmithKline, Stevenage, Herts, UK.
Histamine -  Sigma, Poole, UK.
Hydrochloric acid -  Sigma, Poole, UK.
IgG Antibody Horse radish peroxidise Conjugated -  Biocompare, Harrogate, UK. 
Industrial methylated spirit -  Surgipath Europe Ltd, Peterborough, UK. 
Isoflourane -  Abbott Animal Health, Maidenhead, UK.
Leishman’s solution -  Sigma, Poole, UK.
Mayer’s haematoxylin -  Surgipath Europe Ltd, Peterborough, UK.
Mepyramine -  Sigma, Poole, UK.
Methacholine -  Sigma, Poole, UK.
Methanol -  Fisher Scientific UK, Loughborough, UK.
Methyl cellulose -  Sigma, Poole, UK.
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Mice -  Harlan, UK.
Milk (Powdered, non-fat) -  Shop bought.
O-phenylenediamine dihydrochloride -  Sigma, Poole, UK.
Ovalbumin -  VWR International Ltd., Leicestershire, UK.
Paraffin wax -  Surgipath Europe Ltd, Peterborough, UK.
Periodic acid -  Surgipath Europe Ltd, Peterborough, UK.
Phosphate buffered saline -  Fisher Scientific UK, Loughborough, UK. 
Picric acid -  Sigma, Poole, UK.
Roflumilast -  GlaxoSmithKline, Stevenage, Herts, UK.
SchifPs reagent -  Surgipath Europe Ltd, Peterborough, UK.
Sirius red -  Sigma, Poole, UK.
Sodium pentobarbitone (Euthatal) -  Merial, Harlow, UK.
Sodium phosphate -  Sigma, Poole, UK.
Sterile water -  Sigma, Poole, UK.
Sulphuric acid -  Sigma, Poole, UK.
Tween -  Sigma, Poole, UK.
Xylene -  Surgipath Europe Ltd, Peterborough, UK.
COMPUTER PROGRAMS
Acqknowledge -  Biopac Systems, Inc., Goleta, CA, USA.
Analyze -  AnalyzeDirect, Inc., Overland Park, KS, USA.
GraphPad Instat 3 -  GraphPad software, Inc., La Jolla, CA, USA. 
GraphPad Prism 5 -  GraphPad software, Inc., La Jolla, CA, USA. 
ImageJ -  National Institute of Health - http://rsbweb.nih.gov/ij/index.html
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APPENDIX 2 -  CALCULATION OF sGaw
Airways resistance is based on laminar flow in straight, smooth-walled tubes. The 
physical law that describes such a flow is Poiseuille’s Law, thus pressure drop due to 
friction (AP) is defined as:
1. AP = 8ulv/7n-4 
(p=viscosity; 1 = length of tube; r = radius; v=flow rate)
The airways however can consist of many branches and bends and are subject to dynamic 
changes in the radius of the tubes due to bronchoconstrictions and secretions. Therefore 
as airflow increases it becomes more turbulent and conversely as it approaches zero 
becomes more laminar.
Flow through the airways is induced by the alveolar pressure difference (Pd) i.e. the 
difference between mouth pressure (P m) and alveolar pressure (Paiv).
P d  =  P m  ~ P a lv
Airways resistance ( R aw )  is defined as the relationship between instantaneous flow (v) 
and alveolar pressure difference.
R a w  = Pd/v
Conductance is the reciprocal of resistance, therefore airways conductance (Gaw) is 
defined as:
Gaw = Raw 1 = v/Pd
To compare between different subjects the differences in thoracic gas volume (TGV) 
must be eliminated, hence specific airway conductance (sGaw) is used.
2. sGau, = v/Ph.TGV
317
Plethysmograph -  In a sealed box at a constant temperature, changes in pressure are 
related to changes in volume according to Boyle’s Law, i.e. the volume of a gas changes 
inversely with the changes in pressure at a constant temperature.
P1.V1 = P2 .V2 
or
P.V = (P+5P).(V-8V) 
by multiplying the two brackets 
P.V = P.V -  P.8V + V.8P -  8P.8V 
As 5P.8V is negligible 
V.8P = P.8V
For a sealed plethysmograph changes in the alveolar pressure difference will be seen as 
changes in box pressure. Box pressure changes result from the difference in chest volume 
changes (Vc) and respired air volume changes (Vr) at atmospheric pressure ( P atm ), 
corrected for saturated water vapour pressure ( P svp)-  So from Boyle’s Law:
3. 8Pri.TGV = 8(V c - Vr ) - ( P a tm - P s v p l  
For Poiseuille’s Law to be true, in order to have laminar flow, v must tend towards zero, 
i.e. at flow manoeuvre reversal (end inspiration or end expiration). Conventionally end 
expiration is frequently used since TGV approximates to the functional residual capacity 
(FRC). Hence any changes in Pd must be small, i.e. SPd which in turn will induce small 
changes in flow (8v).
Therefore substituting 2. into 3. gives:
sGaw = 8v/8(Vc-Vr).(Patm-Psvp)
3 1 8
Using computerised data acquisition it is possible to measure 5(VC-Vr) as the slope of the 
change in box volume where flow tends towards zero. It is then possible to record the 
simultaneous change in flow (5v).
P atm — 1010cmH2O 
Psvp = 63cmH20
Therefore by knowing 5v and 5(VC-Vr) from the slopes of the flow and box volume traces
respectively sGaw can be calculated:
sGaw = 5[flow]/8[box volume].947.c/s'1cmH20'1
cf is a correction factor to account for the volume of air displaced by the guinea pig (Vgp).
The density of a guinea pig (Pgp) is approximately 1.07kg!'1 and the volume of the
plethysmograph chamber ( V b o x )  is 5.5 litres. Thus:
Vgp = Wgp/ Pgp litres
The net volume of the plethysmograph:
Vn Vbox Vgp litres 
* * * * * *
cf=  (Vbox-Vgp^box 
cf=  1 -  (Vgp/Vbox)
cf=  1 - W g p / P g p .  V b o x
cf — 1 -Wgp/5.885 
Therefore:
sG,w = Slflowl/dfbox volumel.947.1-Wgn/5.885 cmHiO'1
Adapted from John (2007).
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A P P E N D I X  3  -  C A L C U L A T I O N  O F  P enh
The waveform from a flow whole-body plethysmograph can be separated into two regions: 
The first region contains the transition from inspiration to expiration. Region #2 follows 
region #1 but does not include the transition (Lomask, 2006). The ratio between the mean 
height o f  the two regions will respond to resistance. The comparison is made by the 
parameter Pause (Lomask, 2006).
end of breathstart of b reath
+
2
3
C/3
C/3
<13k .
PEP
PIP
36%
a.
Figure A: A schematic diagram to show the box pressure wave in inspiration (down) and expiration (up). 
Using the parameters on this diagram Penh can be derived. Diagram from Hamelmann et al., (1997). Ti = 
Time o f inspiration; Te = Time o f expiration; Tr = Relaxation time; PIP = Peak inspiration pressure; PEP = 
Peak expiration pressure.
Figure A shows a box pressure wave in inspiration and expiration. The amount o f time taken 
from the start to the end o f inspiration is Ti. Time o f  expiration (Te) is the time from the end 
o f  inspiration to the start o f the next inspiration. The time it takes for the pressure to decay to 
36% o f  the total expiratory pressure signal is known as relaxation time (Tr). This may serve 
as a correlate to the time constant o f the decay o f volume signal to 36% of the peak volume in 
passive expiration (Hamelmann et al., 1997). The transition o f the flow o f an animal from 
inspiration to expiration will take place during the Tr interval (Lomask, 2006). Therefore the 
following formula is used to calculated Pause:
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Pause = (Te-TrVTr
Levels of peak inspiration pressure (PIP) and peak expiration pressure (PEP) are used to 
calculation enhanced pause (Penh). Conditioning during expiration is significantly less than 
during inspiration; therefore a change in resistance will be more prominent in the expiratory 
phase (Lomask, 2006). Using the ratio of PEP to PIP will enhance the sensitivity of Pause, in 
other words:
Ppnh (Enhanced pause) = (PEP/PIP) x Pause
